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SUMMARY
There is currently a great deal of interest in the development 
of vaccines using purified recombinant protein antigens. For 
practical and scientific reasons, it would be advantageous if these 
vaccines could be administered orally. This is esssential for 
stimulating widespread immunity at the mucosal surfaces where 
most pathogens are encountered and, as the success of the oral 
polio vaccine shows, this can also protect against systemic infection. 
Furthermore, oral immunisation is one of the few effective means 
allowing passive transfer of immunity from mother to infant via 
milk. The poor immunogenicity of purified soluble proteins, their 
inability to induce class I MHC-restricted CTL responses and the 
systemic tolerance induced by their oral administration are major 
obstacles to the development of synthetic oral vaccines. Thus, there 
is a need for well characterised vaccine vectors which will 
circumvent these difficulties and allow soluble protein antigens to 
be immunogenic when administered orally.
Immune stimulating complexes (ISCOMS) are lipophilic, cage­
like particles composed of cholesterol, phospholipid and the saponin 
adjuvant Quil A. Parenteral immunisation with ISCOMS is known to 
induce humoral and cell-mediated immune responses as well as 
protective immunity against a number of infections. However, their 
efficacy by mucosal routes and their use with non-hydrophobic 
proteins had received little attention. My studies exploited a 
recently established method for incorporating purified OVA into 
ISCOMS and aimed to extend preliminary work in the laboratory 
showing that ISCOMS-OVA were immunogenic by oral and 
parenteral routes. I therefore explored the full range of responses
ii
induced and investigated the immunological basis of the adjuvant 
properties of ISCOMS when used by the oral and parenteral routes.
A single parenteral immunisation with as little as 5-lO^g 
ISCOMS-OVA primed potent OVA-specific systemic DTH and IgG 
responses and high levels of class I MHC-restricted OVA-specific 
CTL activity were detected in the spleen. These findings indicate 
that ISCOMS allow presentation of incorporated protein to the class 
II MHC-restricted T cells required for antibody and DTH responses, 
as well as permitting efficient entry of the protein into the 
endogenous antigen processing pathway required for stimulation of 
class I MHC-restricted CTL responses. A multiple dose oral 
immunisation schedule induced the same range of systemic 
immune responses as parenteral immunisation and also stimulated 
the production of secretory IgA antibodies in the intestine and local 
CTL precursors in MLN. These findings indicate that ISCOMS may 
allow protein antigen to subvert the regulatory mechanisms which 
normally cause protein antigens to induce tolerance at mucosal 
surfaces.
One of the most novel properties of ISCOMS was their ability 
to stimulate potent class I MHC-restricted CTL responses to 
exogenous protein antigens in vivo. As this would be important for 
a vaccine capable of stimulating protection against many viral 
infections, I characterised the CTL responses primed by ISCOMS- 
OVA and investigated the mechanisms involved in their induction. 
My results showed that the CTL primed by ISCOMS-OVA were CD8+ 
T cells which recognised the immunodominant epitope contained 
within the endogenously processed peptide OVA 258-276, 
containing the minimal motif for binding the H-2Kb class I MHC 
molecule. This is the epitope recognised by OVA-specific CTL in H-
2b mice following physiological processing of OVA. OVA-specific 
precursor CTL appeared rapidly in the draining lymph node after 
subcutaneous immunisation with ISCOMS-OVA and these pCTL 
differentiated into effector cells when cultured merely with IL-2, 
indicating the efficiency of priming in vivo.
Phagocytic accessory cells (M<J>) were required for the priming 
of a large proportion of the OVA-specific CTL, as paralysis or 
depletion of these cells produced a marked decrease in the priming 
of OVA-specific CTL in vivo. However, detectable CTL activity 
remained in the absence of M<j>, suggesting that there may be more 
than one pathway of CTL induction utilised by ISCOMS in vivo. The 
CTL responses were entirely dependent on helper T cells, as 
depletion of CD4+ T cells completely abolished priming of CTL 
responses by ISCOMS-OVA. These findings suggest that the 
induction of CTL by ISCOMS is a complicated process, involving both 
phagocytic accessory cells and CD4+T helper cells.
The dependence of the CTL responses on CD4+ T cells, together 
with the potent DTH and humoral responses elicited, suggested that 
the activation of CD4+ Th cells was a critical event in the induction 
of immune responses by ISCOMS. I therefore examined directly the 
priming of antigen-specific CD4+ T cells by ISCOMS-OVA and 
determined if there was any preferential induction of the Th 
subsets. A single subcutaneous immunisation with ISCOMS primed 
strong antigen-specific proliferative responses in the draining 
lymph node. These were entirely dependent on CD4+ T cells and 
purified CD8+ T cells appeared to be unable to proliferate, even in 
the presence of the epitope peptide OVA 257-264 and exogenous 
IL-2. MLN cells proliferated after oral immunisation, but antigen- 
specific proliferative responses could not be detected in ISCOMS
primed spleen cell populations after either oral or parenteral 
immunisation. However, parenteral or oral immunisation with 
ISCOMS primed for substantial amounts of antigen-specific cytokine 
production by spleen cells following restimulation with antigen in 
vitro, indicating efficient dissemination of the initially localised 
response after immunisation with ISCOMS.
ISCOMS primed lymphoid cells produced a characteristic 
pattern of cytokines when restimulated with antigen in vitro, with 
a transient IL-2 response, followed by the later accumulation of 
both IFN-y and IL-5. This evidence that both Thl and Th2 type 
CD4+ T cells were activated by immunisation with ISCOMS 
correlates with the wide range of both humoral and cell-mediated 
immune responses primed by ISCOMS in vivo and is supported by 
the fact that antigen-specific IgGl and IgG2a antibody responses 
were both primed by ISCOMS. The pattern of proliferative and 
cytokine responses induced by feeding ISCOMS was similar to that 
primed by parenteral immunisation, indicating that ISCOMS were 
able to prime a wide range of local and systemic responses, 
regardless of the route of immunisation.
As a vital attribute of any potential vaccine vector is the 
ability to elicit long-lasting specific immunological memory, I 
examined the persistence of immune responses for up to one year 
after prim ary immunisation with ISCOMS-OVA. A single 
subcutaneous immunisation with lO^g protein antigen in ISCOMS 
primed long-lasting memory responses, which included antigen- 
specific DTH and IgG antibody responses in vivo, as well as antigen- 
specific proliferation and cytokine production in vitro . These 
persisted for at least 8-12 months after primary immunisation and 
included both Thl and Th2 type responses, as IL-2 and IL-5
v
responses were both present. The kinetics of all these responses 
were similar, with a marked reduction in magnitude observed 12 
months after priming. Thus, ISCOMS are potent inducers of long- 
lasting immunological memory, which encompasses both B cells and 
Th 1 and Th2 CD4+T cells.
I next went on to examine the properties of the ISCOMS 
themselves which contribute to their adjuvanticity. As the adjuvant 
properties of saponins have been known for some time, it seemed 
likely that Quil A played a crucial role in the activity of ISCOMS. 
However, the range of responses involved had not been studied in 
detail and there had been no comparative studies of Quil A and 
intact ISCOMS. I therefore compared directly the adjuvant effects of 
Qpil A and ISCOMS on a range of local and systemic OVA-specific 
immune responses. Parenteral immunisation with OVA and Qjuil A 
primed systemic antigen-specific DTH, CTL and IgG antibody 
responses in vivo, as well as T cell proliferative activity and Thl 
and Th2-type cytokine production in vitro. In addition, oral 
immunisation with OVA and Qpil A induced local antigen-specific 
intestinal IgA production, together with systemic IgG and CTL 
responses. These findings indicate that, like intact ISCOMS, free Quil 
A allows antigen to gain access to both the exogenous and 
endogenous pathways of antigen processing and presentation in 
vivo. In addition to its effects on the presentation of exogenous 
protein antigen to specific lymphocytes, Quil A also had marked 
effects on innate immune responses including the activation of M<t> 
and NK cells, as well as the non-specific stimulation of regulatory 
cytokines such as IFN-y. However, as 5-10 fold more free Quil A 
was required to elicit the same magnitude of responses as those
elicited by Quil A in ISCOMS, factors additional to Quil A must be 
important for the potent adjuvanticity of intact ISCOMS.
I therefore compared ISCOMS-OVA with OVA incorporated in 
a particulate vector lacking Quil A, biodegradable microparticles 
composed of poly(lactide-co-glycolide) (PLG-OVA). Oral or 
parenteral immunisation with PLG-OVA microparticles primed a 
wide range of humoral and cell-mediated immune responses, both 
locally and systemically, including antigen-specific CTL activity. 
However, the CTL responses induced by ISCOMS were usually 
higher than those induced by PLG microparticles, requiring fewer 
or lower doses of antigen. It was also impossible to detect CTL 
activity in PLG-OVA immunised mice without in vitro restimulation 
with antigen. Interestingly, PLG seemed relatively more efficient 
when given by the oral route and induced good antigen-specific IgA 
responses in the small intestine itself. These findings indicate that 
only part of the adjuvant effect of ISCOMS can be ascribed to their 
particulate nature, supporting my observations on the adjuvant 
properties of free Quil A.
My results thus extend previous observations on the 
induction of immune responses by ISCOMS and highlight their 
potential as oral vaccine vectors of the future. ISCOMS have several 
advantages over existing oral adjuvants, as they combine the 
benefits of a stable particulate structure with a built-in adjuvant, 
Quil A. In addition, they induce an unparalleled range of local and 
systemic immune responses by both parenteral and oral routes and 
if concerns over their safety for admininstration to humans can be 
satisfied, then they may form the basis of future oral vaccines 
against almost any class of pathogenic organism.
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CHAPTER 1: INTRODUCTION
Preface
Vaccination is the most cost-effective form of medical 
treatment and the worldwide eradication of smallpox through 
vaccination is considered one of modern medicine's greatest 
triumphs. Mass immunisation programs have also led to the virtual 
eradication, at least in developed countries, of several other 
diseases associated with significant mortality, including diphtheria, 
polio and measles.
Most of the highly successful vaccines currently available 
were developed before 1970 and, despite the considerable 
advances in our understanding of the immune system which have 
occurred during the intervening period, there are still many 
diseases for which we lack effective vaccines. For example, WHO 
estimates that 300-500 million clinical cases of malaria occur each 
year, resulting in up to 2.7 million deaths (1). Similarly, respiratory 
infections and diarrhoeal diseases remain major causes of mortality 
and morbidity, particularly in children.
An additional problem is that although vaccines such as 
measles or polio can be used effectively in developed countries, 
technical and economic problems impede their widespread use in 
developing world. For instance, the current, highly effective 
measles vaccine is heat-sensitive, making its use difficult in tropical 
countries (2). Finally, the emergence of diseases for which there is 
no currently available therapy, such as HIV and antibiotic-resistant 
tuberculosis, pose major public health risks in both developed and 
developing nations.
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Traditional vaccine research has focussed on the induction of 
systemic immunity through parenteral immunisation. However, 
while this approach may be appropriate against diseases which gain 
acccess to the body through damaged or punctured skin, the 
majority of pathogens infect hosts via mucosal surfaces, particularly 
the respiratory, intestinal and urogenital tracts. Parenterally 
administered vaccines generally do not induce the mucosal immune 
responses required to prevent infection with pathogens 
encountered at mucosal sites (3).
Orally administered vaccines are widely favoured because, in 
addition to inducing local immunity in the intestine, oral 
immunisation may also stimulate immune responses at distal 
mucosal surfaces and can induce widespread systemic immunity. 
The potential of such an approach is illustrated by the success of 
the oral polio vaccine (4). Oral immunisation is also one of the few 
effective means of promoting vertical transfer of immunity from 
mother to infant, via secretory IgA antibodies contained in breast 
milk (5). Oral vaccines have several economical and practical 
advantages, including ease of administration, reduced side-effects 
and the potential for almost unlimited frequency of boosting 
without the need for trained personnel. Furthermore, the avoidance 
of the use of needles eliminates any risks of infection or cross­
contamination and reduces the cost of vaccination. For these 
reasons the development of orally active vaccines was one of the 
major goals outlined by the Children's Vaccine Initiative (CVI) 
initiated by WHO in 1990 (6).
2
1. THE DEVELOPMENT OF EFFECTIVE VACCINES
A) The Induction of Protective Immunity
An effective vaccine must stimulate all forms of the immune 
response which would normally be provoked by the candidate 
pathogen itself. In most cases, this will require activation of more 
than one limb of the immune response, including local and systemic 
antibody responses, cytokine production, and cytotoxic T cells (CTL). 
In order to appreciate the magnitude of this challenge, it is first 
important to consider briefly the different types of immune 
response which may play a role in immunity against infection.
The spectrum of mechanisms employed by microorganisms to 
infect and persist in mammalian hosts is matched by the variety of 
immune effector mechanisms which have evolved to counteract 
such infections.
i) Extracellular infections
Pathogens which inhabit the extracellular milieu are first 
attacked by a combination of non-specific mechanisms, such as 
co m p lem e n t-m ed ia ted  lysis and  phagocy tosis  by 
polymorphonuclear cells (7). If these fail, specific antibodies can 
participate in clearance of infectious agents by neutralization (8, 9), 
opsonization (10, 11) or complement activation, thus promoting 
lysis and phagocytosis (12).
The majority of specific antibody responses are dependent on 
antigen-specific CD4+ helper T cells (Th) (13,14). In turn, activation 
of these CD4+ T cells requires efficient uptake and processing of 
antigens by professional antigen-presenting cells (APC) such as
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macrophages (M<j>) and dendritic cells (DC) (15, 16). These cells 
aquire exogenous antigens via an endocytic pathway, and digest 
and process the antigens with lysosomal enzymes in an acidic 
compartment, resulting in the generation of antigenic fragments of 
around 12-24 amino acids in length (17-20). These peptides are 
then bound by newly synthesized class II MHC molecules which 
transit through the late endosomes on their way to the cell surface 
(21, 22). The resulting cell surface peptide-MHC complexes are then 
recognised by specific CD4+ Th cells which, when activated, provide 
the stimuli necessary to promote the proliferation and 
differentiation of antigen-specific B cells (14, 23). These factors 
include cell-surface molecules such as CD40-ligand (24, 25), as well 
as secreted cytokines like IL-4, IL-5 and IL-6 (26-29). A schematic 
representation of the processing and presentation of exogenous 
antigens is shown in Figure 1.1.
ii) Intracellular infections
The intracellular habitat occupied by most viruses, many 
parasites and some bacteria allows them to evade the humoral arm 
of the immune response. Under these circumstances, specific 
antibody responses are of little use in eradicating primary infection 
and cell-mediated immune (CMI) responses are required. Two main 
effector mechanisms have evolved for this purpose.
Infectious agents which replicate in the cytoplasm or nucleus 
of host cells, such as viruses and some intracellular bacteria and 
parasites, are eradicated via the lysis of infected cells by cytotoxic T 
lymphocytes (CTL) (30-32). These CD8+ T cells recognise 8-10 
amino acid long antigenic peptides expressed in association with 
class I MHC molecules, which, unlike the peptides presented to CD4+
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T cells, are derived from proteins degraded in the cytosol itself, 
probably by the organelles known as proteasomes (20, 33-35). 
These peptides are then transported by specific transporters of 
antigen presentation (TAP) (3 6) into the endoplasmic reticulum (ER) 
where they associate with newly synthesised class I MHC molecules 
and the complexes are then exported to the cell surface (37). A 
schematic representation of the endogenous antigen processing 
processing and presentation pathway is shown in Figure 1.2. Upon 
recognition of the appropriate peptide-class I MHC complex on 
infected cells, the CTL delivers a 'lethal hit', resulting in the death of 
the infected cell (30). This can occur either by directed release of 
cytolytic granules from the CTL to the target cell (31, 32), or by 
crosslinking of the fas molecule on the surface of the target cell by 
its ligand on the CTL surface (fas-L) (32, 38-40). In both cases, 
death of the target cell occurs via the process of apoptosis, in which 
target cell endonucleases produce DNA fragmentation and death 
(30, 41). In this way, infected cells can be killed and the infection 
eliminated rapidly, while neighbouring uninfected cells are 
preserved intact.
Pathogens such as mycobacteria or leishmania, persist within 
cells of the reticulo-endothelial system (M<j> and monocytes), and 
these infections are usually controlled by a chronic inflammatory 
response triggered by the release, from CD4+ T cells, of cytokines 
such as IFN-y and TNF-a (42, 43). These cytokines activate powerful 
microbicidal mechanisms within M<|> and monocytes, leading to the 
destruction of the pathogen (44). As with Th-dependent antibody 
production, these delayed-type hypersensitivity (DTH) responses 
require the presentation of antigens which have been acquired and
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degraded in endocytic cellular compartments and expressed on the 
cell surface in association with class n MHC molecules.
In mice, the subset of CD4+ Th cells which triggers DTH 
responses can be distinguished from that which provides help for 
antibody production, by the pattern of cytokines which each 
produces upon activation (27, 45). The former subset, referred to as 
Thl cells, produce predominantly IL-2, IFN-y, and TNF-a, while the 
latter, designated Th2 cells, produce IL-4, IL-5, IL-6 and IL-10. 
Although it is now clear that these distinct cytokine profiles can 
determine different immune effector functions, the factors which 
enable different organisms to elicit Thl or Th2 responses 
preferentially are not clearly understood and are the focus of much 
current research. It is clear however, that cytokines, APC and the 
local microenvironment as well as the pathogens themselves may 
all play a role (23, 27,45,46).
iii) Interactions between different protective mechanisms
Although the individual responses outlined above account for 
protective immunity against many pathogens, it should be noted 
that in several infections, more than one protective mechanism may 
be required. This is particularly the case with large, multicellular 
organisms such as parasitic worms, which are too large to be 
phagocytosed and often occupy sites not easily accessible to the 
immune system, such as the lumen of the intestine. In these cases, 
both cell-mediated and humoral responses are involved in the 
destruction and/or expulsion of the parasite (47, 48). In other 
instances, the induction, expansion and differentiation of anti­
pathogen CTL responses may be dependent on cytokines derived 
fromCD4+T cells (49-51). Different effector mechanisms may also
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be required for eradicating primary infection and preventing 
reinfection with the same pathogen. This occurs in viral infections, 
such as influenza, where CTL are required to clear primary 
infection, while neutralising antibodies may be important in 
limiting the spread of infection and in preventing subsequent 
reinfection (52).
B) The fIdear Vaccine
It is clear that the immune system of higher vertebrates 
contains a powerful and diverse armoury of protective mechanisms 
which have to be tailored carefully to eradicate primary infections 
and to prevent reinfection by individual pathogens. The ideal 
vaccine will trigger the appropriate protective response required. 
Of particular importance, the vaccine must allow antigen to be 
processed and presented via the appropriate pathway and in 
association with the appropriate class of MHC molecule, in order to 
elicit the necessary effector mechanism(s). The ideal vaccine would 
also be able to provide lorcj-kjshng protection in the genetically 
disparate human population after a single or limited numbers of 
administration. It should also contain a defined protective antigen, 
rather than the entire organism.
Although traditional vaccines have been derived through an 
empirical process of attenuation of live microorganisms, this 
method is not applicable to all pathogens, as it usually requires 
repeated passage through experimental hosts in vivo or long term 
culture in mammalian cells in vitro. Furthermore, such attenuated 
organisms are often poorly characterised and it is not always 
possible to be sure that they are safe for use in vaccines. An
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alternative approach, which forms the background to this thesis, is 
to develop vectors which would allow recombinant proteins to form 
the basis of non-living vaccines. However, as purified protein 
antigens are generally poorly immunogenic (3, 53), some form of 
adjuvant is a vital prerequisite for such a strategy. Unfortunately, 
many of the traditional adjuvants that are used in experimental 
systems, such as Freund’s adjuvant, are too toxic for use in humans. 
Conversely, the only adjuvants curren tly  licensed for 
administration to humans are the alum salts, which generate 
mainly humoral immune responses and do not promote immunity 
at mucosal surfaces (53). Furthermore, most conventional adjuvants 
allow only for antigen presention via the exogenous pathway, and 
do not facilitate the induction of class I MHC-restricted CTL 
responses. Thus, there is currently a great deal of interest in the 
development of safe adjuvants which will promote a full range of 
immune responses. Additionally, such vectors should be stable 
under a wide range of storage conditions, should be easy and 
economical to manufacture and simple to administer. Finally, as I 
have discussed, it would also be extremely advantageous if the 
adjuvant vector could be used for oral vaccination.
2. ORAL IMMUNISATION AND MUCOSAL IMMUNITY
A) General Considerations
Putative oral recombinant vaccines must overcome a number 
of problems additional to those described above. Firstly, the vaccine 
must be able to withstand the harsh environments of the stomach 
and intestine, by being resistant to acid pH and the actions of
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digestive enzymes and bile salts. Secondly, the usual result of oral 
adm inistration of protein antigens is a state of profound 
immunologic unresponsiveness (54, 55). This oral tolerance 
abrogates any local or systemic primary immune response to the 
initial dose of antigen and prevents secondary responses to 
subsequent challenge with the antigen, irrespective of its route of 
administration (54, 55). As it is probably the homeostatic 
mechanism which prevents hypersensitivity to food proteins, the 
phenomenon of oral tolerance represents the single greatest barrier 
to the development of oral vaccines utilising defined protein 
antigens.
The last prerequisite for a new oral vaccine is that it must 
prom ote high levels of protective immunity locally and 
system ically, while ensuring that potentially damaging 
immunopathological reactions do not occur if the antigen is 
subsequently encountered in the small intestine. Unlike most 
parenteral tissues, where inflammatory responses are unlikely to 
cause serious health problems, immunopathological reactions in the 
intestine may have major consequences for the host (54, 55).
B) The Mucosa-Associated Lymphoid Tissue (MALT)
The development of effective oral vaccines must take into 
account our knowledge of the induction of immune responses at 
mucosal surfaces and the possible consequences of stimulating 
mucosal immunity. In man, the mucosal epithelia have a total 
surface area of over 400 square metres, which is more than 200 
fold greater than the surface area of the skin (56). In order to 
protect this large and fragile epithelium, and so prevent disruption
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of essential physiological functions, higher vertebrates have 
developed a complex local immune system.
The mucosal immune system can be divided anatomically and 
functionally into inductive and effector compartments, collectively 
known as the mucosa-associated lymphoid tissue (MALT) (57, 58). 
MALT consists of several components including the gut-associated 
tissue (GALT), bronchial-associated lymphoid tissue (BALT), 
nasopharyngeal-associated lymphoki tissue (NALT), the mammary, 
lacrimal and salivary glands and the lymphoid tissues of the 
Ofogert\Va\. tract and inner ear. All the tissues of the MALT share 
similarties in their organisation and function. MALT is characterised 
by the predominance of local secretory IgA production (59) and by 
the ability of activated lymphocytes from one mucosal surface to 
recirculate and localise selectively in other mucosal surfaces (60). 
This permits immunity initiated in one part of the MALT to protect 
other mucosal sites, hence providing the opportunity to use oral 
vaccination to protect against respiratory pathogens such as 
influenza or RSV.
i) The Gut-Associated Lymphoid Tissue (GALT)
Most of what is known about the nature and function of 
MALT is based on extensive studies of the GALT as a site of 
induction and expression of mucosal immunity (57, 58, 61).
The GALT consists partly of organised lymphoid aggregates, 
represented by the Peyer's patches, appendix, mesenteric lymph 
nodes and solitary mucosal lymphoid nodules. In addition, there are 
substantial numbers of lymphoid cells scattered throughout the 
epithelium and lamina propria of the intestine itself.
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ii) Induction of Mucosal Immune Responses
The major inductive sites for intestinal immunity are the 
Peyer’s patches (PP), first described by Johann Conrad Peyer in 
1677 (61). These clusters of lymphoid tissue are found in the wall 
of the small intestine, from the ileum to the colon and extend 
through the lamina propria and submucosa. On the mucosal surface, 
PP appear as mounds protruding between the intestinal villi and 
consist of secondary lymphoid aggregates covered by a single layer 
of columnar epithelial cells. The PP have a typical secondary 
lymphoid organ structure, with T cell areas and B cell follicles (61) 
(Figure 1.3).
Peyer's patches differ from secondary lymphoid organs 
elsewhere in the body because they lack afferent lymphatics. 
Instead, antigen is sampled directly from the intestinal lumen via 
the overlying epithelium, and thence to adjacent APC and lymphoid 
cells. This function is performed by specialised epithelial cells, 
known as M cells because of the characteristic irregular microfolds 
present on their luminal surface, in contrast to the microvilli found 
on normal enterocytes (62, 63). M cells take up materials from the 
intestinal lumen and transport them to lymphocytes and 
macrophages enfolded in pockets formed by the basolateral 
membranes of the M cells (64). A variety of antigenic structures 
can be taken up by M cells, including particles and macromolecules, 
as well as intact viruses, bacteria and parasites (65). Antigens 
transported by M cells may also pass downward through the basal 
lamina into the lymphoid follicles before being carried into 
mesenteric lymph nodes via draining lymphatics.
The PP contain discrete B cell areas, or follicles, which have 
germinal centres that contain the major source of of surface IgA+ B
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cell precursors, although few IgA plasma cells are found within the 
PP (66). The parafollicular areas of the PP are the T cell areas and 
are also the sites where lymphocytes enter the patch via high 
endothelial venules (HEV). The T cells present in the parafollicular 
regions are virtually all mature ap T cells (67).CD4+ T cells account 
for 50-60% of PP T cells, and some of these are found in the 
germinal centre. The PP also contain many APC, including dendritic 
cells and M<t>, which are found throughout the patch in both the T 
and B cell areas.
Thus, the PP contain all the components required for the 
initiation of immune responses to antigens encountered in the 
lumen of the small intestine.
iii) Effector Arms of the Mucosal Immune System
Upon encountering the appropriate antigen in the PP, 
activated lymphocytes exit the PP via the afferent lymphatics into 
the draining mesenteric lymph nodes (MLN) and hence via the 
thoracic duct (TD) to the bloodstream. Lymphocytes which have 
been activated in mucosal inductive sites show a striking 
predominance to recirculate back to mucosal tissues, particularly 
those associated with expression of effector functions, such as the 
intestinal wall (60, 68, 69). This preferential homing is thought to 
be due to interactions between adhesion receptors selectively 
expressed on mucosal endothelia and unique ligands present on 
lymphocytes. One such adhesion receptor, mucosal addressin cell 
adhesion molecule 1 (MAdCAM-1) is expressed on endothelia in 
mucosal tissues, such as HEV in PP, as well as venules in the 
intestinal lamina propria and in the lactating mammary gland, but 
is not found on HEV in peripheral lymphoid tissues. MAdCAM-1
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binds to the a4p7 integrin molecule (LPAM-1) expressed on the 
surface of lymphocytes activated in mucosal tissues and this 
interaction is thought to play a key role in the homing of effector 
lymphocytes to mucosal tissues (70, 71).
The main effector sites for mucosal immune responses are the 
lamina propria of the gastrointestinal, respiratory and urogenitary 
tracts, as well as the parenchyma of the mammary, salivary and 
lacrimal glands. Both humoral and cellular immune responses can 
be expressed in these tissues.
iv) Secretory IgA: Humoral Immunity at Mucosal Surfaces
The lamina propria of the gut contains 40-60% T cells and 20- 
40% B cells, including many plasma cells (67). The majority (up to 
90%) of these plasma cells synthesize IgA and are responsible for 
the antigen-specific IgA found in external secretions, which is the 
hallmark of mucosal humoral immunity (72).
Secretory IgA contains an IgA dimer held together by a small 
polypeptide known as the J (joining) chain, which forms disulphide 
bonds with the IgA monomers (72). This polymeric molecule is 
secreted intact by mucosal plasma cells and binds specifically to a 
molecule called the poly-Ig receptor expressed on the basolateral 
surfaces of the overlying epithelial cells (Figure 1.4). When the 
poly-Ig receptor has bound a molecule of dimeric IgA, the complex 
is internalised and transported in an endocytic vesicle through the 
cytoplasm of the epithelial cell to its apical surface, a process 
known as transcytosis. At the apical surface the poly-Ig receptor is 
enzymatically cleaved, releasing the dimeric IgA which retains part 
of the poly-Ig receptor bound to its Fc regions. This fragment of the 
poly-Ig receptor, called secretory component, may help to protect
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dimeric IgA from proteolytic cleavage. In this way, IgA is 
transported across epithelia into the lumen of several organs that 
are in contact with the external environment (Fig. 1.4). The poly-Ig 
receptor is also expressed by cells of the hepatobiliary system and 
may contribute to the removal of immune complexes containing 
polymeric IgA from the circulation (73).
Secretory IgA has a number of biological properties, although 
its overall function remains uncertain. It can neutralize several 
viruses, bacteria and toxins, including cholera toxin and the heat- 
labile toxin produced by some strains of Ecoli, LT (74). Protection 
against influenza correlates with levels of neutralising secretory 
IgA antibodies (52, 75). Intranasal administration of specific 
monoclonal IgA also protects against Sendai virus infection in mice 
(76) and intestinal IgA is thought to be the major protective 
mechanism against cholera toxin (74).
By binding to the mucus layer overlying the epithelia, 
secretory IgA can also inhibit the adherence of microorganisms to 
mucosal surfaces and promote agglutination and entrapment in 
mucus, thus preventing colonisation (77). It is particularly efficient 
at preventing bacterial attachment because of its multiple binding 
sites (78, 79). A similar mechanism may also reduce the absorption 
of other dietary and respiratory antigens (80). This function, known 
as immune exclusion, may explain why individuals with IgA 
deficiency have a higher incidence of atopic reactions to 
environmental antigens (81). As noted above, the ability of IgA to 
bind to absorbed antigen and be excreted by the hepatobiliary 
route may also contribute to this process (73). The agglutination, 
neutralization and exclusion of pathogens and antigens by IgA 
represent non-inflammatory mechanisms of protection. In addition,
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IgA possesses poor complement activating properties (82, 83), 
consistent with its role in protecting the fragile epithelia while 
avoiding potentially harmful inflammatory reactions.
Although secretory IgA is by far the predominant Ig isotype 
found in mucosal secretions, there are also small amounts of other 
isotypes present. Polymeric IgM can bind the poly-Ig receptor and 
in humans with IgA deficiency, the production of secretory IgM 
probably compensates (84). IgG is not found in normal intestinal 
secretions, but is relatively abundant in respiratory tract secretions 
and large amounts are found in all mucosal secretions during 
inflammatory conditions (85). Similarly, IgE is normally absent 
from mucosal secretions and is usually only present during 
immediate type hypersensitivity reactions or parasitic infections 
(86).
v) Cellular Immunity at Mucosal Surfaces
Despite the predominance of IgA in mucosal secretions, 
selective IgA deficiency occurs in around 1 in 500 individuals in 
Western populations (81). As the majority of these subjects do not 
suffer serious consequences, additional protective mechanisms 
must operate at mucosal sites. Indeed, all conventional T cell 
subpopulations, as well as some novel ones, are represented in the 
inductive and effector mucosal lymphoid tissues.
The majority of T cells found in PP and lamina propria are 
CD4+ T cells. One of their primary functions is to provide help for 
the induction and expression of secretory IgA responses, with the 
differentiation of surface IgA+ B cells into plasma cells being 
dependent on factors produced by the Th2 subset of CD4+ T cells, 
including IL-5 and IL-6 (26, 87-89). In addition, isotype switching
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of IgM+ B cells to IgA+ B cells is also dependent on T cells, probably 
via the production of TGFp (90). Consistent with these findings, CD4+
T cells secreting Th2 cytokines are abundant in the mucosal lamina 
propria, glandular tissues and PP (91).
Mucosal inductive and effector sites also contain large 
numbers of CD4+ cells of the Thl subset which produce IFN-y (91). 
The precise role of Thl cells in mucosal immunity is not clear, 
although they are presumably im portant in counteracting 
intracellular bacterial and parasitic infections and in assisting the 
development of mucosal CTL responses, through production of IL-2 
and IFN-y. As immunopathological reactions in the intestine are 
often associated with the production of Thl cytokines, including 
IFN-y and TNF-a (92), Thl cell activation must normally be tightly 
regulated. The relative predominance of Th2 type cells in mucosal 
effector sites, together with oral tolerance, may reflect the need to 
avoid inflammatory reactions at these surfaces.
CD8+ T cell responses can also be mounted by the mucosal 
immune system. Antigen-specific CTL have been observed in the PP 
and in lamina propria after oral immunisation with rotavirus or 
reovirus (93, 94) and these protocols also induced CTL activity in 
the systemic lymphoid tissues. Although it is believed that 
mucosally induced CTL are derived from precursor CTL (pCTL) in 
the PP, the pathways of mucosal CTL induction have not been 
elucidated clearly. A better understanding of the induction and 
functional characteristics of CTL in mucosal tissues is necessary in 
order to understand their role in protection against infection.
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vi) Intra-Epithelial Lymphocytes (IEL)
The mucosal immune system also contains a unique 
population of T lymphocytes, known as intraepithelial lymphocytes 
(IEL). IEL are found interspersed between the columnar epithelial 
cells of the villi in the small and large intestine (95) and hence may 
constitute the first line of defense against luminal antigens.
IEL have a number of unique phenotypic characteristics 
which distinguish them from other T cells. The majority («90%) are 
CD8+ T cells, which can be divided into distinct subpopulations 
based on the surface molecules that they express (95-97). In 
rodents and some other species, a high proportion express the y6TcR 
and also express a homodimeric aa form of the CD8 molecule, not 
found on peripheral CD8+ T cells. A substantial proportion of 
murine y5TcR+ IEL are extrathymically derived (98).
IEL also contain CD8+ cells which express the apTcR and these 
can also be subdivided depending on the form of CD8 expressed and 
whether they are of thymic or extrathymic origin. There are also a 
number of other minor populations including CD4+8-, CD4+8+ and 
CD4-8" T cells, each accounting for <10% of apTcR+ IEL.
The exact function of IEL is not known, but one suggestion is 
that they constitute a primitive population specialised for immune 
surveillance of epithelial surfaces (99). In support of this 
hypothesis, it has been shown that IEL exhibit restricted usage of 
particular TcR V region genes, suggestive of a locally expanded 
oligoclonal T cell population (100). In addition, IEL exhibit 
constitutive cytotoxic activity in vitro (101) and there is some 
evidence that they may recognise non classical MHC IB molecules or 
heat shock proteins, which may be expressed by infected epithelial 
cells (102). Other suggestions are that IEL may play a role in oral
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tolerance or in other aspects of local immunoregulation, as they 
produce a variety of cytokines including IL-2, IFN-y, IL-5 and TGF- 
p (91, 103).
vii) Immune Regulation in the Intestine
The mucosal immune system has the task of protecting the 
epithelium, while at the same time avoiding harmful inflammatory 
reactions which may have serious consequences for homeostasis. It 
is continually exposed to a diverse antigenic load and it must 
distinguish food antigens and harmless normal gut flora from 
potentially dangerous pathogens.
In addition to the specific immune mechanisms discussed 
above, mucosal surfaces are also rich in non-specific inflammatory 
cells, such as M<j> and mucosal mast cells. Although these mucosal 
inflammatory responses are designed for protective immunity, 
inappropriate expression of their activities has the potential to 
cause immunopathology. Aberrant inflammatory responses of this 
type are associated with a number of human pathological conditions 
including coeliac disease, Crohn's disease and ulcerative colitis (85, 
92). Recent studies in transgenic mice have confirmed the 
importance of a tight immunoregulatory system to prevent 
immunopathology in normal animals, as targeted depletion of 
cytokines such as IL-2 or IL-10, or of apTcR+ T cells all lead to 
inflammatory bowel-like disease (104-106). Furthermore, other 
animal models make it clear that different subsets of CD4+ T cells 
may normally interact to maintain mucosal homeostasis. Thus CD4+ 
T cells expressing high levels of CD45RB molecule can mediate IBD 
when transferred in isolation into naive immunodeficient 
recipients, while T cells expressing low levels of CD45RB can
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prevent this activity (107). Hence the intestinal epithelium and 
immune system operate in a delicate equilibrium, where alterations 
of one may have profound effects on the other.
The precise factors which determine whether a given antigen 
will induce tolerance or immunity when administered orally are not 
clear, but they remain an important consideration for oral vaccines. 
The nature of the antigen is obviously important, since oral 
administration of soluble ovalbumin induces tolerance, while OVA 
coated onto polyglycoside microparticles, or expressed in live 
bacteria, stimulates active immunity by the oral route (108, 109). 
Antigen dose is also important, as feeding very low amounts (1- 
50fig) of soluble OVA may actually promote systemic priming, while 
high doses (>l-2mg) induce tolerance (55). Other factors, including 
the age and genetic background of the host, the presence of normal 
intestinal flora and the permeability of the intestine, also contribute 
to the uptake and processing of intestinal antigens (55).
3. MODERN APPROACHES TO ORAL VACCINATION
In view of the complex factors underlying the induction and 
expression of mucosal immunity, it is unsurprising that a number of 
different strategies have been proposed as oral vaccines. These 
include live vectors which have been genetically altered to 
attenuate their pathogenicity and to express antigens derived from 
other pathogens in order to elicit protective immunity, as well as a 
variety of non-replicating adjuvant vectors. I shall now review 
some of the main strategies currently employed in this rapidly 
developing field.
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A) Live Vectors for Oral Vaccines
Immune responses to live organisms are generally of greater 
magnitude and of longer duration than those produced by non­
replicating immunogens and are particularly efficacious at eliciting 
cell-mediated immune responses. As noted above, the efficacy of 
the attenuated oral polio vaccine provides a precedent for the use 
of such vectors in mucosal immunisation.
i) A ttenuated Recombinant Bacteria
Many different bacteria have been investigated for their 
potential as vaccine vectors. Attenuated Salmonella are the most 
extensively studied and results obtained from these mutants 
highlight many of the benefits and problems associated with live 
vaccine vectors, particularly those administered orally.
Oral immunisation with avirulent Salmonella strains which 
have been attenuated by mutating genes essential for growth and 
survival in vivo and/or in vitro, such as aroA, purA or op , can elicit 
secretory IgA production, as well as systemic IgG responses and 
CMI responses (110-112). Recombinant Salmonella mutants have 
also had a number of successes as vectors for inducing immunity to 
heterologous antigens from bacteria, viruses and parasites. Oral 
immunisation of mice with such mutants induced protective 
immunity against tetanus, Streptococcus pyogenes and Leishmania 
major (113-115).
A major advantage of enteric pathogens such as Salmonella is 
that they can be administered by the natural route of infection 
(peroral) and interact directly with mucosal associated lymphoid
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tissue (MALT). Salmonellae persist and replicate in the Peyer's 
patches and are also taken up by macrophages in the liver, spleen 
and regional lymph nodes, thus presenting and retaining antigens 
at inductive sites of both mucosal and systemic lymphoid tissues 
(116).
Although attenuated Salmonellae have excellent potential as 
oral vaccine vectors, they are also associated with a number of 
problems. Firstly, the possibility of reversion to virulence in vivo 
must be avoided absolutely and, unfortunately, over-attenuation 
can reduce immunogenicity in vivo. Secondly, it is often difficult to 
obtain stable expression of foreign genes at sufficient levels in 
recombinant Salmonellae and the plasmids are often quickly lost in 
vivo (111). A further disadvatage is that the way in which the 
immune response is polarised by Salmonella itself influences the 
nature of the immune response to the heterologously expressed 
antigen. Although they elicit secretory IgA responses, Salmonellae 
are most effective at promoting systemic Thl type responses, thus 
limiting the range of potential pathogens for which attenuated 
Salmonella vaccines could be adapted (56, 115). Furthermore, the 
ability of Salmonellae to induce antigen-specific CTL responses has 
not yet been clearly demonstrated. In addition, the strong 
responses induced by Salmonellae to themselves may limit the use 
of booster doses. Finally, like all live vectors, attenuated 
Salmonellae may not be sufficiently temperature stable or able to 
survive lyophilization to make them practical vectors in the field.
Although other bacteria are also being investigated as 
possible vaccine vectors, including BCG, Listeria, Shigella and Vibrio, 
most of these show the same disadvantages as Salmonella based
vaccines (56). Most have not been studied to the same extent and 
thus their potential as oral vaccine vectors remains uncertain.
ii) Recombinant Viral Vaccines
Mucosal vaccine delivery may also be accomplished by viral 
agents and these have the added advantage that they should allow 
antigen to be presented to CD8+ T cells. However, very few have 
been examined for their ability to induce mucosal immunity.
Of these, vaccinia virus is one of the best studied and 
recom binant vaccinia viruses containing the rabies virus 
glycoprotein gene (VRG) can immunize a variety of wild animal 
species when adminstered orally (117,118). This approach is likely 
to be an important future strategy for eradicating rabies from wild 
anim al reservoirs. Intranasal or oral immunisation with 
recombinant vaccinia virus expressing the F glycoprotein of 
respiratory syncytial virus (RSV F-Gp) also induces protective 
immunity in rats (119). However, the major drawback with the 
current vaccinia vectors is their reactogenicity and the risk of 
disseminated disease in immunocompromised individuals (120).
Oral or intranasal immunisation with a num ber of 
recombinant adenovirus vaccines has also been shown to induce 
protection against rabies glycoprotein, vesicular stomatitis virus 
(VSV) Gp and hepatitis B virus surface antigen (121-123). However, 
there are concerns over the potential oncogenicity of adenoviruses, 
while pre-existing immunity within human populations may limit 
their effectiveness (124). Not surprisingly, poliovirus has also been 
explored as a vaccine vector. Despite the small size of its genome 
limiting the size of foreign genes which can be inserted, 
heterologous antigen fragments of up to 400bp can be expressed in
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poliovirus (125). Mucosal immunisation of a primate with one such 
recombinant was able to induce secretory IgA and systemic IgG 
responses specific for the heterologous antigen (125). Aside from 
these isolated reports, the use of viral vectors for mucosal 
immunisation is still in its infancy and even less is known about 
other potentially appropriate mucosal virus systems, such as 
rotaviruses and herpesviruses.
B) Non-Replicating Vectors for Oral Immunisation
The disadvantages of live vaccine vectors outlined above, 
together with technological advances permitting the identification 
and manufacture of microbial antigens which are the target of 
successful immune responses, have enhanced interest in the use of 
non-viable antigen delivery systems as vaccine vectors.
i) Particulate Delivery Systems for Oral Immunisation
It has been known for some time that particulate antigens are 
more potent inducers of immune responses than soluble antigens 
and this is also true of orally administered antigens (126, 127). 
There are a number of factors which may explain why particulate 
antigens are more effective oral immunogens than soluble antigens 
(128). Firstly, macromolecular complexes may survive better in the 
harsh environments encountered following ingestion. In addition, 
particulates may be absorbed by M cells with greater efficiency 
than soluble molecules, thus increasing their concentration in 
mucosal inductive sites and avoiding the induction of oral tolerance 
which occurs to soluble antigen (129).
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ii) Liposomes
A variety of vectors of this type have been explored, of which 
liposomes are the most extensively studied. These bilayered 
phospholipid membranes have a number of additional theoretical 
advantages such as biodegradability, the ability to be lyophilized 
and freeze-dried and the potential for the incorporation of 
additional targetting agents and adjuvants (128, 130). The 
immunoentandfg properties of parenterally administered liposomes 
are probably related to their ability to promote phagocytosis by 
professional APC (131, 132), but the precise mechanisms by which 
they present antigen to host cells for the induction of immune 
responses requires further investigation. Similarly, the potency of 
liposomes as oral vaccine vectors is controversial, and although the 
induction of antigen-specific IgA has been reported (133), little is 
known on the the induction of cell-mediated immune responses 
after oral administration of liposomes. Finally, although liposomes 
are relatively easy to manufacture, it is possible that the 
immunogenicity of some antigens may be altered by entrapment 
within liposomes.
iii) Biodegradable Microparticles as Oral Vaccine Vectors
These are microspheres constructed from synthetic 
biodegradable polymers into which antigens can be entrapped. The 
best characterised are the poly(D,L-lactide-co-glycolide) (PLG) 
microspheres which degrade slowly in vivo, via hydrolysis, to yield 
the biocompatible products, lactic acid and glycolic acid (134). The 
degradation rate of PLG copolymers can be adjusted by altering 
their size and/or lac tide to glycolide ratio (135). They have been 
used safely in humans for over 30 years as resorbable sutures and
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surgical clips and recently attention has focussed on their potential 
as drug and antigen delivery systems.
Parenteral immunisation with OVA or staphylococcal 
enterotoxin B (SEB) entrapped in PLG microparticles elicited serum 
IgG responses equivalent in magnitude to those induced by these 
antigens in complete Freund’s adjuvant (108, 136). Furthermore, 
oral immunisation with these microparticles induced both antigen- 
specific secretory IgA and systemic IgG responses (137, 138). 
Interestingly, fluorochrome-containing m icroparticles were 
detected sequentially in the PP, MLN and spleen after oral 
administration (137), suggesting that they can deliver antigens to 
both mucosal and systemic lymphoid tissues.
One possible problem with microparticle-based vaccines is 
that during the construction process, antigens are subjected to 
potentially damaging conditions including exposure to organic 
solvents and high shear, which may influence their 
immunogenicity. Finally, as with liposomes, the cell-mediated 
immune responses induced by PLG microparticles, particularly 
following oral immunisation, have not yet been well defined and 
this area is investigated more fully in chapter 8 of this thesis.
iv) Non-Particulate Adjuvants for Mucosal Immunisation
Despite the apparent advantages of particulate vectors, most 
practical immunisation regimes require use of an adjuvant which 
non-specifically stimulates the immune system as well as 
enhancing uptake or presentation. However, only a limited number 
of these substances have shown reproducible adjuvant activity 
when administered orally.
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v) Cholera Toxin and Escherichia coli Heat-Labile Toxin
The most potent non-viable mucosal adjuvants are cholera 
toxin (CT), the exotoxin produced by Vibrio cholerae, and the 
closely related heat-labile enterotoxin (LT), produced by several 
strains of Ecoli.
These molecules are composed of 5 binding (B) subunits 
which form a ring structure into which a toxic-active (A) subunit is 
inserted (139). The CT-B subunits bind to the GM1 ganglioside 
expressed on intestinal epithelial cells resulting in translocation of 
the CT-A subunit into the cell (140). CT-A has ADP-ribosylating 
activity, which activates adenylate cyclase leading to an increase in 
intracellular cAMP in the affected cell (141). This stimulates the 
electrolyte and fluid secretion responsible for the potentially fatal 
diarrhoea found in cholera.
Unlike most proteins, CT is highly immunogenic when given 
orally and can also promote secretory IgA responses to co­
administered antigens (142, 143). In addition, CT can prime for 
antigen-specific T cell proliferative and cytokine responses, both 
locally and systemically after oral administration and is effective 
by the intranasal route (142-145). The responses primed by CT are 
long-lasting, persisting for up to 18 months after a single oral 
immunisation (146).
Toxicity is the major obstacle to the use of CT as an adjuvant 
in humans, with oral administration of as little as 1-5 ng CT able to 
cause severe diarrhoea (147). Although considerable effort has 
been devoted into evaluating the mucosal adjuvant potential of the 
non-toxic CT-B subunit, conflicting results have been reported (143, 
145) and current evidence suggests that this agent has no inherent 
adjuvant effect (148). Although this problem may be overcome by
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covalently linking CTB to antigen, this technology is complex and 
may not be appropriate to many antigens (148).
The mechanisms responsible for the adjuvant effects of CT are 
also controversial and complicated by the fact that CT may directly 
affect a number of cell types including B and T cells, M<J> and 
enterocytes as well as increasing gut permeability (149-152). 
Furthermore, the spectrum of immune responses primed by CT may 
be biased toward Th2 types (153-155). Together, these problems 
indicate that the use of CT as an oral adjuvant must remain 
questionable.
vi) Other Soluble Mucosal Adjuvant Molecules
Few other compounds with systemic adjuvant activity have 
been examined as oral adjuvants. Oral administration of muramyl 
dipeptide (MDP), the smallest structural component of the 
mycobacterial cell wall that retains adjuvanticity, has been shown 
to stimulate non-specific immune mechanisms and also to augment 
specific mucosal immune responses to fed antigens (156, 157). 
Avridine is a synthetic lipoidal amine which is able to augment 
secretory IgA responses when given intraduodenally (158), but its 
ability to stimulate systemic immunity when administered 
mucosally is unclear.
In summary, although there appear to be many living and 
non-viable vectors with the potential to function as mucosal 
adjuvants, much further work is required to elucidate those with 
realistic vaccine potential and no toxicity. For these reasons the 
search continues for novel alternative oral vaccine vectors.
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4. ISCOMS AS VACCINE VECTORS
A) Definintion and Discovery of ISCOMS
Immunostimulating complexes (ISCOMS) were first described 
by Morein and colleagues in 1984 (159). Upon mixing solublised 
membrane viral glycoproteins with saponin (Quil A), in the 
presence of detergent, they observed the formation of hydrophobic 
matrices of around 30-40nm in diameter with a characteristic cage­
like structure (159), see also Figure 2.1. Initial studies showed that 
these ISCOMS were far more potent inducers of antigen-specific IgG 
antibodies than micelles formed from the viral glycoproteins alone.
ISCOMS form spontaneously when detergent is dialysed out of 
a lipid mixture in the presence of QjluI A at or above its critical 
micellar concentration (0.03%) (160). Cholesterol is an essential 
component of such ISCOMS and most preparations also contain a 
less rigid lipid such as phosphatidyl choline or phosphatidyl 
ethanolamine. The constituents of the ISCOM are held together by 
hydrophobic interactions, with the binding between cholesterol and 
Quil A crucial for ISCOM formation (161, 162). Electron microscopy 
shows that ISCOMS are composed of 20 ring-like subunits of about 
12nm in diameter which form an icosahedral structure (163). The 
resulting honeycomb-shaped micelles have hydrophilic pores, 
through which small water-soluble molecules may diffuse into the 
interior of the ISCOMS particle (163).
Most early studies of ISCOMS used viral or bacterial 
membrane glycoproteins which interacted readily with the other 
hydrophobic constituents of ISCOMS. However, more recently, 
strategies have been developed to allow construction of ISCOMS
containing a variety of non-hydrophobic protein antigens. For 
example, acidification has been used to expose hydrophobic groups 
on BSA, allowing its successful incorporation into ISCOMS (164). The 
approach used by our laboratory has been to render globular 
proteins, such as OVA, hydrophobic by addition of palmitic acid 
residues, thus facilitating its incorporation into ISCOMS (165).
Once formed, ISCOMS are very stable structures, which 
withstand low pH conditions and are not degradable by bile salts 
(166). Furthermore, they are amenable to lyophilization and 
freezing and can be produced in large quantities (167), making 
them good candidates for use as potential vaccine vectors which act 
by the oral route.
B) In d u c tio n  of Immune Responses by P a ren te ra l 
Immunisation with ISCOMS
As noted above, initial experiments using ISCOMS 
concentrated on viral membrane proteins as antigens and their 
immunogenicity was monitored only by examining their ability to 
induce serum antibody responses (159). However, as ISCOM 
technology has advanced over the last decade, a great many 
different types of antigens have been incorporated into ISCOMS and 
evaluated for their ability to provoke a range of different 
protective immune responses.
Many studies have demonstrated the induction of specific 
antibodies after parenteral immunisation with ISCOMS containing 
antigens from many viruses, including FeLV (168), HSV-1 (169), 
BHV-1 (170, 171), influenza (172, 173) and CDV (174), as well as 
surface antigens from E. coli and B. abortus (175, 176) and parasite
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antigens from Toxoplasma and Trypanosoma cruzi (177, 178). The 
biological relevance of ISCOMS-induced antibodies has been 
confirmed by their virus neutralising capabilities in vitro and/or by 
the demonstration of protection against subsequent challenge with 
the intact pathogen in vivo (159, 168-172, 174, 176, 178). In 
addition, ISCOMS incorporated antigens induce the production of all 
antibody isotypes, including IgM, IgG subclasses and IgA (179, 
180).
In contrast to the numerous reports on humoral immunity, 
the induction of cellular immune responses by ISCOMS has been 
less well characterised, although those studies which have 
examined CMI have reported positive findings. Mice immunised 
with ISCOMS containing the fusion (F) protein from measles virus 
exhibited specific DTH responses in vivo and virus-specific Th cell 
clones could be generated from these mice (181). Similarly, 
splenocytes isolated from mice primed with influenza virus 
proteins in ISCOMS secreted IL-2 and mounted antigen-specific 
proliferative responses when restimulated with the same ISCOMS in 
vitro (182). Together with the range of antibody isotypes, these 
findings suggest that ISCOMS are able to prime CD4+ T cells in vivo.
One unusual property of ISCOMS is their ability to elicit 
antigen-specific CTL responses against incorporated protein 
antigens. This was first demonstrated in studies in mice primed 
twice intranasally with influenza virus proteins in ISCOMS, which 
showed a 10-fold increase in antigen-specific CTL precursor 
frequency being observed in lung cells (183). More recently, it has 
been shown that parenteral immunisation of mice with ISCOMS 
containing HIV-1 gpl60 or influenza haemagglutinin (HA) elicits
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antigen-specific CTL responses and these were confirmed to be due 
to MHC class I-restricted CD8+T cells (184).
Thus ISCOMS provoke a wide range of humoral and cellular 
immune responses in vivo, including class I MHC-restricted CD8+ 
CTL activity.
C) Experimental Models of Protection Using ISCOM-Based 
Vaccines
The potential relevance of these findings to the development 
of successful vaccines has been highlighted by studies in mice, 
showing that parenterally administered ISCOMS-based vaccines 
elicit protection against many experimental viral infections, 
including rabies (185), influenza virus (172, 173), herpes simplex 
virus 1 (169) and measles (181, 186). Protection has also been 
achieved with antigens derived from other types of pathogens, with 
ISCOMS containing the porin and O-polysaccharide antigens from 
Brucella abortus protecting against challenge with virulent B. 
abortus (176). Furthermore, ISCOMS incorporating antigens from 
the extracellular parasite Trypanosoma cruzi, completely protect 
mice against a lethal challenge with virulent trypanosomes (178).
ISCOMS induce protective immunity in a range of different 
mammalian species, including rabbits (170), cats (168), dogs (174, 
185), seals (187), sheep (188), pigs (189) and cattle (171), while 
there is now a commercially available ISCOMS-based vaccine 
against equine influenza virus (167, 172). Of particular note, 
ISCOMS have been found to induce protective immunity against 
experimental retroviral infections. Thus, ISCOMS containing the 
gp70/85 envelope protein of feline leukaemia virus (FeLV) induce
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protection in cats (168), while rhesus monkeys immunised with a 
SIV-ISCOM preparation were protected against challenge with live 
SIV (190).
Taken together, these studies show tha t parenteral 
immunisation with ISCOMS can induce protective immunity against 
a variety of pathogenic agents in a range of mammalian hosts and 
have raised interest that ISCOMS-based vaccines could be used to 
vaccinate against lentivirus infections in primates.
D) Rationale for Using ISCOMS as Oral Vaccine Vectors
Although the results above highlighted the potential of 
ISCOMS as vaccine vectors, most studies only assessed their 
immunogenicity when administered parenterally.
However, when I began this study a number of factors 
suggested that ISCOMS might also be effective oral vaccine vectors. 
Firstly, the oral adjuvant effects of Quillaja saponins had been 
known for some time (191-194). Mice fed an inactivated rabies 
vaccine mixed with saponin had enhanced serum neutralizing 
antibody production, lymphocyte proliferation and CTL activity, 
compared with mice fed the vaccine alone (191, 192, 194). 
Furthermore, feeding saponin increased the ability of spleen cells to 
transfer resistance to intracerebral challenge with rabies virus 
(192) and greatly potentiated the efficacy of an intraperitoneally 
administered inactivated rabies vaccine (193).
ISCOMS themselves had a number of properties that 
suggested they might be effective oral immunogens. As noted 
above, they are extremely stable structures, resistant to both the 
low pH conditions and to the degradative actions of bile salts that
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they would encounter in the gastro-intestinal tract (166). 
Furthermore, their particulate nature may facilitate their uptake by 
M cells in the Peyer's patches, thus enhancing the induction of 
mucosal immune responses (128). Finally, ISCOMS had been shown 
to prime local and systemic humoral and cell-mediated immune 
responses when administered intranasally (179, 183) o r 
intravaginally (180)
The final consideration which suggested the oral route might 
be appropriate for delivery of ISCOMS was that this may decrease 
the toxicity commonly associated with saponin-based adjuvants. 
Saponins are surface active compounds which bind to free or 
membrane-bound cholesterol (162, 195). As a result they can be 
strongly haemolytic, creating pores of around 8nm diameter in 
biological membranes (162, 196). However, the toxicity of saponins 
is much reduced when given orally (194, 197) and indeed saponins 
occur naturally in many food plants and are widely used as food 
additives (198).
For these reasons, we thought it important to investigate 
directly the ability of ISCOMS to act as oral vaccine vectors.
E) Mechanisms of Adiuvanticitv of ISCOMS
For vectors which have proved to be so efficacious in such a 
wide variety of animal models, surprisingly little is known about 
the cellular and chemical basis of their adjuvant activities or how 
they induce such a range of immune responses in vivo. The potent 
humoral responses described above indirectly suggest that ISCOMS 
allow for processing of incorporated antigens via the endocytic 
pathway, leading to the induction of CD4+ T cells and subsequently,
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the activation and differentiation of antigen-specific B cells. 
However, aside from the few isolated reports describing spleen cell 
proliferation and IL-2 production (182) and generation of virus- 
specific CD4+T cell clones (181), there has been little direct analysis 
of how ISCOMS can prime CD4+T cells in vivo.
Similarly, the novel ability of ISCOMS to promote the 
induction of CTL responses directed against exogenous protein 
antigens (183, 184) suggests that incorporation of protein antigens 
within ISCOMS facilitates their entry into the class I MHC processing 
and presentation pathway, but how this occurs is not yet known. 
Therefore the processing and presentation of proteins incorporated 
within ISCOMS is clearly an area which merits further study.
In addition to host factors, there is also little known about the 
properties of the ISCOMS themselves which are responsible for 
their adjuvant effects. The precise roles of Qjail A and of the 
physical structure of the ISCOMS in adjuvanticity is not clear. As 
outlined above, the adjuvant properties of saponins have been 
known for some time but the mechanisms responsible have not 
been well defined. In addition to the adjuvant effects of orally 
administered saponins, it has also been reported that parenteral 
administration of Quil A can enhance antibody responses to both T- 
dependent and T-independent antigens (199, 200). Interestingly, 
the augmentation of antibody responses to T-independent antigens 
was also observed in nude mice (200), suggesting that Quil A may 
have direct adjuvant effects on B cells.
Whether the inherent toxicity of Quil A can be completely 
separated from itfs adjuvanticity is also not yet clear. However it is 
encouraging to note that Quil A can be separated by reverse phase 
chromatography into over 20 distinct fractions (201), two of which,
i
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QS-7 and QS-21, augmented antibody responses to a nominal 
protein antigen to the same degree as conventional adjuvants such 
as IF A and CFA (201). Furthermore, no significant toxicity was 
observed after parenteral administration of the purified fractions. 
Whether these fractions are able to enhance cell-mediated immune 
responses, retain the ability to form ISCOMS, or are effective when 
given orally are all areas requiring further attention in order to 
assess their suitability as oral vaccine vectors.
7. AIMS OF THIS STUDY
The first aim of this study was to examine the efficacy of 
ISCOMS as oral vaccine vectors, by assessing the induction of local 
and systemic immune responses after oral or parenteral 
immunisation.
ISCOMS containing the protein antigen ovalbumin (ISCOMS- 
OVA) were used for this purpose for the following reasons. Firstly, 
OVA is an immunologically well characterised protein antigen 
which was inexpensive and readily available from commercial 
sources. Secondly, it had been extensively utilised in this laboratory 
as an oral antigen and the techniques for assessing local and 
systemic OVA-specific humoral and cellular immune responses 
were well established. Lastly, the availability of an OVA- 
transfected H-2b cell line (EG7.OVA)(202) made it possible to 
examine antigen-specific CTL responses induced by ISCOMS-OVA. 
The immune responses induced by oral or paren teral 
administration of ISCOMS-OVA form the basis of Chapter 3 of this 
thesis.
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The second important aim of this thesis was to look at the 
mechanisms involved in the induction of immune responses by 
ISCOMS. In particular, I wished to examine the effects of ISCOMS on 
the induction of T cells of both the helper (CD4+) and cytotoxic 
(CD8+) phenotype, as this area had received little previous 
attention. By virtue of their ability to prime antigen-specific CTL 
responses, ISCOMS offered an ideal model to study the induction of 
CTL responses to an exogenous protein antigen. The characterization 
of the CTL primed by ISCOMS-OVA, and of the mechanisms 
involved in their induction, is described in Chapter 4.
As it is now well established that CD4+Th cells play a key role 
in the induction and regulation of many immune responses, I also 
examined whether ISCOMS were able to prime these cells directly. 
Furthermore, as the actions of activated CD4+ Th cells are largely 
governed by the pattern of cytokines which they secrete, I also 
explored the nature of the CD4+ T cell response in terms of both 
Thl and Th2 subpopulations of these cells. Chapter 5 details the 
priming of CD4+T cells by ISCOMS.
In the second part of this study, I explored additional aspects 
of ISCOMS, which although not directly concerned with the nature 
of immune responses induced by ISCOMS, were relevant to vaccine 
development. A vital prerequisite for any successful vaccine vector 
is that it is able to induce long lasting immune responses. As 
previous studies had not examined whether ISCOMS were capable 
of this, I decided to look at the longevity of immune responses 
primed by ISCOMS. The results of these experiments are described 
in Chapter 6.
As noted above, the factors of the ISCOMS themselves which 
are important for their adjuvant properties are not yet clear.
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However, it appeared possible that many of these activities could 
have been contributed by the saponin adjuvant Quil A, which is an 
essential constituent of ISCOMS. Therefore, in an attempt to 
examine whether the physical structure of the ISCOMS played a key 
role in their adjuvanticity, I analysed the role of Q.uil A in the 
adjuvanticity of ISCOMS. This is described in Chapter 7.
Finally, ISCOMS are one of many different vectors which are 
currently under evaluation as potential oral vaccine vectors. It is 
therefore important to compare these putative vectors in order that 
the best can be selected for further development. Chapter 8 of this 
thesis describes a study in which I compared the oral adjuvant 
properties of ISCOMS, with another oral vaccine vector which is 
attracting much current interest, poly-lactide-co-glycolide (PLG) 
microparticles.
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Schematic representation of class II MHC processing and 
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Schematic view of a typical Peyer?s Patch. Antigen is sampled 
from the gut lumen by M cells, passed down through the Peyer's 
patch and via the draining lymphatics to the MLN.
FAE = Follicle-associated epithelium.
GC = Germinal centre.
TCA = T cell area.
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CHAPTER 2: MATERIALS AND METHODS
Animals
Female BALB/c (H-2d) and C57B1/6 (H-2b) mice obtained from 
Harlan Olac Ltd (Bicester, Oxon) were maintained in the Joint 
Animal Facility, University of Glasgow and were normally used 
when 6-10 weeks old.
All animals had access to standard rodent pellets containing 
no OVA and water ad libitum.
A naesthesia
Procedures such as footpad injection and eye bleeding were 
carried out under light anaesthesia using 5% Halo thane BP (Rhone 
Merieux Ltd, Harlow, Essex).
Antigens and Mitogens
Ovalbumin (OVA, Grade V) and Concanavalin A (Con A) were 
obtained from Sigma Chemical Co. (Poole, Dorset).
The ovalbumin peptides OVA 111-122 and OVA 258-276 
were purchased from Multi Peptide Systems (San Diego, U.S.A.), 
while the octameric peptide OVA 257-264, was purchased from 
Medprobe A.S. (Oslo, Norway). Peptides were diluted to ImM in 
dH20 and stored at -70°C until required.
Heat-aggregated OVA (HAO) was prepared by heating a 2% 
(w/v) solution of OVA in saline (Baxter Healthcare Ltd, Thetford, 
Norfolk) at 70°C for 60min in a water bath. After centrifuging, the
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supernatant was then removed and the precipitated OVA washed 
with cold (4°C) saline at 450g for lOmin. The HAO was resuspended 
at 20mg/ml in saline and stored at -20°C until required. Before 
challenge of mice in vivo, the HAO was diluted to 2mg/ml in saline 
and sonicated for 20min to give a colloidal suspension.
A djuvants
Quil A ('Spikoside', Iscotec AB, Lulea, Sweden) was kindly 
provided by Prof. Bror Morein (Dept, of Vet. Med. Microbiology, 
Swedish University of Agricultural Sciences, Uppsala, Sweden). Qpil 
A was stored at 4°C and dissolved in saline before being mixed with 
OVA solution immediately prior to immunisation.
Complete Freund's adjuvant (CFA) was purchased from Difco 
(Detroit, Michigan, U.S.A.) and was emulisified with an equivalent 
volume of antigen in PBS immediately prior to immunisation.
Preparation of ISCOMS Containing OVA
ISCOMS containing OVA (ISCOMS-OVA) were prepared using a 
slightly modified method of that described previously (165, 203)
As ISCOMS are lipophilic particles composed of lipids and Quil A, 
non-hydrophobic proteins such as OVA are not incorporated 
spontaneously. Thus, in the procedures used here, OVA was first 
palmitified using a succinimide esterification reaction to attach ^ 
hydrophobic palmitic acid groups. This facilitates incorporation into 
ISCOMS, while maintaining the native structure and antigenic 
characteristics of the OVA. The palmitified OVA was then mixed
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with the lipids cholesterol and phosphatidyl choline in the presence 
of Qpil A allowing spontaneous formation of ISCOMS-OVA.
i) Palmitification of OVA
20mg OVA dissolved in 2.5ml of 50mM carbonate buffer (pH 
9.0) was passed through a Sephadex PD10 column (Pharmacia, 
Uppsala, Sweden) to remove any low molecular weight 
contaminants. Intact OVA was then eluted with 50mM carbonate 
buffer and 0.2ml fractions assayed for protein content by the 
Bradford assay (see below). The protein-containing fractions were 
pooled and adjusted to lmg/ml OVA by dilution in carbonate buffer 
containing 5% (w/v) sodium deoxycholate (BDH Ltd, Poole, Dorset) 
and 10% (v/v) dimethyl sulfoxide (DMSO, Sigma).
Purified OVA was then palmitified by the addition of 314^1 of 
N-(palmitoyloxy) succinimide solution (NPS, Sigma, dissolved at 
lOmg/ml in DMSO) to 20mg OVA (lmg/ml), giving a molar ratio of 
20 palmitic acid molecules to each protein molecule. The NPS 
solution was added slowly, in 25^1 aliquots, with constant stirring 
and heating in order to prevent precipitation and the mixture was 
then incubated overnight at 37°C in a shaking water bath with a 
stroke rate  of 100/min. 1ml of 1M Tris(hydroxymethyl) 
methylamine (TrisHCl, pH8.5) was then added and the mixture 
incubated for a further 30min at 37°C. By providing free amino 
groups, excess TrisHCl prevents further palmitification of the 
protein.
Free palmitic acid was then separated from the palmitified 
protein by ultracentrifugation. First, sucrose (BDH) was added to the 
protein/NPS mixture to a final concentration of 5% (w/v) and 4ml 
aliquots of this solution were then overlaid on to 6ml of 40%
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sucrose in phosphate buffered saline (PBS) in Ultraclear tubes 
(Beckman Ltd, High Wycombe, Bucks.). 3ml of PBS containing 2% 
(w/v) decanoyl-N-methylglucamide (Mega-10, Sigma) was overlaid 
on to the top of each tube, which were then centrifuged at 100,000g 
for 4hr at 4°C using a SW41.14 rotor in a Beckman ultracentrifuge. 
The top PBS layer containing free palmitic acid was then discarded 
and the palmitified OVA was harvested from the 5% sucrose layer.
ii) Preparation of ISCOMS-OVA
A lipid mixture containing phosphatidylcholine and 
cholesterol (both Sigma) was prepared by dissolving 50mg of each 
lipid in 1ml chloroform (Aldrich Chemical Co., Poole, Dorset) and 
then adding 5ml of dH20 containing 20% (w/v) Mega-10. The 
ch loro  form was then evaporated under a stream of N2 until the 
solution cleared, giving a final concentration of lOmg/ml of each 
lipid. The resulting lipid mixture was stored at -20°C until required.
To prepare ISCOMS-OVA, the lipid mixture was added to the 
palmitified OVA solution to a final concentration of 0.5mg/ml, and 
Quil A was then added at a final concentration of 0.1% (w/v). The 
resulting mixture was sonicated for 15min before being transferred 
to dialysis tubing (Visking; Medicell International Ltd, London) and 
dialysed extensively against 50mM TrisHCl or PBS. Dialysis was 
performed for 4-5 days at 20°C against 4 litres of buffer, which was 
changed every 12hr. The formation of ISCOMS was indicated by a 
slightly cloudy appearance of the dialysate and was confirmed by 
electron microscopy (EM).
The ISCOMS particles were separated from unincorporated 
reaction products using a discontinous sucrose gradient, prepared in 
Ultraclear tubes by overlaying 4ml of 10% sucrose in PBS on to 4ml
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of 40% sucrose in PBS. The mixture containing ISCOMS was then 
overlayed on to the 10% sucrose and centrifuged at 100,000g for 
16hr at 4°C using a SW41.14 rotor and a Beckman Ultracentrifuge. 
The ISCOMS were harvested from the interface between the 10% 
and 40% sucrose layers and then dialysed for 24hr against 4 litres 
of PBS to remove the sucrose.
After removal of aliquots for EM analysis and protein assay, 
the ISCOMS were sterilised by filtration through a 0.2nm filter 
(Acrodisc, Gelman Sciences, Ann Arbor, U.S.A.) and stored at -20°C 
until use. The ISCOMS-OVA used in this study were 30-40nm in 
diameter (Figure 2.1) and contained OVA and Quil A at a ratio of 
10:1(165,203).
iii) Estimation of Protein Content using Bradford’s Assay
The concentration of OVA in samples of purified proteins and 
ISCOMS-OVA was estimated using Bradford’s assay (204). 20^1 
aliquots of test samples were added to 180^1 Bradford's reagent 
(Coomassie Blue Dye in 55% phosphoric acid with 15% methanol, 
diluted 1:5 in CIH2O, Bio-Rad, Hemel Hempstead) in 96 well 
microtitre plates (Falcon, Becton Dickinson, Cowley, Oxford). After 
10-15min incubation at room temperature, the O.D. 570nm of the 
samples was read in an MR5000 automatic plate reader (Dynatech 
Laboratories Ltd, Billingshurst, West Sussex) and the concentration 
of OVA was calculated by comparison with a standard curve 
constructed using dilutions of OVA in PBS.
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Electron Microscopy
Electron microscopical (EM) analysis of ISCOMS was 
performed by Mrs Jane Hare (Dept, of Pathology, Western 
Infirmary, Glasgow). The ISCOMS were negatively stained with 3% 
phosphotungstic acid (pH6.6) and analysed on a Philips CM10 
transmission electron microscope (TEM) at a final magnification of 
73000x.
Preparation of OVA-Containing Microparticles
Microparticles were prepared in the laboratory of Dr. Derek 
O'Hagan (Department of Pharmaceutical Sciences, University of 
Nottingham) using a solvent evaporation technique as described 
previously (205). Briefly, a solution of poly(D,L-lactide-co-glycolide) 
polymer (PLG, Resomer RG503, 50:50 lactide:glycolide ratio; 
Boehringer, Ingleheim, Germany) in dichloromethane (HPLC Grade, 
May and Baker, Dagenham) was emulsified with an OVA solution in 
dH20 using a Silverson homogeniser (Silverson Machines Ltd, 
Chesham). The resulting water-in-oil emulsion was then added to a 
much larger volume of an aqueous solution of polyvinyl alcohol 
(PVA, 88% hydrolysed, Aldrich) and homogenised to produce a 
stable water-in-oil-in-water emulsion. This was then stirred 
overnight at room temperature to allow solvent evaporation, with 
resultant microparticle formation. Microparticles were collected by 
centrifugation, washed three times to remove non-entrapped OVA 
and freeze dried. The protein content was determined in a 
bicinchonic acid assay (Sigma) after extraction of the protein as 
described previously (206). The mean particle size as determined
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by photon correlation spectroscopy was 660nm volume mean 
diameter (VMD, Figure 2.2).
Maintenance of Cell Lines in vitro
EL4 cells (a thymoma of C57B1/6 origin), P815 cells (a 
methylcholanthene-induced mastocytoma of DBA/2 origin) and 
YAC-1 cells (a thymoma of A strain origin) were maintained in 
RPMI 1640 medium containing 10% heat-inactivated foetal calf 
serum (FCS), lOOU/ml penicillin, lOO^g/ml streptomycin, 1.25ng/ml 
fungizone and 2mM L-glutamine, (all Gibco BRL, Paisley, Scotland; 
"complete RPMI") at 37°C in 5% CO2 in air in a humidified incubator.
EG7.0VA cells were obtained from Dr M. Bevan (University of 
Washington, Seattle, U.S.A.). These were derived from EL4 cells 
transfected with a single copy of a plasmid containing a cDNA copy 
of the chicken OVA mRNA (202). As this plasmid also carries a 
neomycin resistance gene, OVA-expressing cells were selected for 
in culture by maintenance in complete RPMI medium, 
supplemented with 400ng/ml Geneticin (G418 sulphate, Gibco BRL).
All cell lines were subcultured every 2-3 days by adding 1- 
2ml of cell suspension to 10ml of fresh medium and were 
subcultured 2 days before being used as in vitro targets, to ensure 
that the majority of cells would be in the log phase of growth.
Assessment of OVA-Expression by EG7.QVA cells
Flow cytometric (FACS) analysis was used to monitor the 
continued expression of OVA by the EG7.0VA cells as it has been
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observed that this may decline after long-term culture in vitro 
(K.Heeg, personal communication).
Aliquots of 106 cells in 15ml conical plastic centrifuge tubes 
(Falcon, Becton Dickinson) were washed in staining buffer (PBS 
containing 2% FCS and 0.05% sodium azide; SB) by centrifuging at 
450g for 5min. The cells were then resuspended in 50^1 polyclonal 
sheep-anti-ovalbumin antiserum (Serotec Ltd, Kidlington, Oxford; 
diluted 1:50 in SB), incubated on ice for 30-40min and after 
washing twice in SB, the cell pellets were resuspended in 50^1 of 
fluorescein isothiocyanate (FITC) conjugated polyclonal donkey- 
anti-sheep IgG (Serotec; 1:50 in SB), incubated a further 30-40min 
on ice, washed twice in SB and resuspended in 0.5 ml PBS.
The samples were analysed using a FACscan flow cytometer 
as described below. Background fluorescence levels were 
determined using cells incubated with FITC-donkey-anti-sheep IgG 
in the absence of primary antibody. Non-OVA expressing EL4 cells 
stained as above, were used as a negative control. A typical profile 
of EL4 and EG7.0VA cells stained by the above procedure is shown 
in Figure 2.3.
Osmotic Loading of Cell Lines with OVA
OVA was introduced directly into the cytoplasm of target cell 
lines by the osmotic lysis of pinosomes, as described previously 
(202, 207). 2.5 x 106 cells were washed in RPMI 1640 and 
resuspended in 0.5ml hypertonic RPMI medium containing 20mM 
HEPES (Sigma), lOmg/ml OVA, 10% (w/v) polyethylene glycol (PEG, 
Mol. Wt. 1000, Sigma) and 0.5M sucrose. After lOmin incubation at 
37°C, 14.5ml of hypotonic medium comprising 60% RPMI and 40%
49
dH20 was added and the cells were incubated for a further 2-3min 
a t 37°C. After pelleting at 400g for 5min, the cells were 
resuspended in 5ml of their normal culture medium and incubated 
overnight at 37°C in 5% CO2 in air in a humidified incubator.
Induction of Immune Responses in vivo
i) Parenteral Immunisation
Subcutaneous (s.c.) immunisations were performed by 
injection of a total volume of 50*il into one rear footpad under 
halothane anaesthesia.
Intraperitoneal (i.p.) immunisations were performed by 
injection of a total volume of 0.2ml.
ii) Oral Immunisation
Oral immunisations were performed by feeding volumes of up 
to 0.5ml using a rigid steel gavage tube.
Collection of Plasma
Under halothane anaethesia, mice were bled from the retro- 
orbital plexus using heparinised capillary tubes (Hawksley & Sons 
Ltd, Lancing, Sussex). A maximum of 200^1 was taken on each 
occasion and plasma was separated by centrifuging for lOmin at 
500g and stored at -20°C until use.
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Collection of Intestinal Secretions
Intestinal fluid for the measurement of IgA antibodies was 
obtained by a modification of a published technique (208). Mice 
were fed 0.2ml of a 16% PEG solution (Mol. Wt. 3350, Sigma) in PBS, 
four times over a 60min period. The entire small intestine and 
caecum was then removed and washed through with 6ml ice-cold 
PBS containing 0. lmg/ml soyabean trypsin inhibitor and 50mM 
ethylenediaminetetraacetic acid (EDTA) (both from Sigma). The 
resulting fluid was clarified by centrifugation at 1500g for lOmin 
an d  3ml of supernatant removed. 30^1 of lOOmM 
phenylmethylsulfonyl fluoride (PMSF, Sigma) in 95% ethanol 
(Aldrich) was then added and the supernatants were centrifuged in 
eppendorf tubes at 27,000g for 15min at 4°C. 1ml of clarified 
supernatant was removed and 10^1 PMSF solution, lOjil sodium 
azide (1% in PBS, Sigma) and 50\d FCS were added to each 
supernatant which were then stored at -20°C until required.
Depletion of CD4+ T Cells in vivo
Mice were depleted of CD4+ T cells in vivo by i.p. injection of 
50CVg (NH^SO^purified anti-CD4 monoclonal antibody (YTS191.1, 
kindly provided by Prof F.Y. Liew) on two occasions 4 days apart. 
Mice were immunised four days after the final injection of 
antibody.
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Depletion of Macrophages in vivo
i) Paralysis of Macrophages using Silica
Mice were injected with lmg silica (Sigma) in 0.2ml saline i.v., 
followed 24 hr later by 0.5mg silica in 0.2ml saline i.p. Before 
injection the silica solution was sonicated for 15min to ensure an 
even colloidal suspension. Mice were immunised 24hr after the 
second treatment.
ii) M acrophage Depletion using Liposomes Containing 
Dichloromethylene Diphosphonate
Mice were depleted of macrophages in vivo as described 
previously (209, 210), by i.v. injection of 0.2ml liposomes 
containing dichloromethylene diphosphonate (CI2MDP), kindly 
provided by Dr. N van Rooijen (Free University, Amsterdam, 
Holland, with permission from Boehringer Ingleheim), 24hr before 
immunisation.
M easurement of OVA-Specific Antibody Responses
Serum IgG and intestinal IgA antibody responses were 
measured using an enzyme-linked immunosorbent assay (ELISA). 
OVA (10^g/ml in 50mM carbonate buffer) was adsorbed to 
microtitre plates (Immulon 4, Dynatech) by overnight incubation at 
4°C and the plates were then washed three times with PBS/0.05% 
Tween 20 (BDH) before addition of 100^1 samples. These were 
either sera diluted 1:400 in PBS/Tween containing 1% normal 
rabbit serum or neat intestinal washes. The plates were incubated 
with the samples for 2.5hr at room temperature and washed three
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times with PBS/Tween before addition of 100^1 of a 1:1000 dilution 
of alkaline phosphatase conjugated goat-anti-mouse IgG or goat- 
anti-mouse IgA (both Sigma), respectively. After a further 3hr 
incubation at room temperature, the plates were washed three 
times with PBS/Tween and 100^1 of phosphatase substrate (p- 
nitrophenyl phosphate, Sigma) at lmg/ml in dt^O containing 10% 
diethanolamine (DEA, Aldrich) was then added to each well. After a 
10-30min incubation at room temperature, the O.D. 405nm of the 
samples was measured using an MR5000 automatic microplate 
reader.
Samples from individual mice were assayed in triplicate and 
expressed as O.D. 405nm. In some experiments, OVA-specific IgG 
levels are expressed as a percentage of a hyperimmune standard, 
which was a (NH^SO^purified anti-OVA IgG preparation obtained 
from mice which had been immunised twice with lOO^g OVA in 
CFA (kindly provided by Miss Margaret Steel, Dept, of Immunology, 
Western Infirmary).
M easurement of OVA-Specific Serum IgG Isotvpes
OVA-specific serum IgG isotypes were also measured using an 
ELISA. After coating with OVA as above, the plates were washed 
three times with PBS/0.05% Tween 20 and non-specific protein 
binding sites were blocked with 100^1 of 3% bovine serum albumin 
(BSA, Sigma) in PBS/Tween for lh r  at room temperature. After 
three washes with PBS/Tween, 50^1 aliquots of test sera in doubling 
dilutions (1:20 to 1:2560) in PBS/Tween were added to the plates 
and incubated at room temperature for 90min. Following three 
washes with PBS/Tween, 50^1 of either biotinylated rat anti-murine
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IgGl diluted 1:16,000 or biotinylated rat anti-murine IgG2a (both 
Pharmingen, San Diego, CA, USA) diluted 1:1000 in PBS/Tween 
were added and the plates incubated for lh r at room temperature. 
The plates were then washed 4 times with PBS/Tween and 75^1 
extravidin-peroxidase (Sigma, 2mg/ml in PBS/10% FCS) was added. 
Following a final incubation for lh r at room temperature, the plates 
were washed 6 times, before lOOjxl 3,3f5,5f-tetramethylbenzidine 
(TMB) peroxidase substrate (Dynatech) was added to each well. 
The plates were read at 630nm using an MR5000 automatic 
microplate reader.
Individual samples were assayed in triplicate and their titres 
expressed as the reciprocal of the lowest dilution which gave an OD. 
630nm value of ^20% of the maximal O.D. obtained with the 
hyperimmune standard anti-OVA IgG.
M easurement of Systemic Delaved-Type H ypersensitivity 
(DTH) Responses
Systemic DTH responses were determined by measuring the 
increment in footpad thickness 24hr after subcutaneous challenge 
with lOO^g heat-aggregated OVA (211). Footpad thicknesses were 
measured before and after challenge using calipers (Kroplin 
Limited, Kingston upon Thames, Surrey).
Preparation of Lymphoid Cells
Spleens, Peyer's patches, mesenteric and popliteal lymph 
nodes were removed immediately after sacrifice, placed into a Petri 
dish containing RPMI 1640 medium and after dissection of any
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surrounding material, were teased apart using 21g needles (Becton 
Dickinson). Single cell suspensions were obtained by repeated 
pipetting with a 5ml syringe (Becton Dickinson), followed by 
passage through Nitex mesh (Cadisch and Sons Ltd, London) to 
remove any clumps or debris. After washing twice in RPMI 1640 
by centrifuging for 7min at 45 Og, viable cells were counted with a 
Neubauer haemocytometer (Weber Scientific, Middlesex) using 
phase contrast microscopy (Nikon Labophot microscope, x40 
objective) and the final cell pellet was resuspended at the required 
concentration in appropriate medium.
Phenotypic Analysis of Lymphocytes by Flow Cytometry
Aliquots of 5 x 105 cells were resuspended in 50^1 SB 
containing 3\d of phycoerythrin (PE-) conjugated anti-CD4 (GK1.5) 
and FITC-anti-CD8 (53.-6.7; both from Becton Dickinson) monoclonal 
antibodies. The samples were incubated for 30-40min on ice and 
washed twice in SB for 7min at 450g. Red blood cells were removed 
from spleen cell suspensions by incubation in 0.5ml 1:10 Facslyse 
solution (Becton Dickinson) for lOmin at room temperature, 
followed by washing in SB. After resuspending in 0.5ml PBS, the 
samples were analysed using a FACscan IV flow cy tome ter (Becton 
Dickinson) with a 488nm argon laser. Lymphocytes were gated on 
the basis of their forward and side light scatter properties and the 
data were analysed using Lysis II program software (Becton 
Dickinson). In all experiments, negative control samples were cells 
incubated with SB in the absence of any antibodies.
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Depletion of T Cell Subsets in vitro
CD4+ and CD8+ T cell subsets were depleted in vitro by 
complement-mediated lysis. Lymphoid cells were resuspended at 
107 cells/ml in RPMI 1640 medium/5% FCS containing 200ng/ml of 
(NH3)2904-purified anti-CD4 mAb (YTS191.1) or anti-CD8 mAb 
(YTS 169.4) (both kindly provided by Prof. F.Y. Liew) and incubated 
for 60min on ice. After two washes in RPMI/5% FCS by centrifuging 
for 7min at 450g, the cells were resuspended at 5 x 106 cells/ml in 
RPMI/5% FCS containing 10% (v/v) rabbit complement (Low-Tox M, 
Vector Laboratories, Peterborough) and incubated for 60min at 
37°C. The cells were then washed twice in RPMI 1640, counted and 
resuspended at 2 x 106 cells/ml in appropriate medium. Control 
cells were incubated in the absence of mAb or complement.
M easurement of Antigen-Specific Proliferative Responses
Spleen or popliteal lymph node cells were plated in 
quadruplicate in 96 well flat-bottomed microtitre plates (Costar, 
Northumbria Biologicals,Cramlington, Northumberland) at 2.5 x 105 
cells/ well in a total volume of 200^1 complete RPMI medium 
containing 5 x 10"5M 2-mercaptoethanol (2-ME, Sigma; 
"proliferation medium"). The cells were cultured with various 
concentrations of OVA or Con A, at 37°C in a humidified incubator 
containing 5% CO2. To assess proliferation, the wells were pulsed 
with ln-Ci 3H-thymidine (West of Scotland Radionucleotide 
Dispensary, Western Infirmary, Glasgow) for 16hr before being 
harvested onto glass fibre filters using a 1295 Betaplate 96 well
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harvester and DNA-bound 3H-thymidine was counted using a 1205 
Betaplate scintillation counter (all LKB Wallac, Turku, Finland).
Measurement of OVA-Specific Cytotoxic T Cell Responses
A) Restimulation of Spleen and Mesenteric Lymph Node 
Cells in vitro
OVA-specific CTL activity in primed spleen and mesenteric 
lymph node (MLN) cells was assayed after in vitro restimulation 
using OVA transfected EG7.0VA cells as described previously (202). 
EG7.0VA cells were incubated at 107 cells/ml in RPMI 1640 
medium containing SO^g/ml mitomycin C (Sigma) for 75min at 
37°C, washed 5 times in RPMI 1640 by centrifuging at 400g for 
5min and then resuspended at 1.5 x 106 cells/ml in complete RPMI 
containing 5% NCTC-135 medium (Gibco) and 5 x 1 0 5M 2-ME ("CTL 
medium"). 1ml of this suspension was added to 25cm2 tissue 
culture flasks (Costar) containing 3 x 107 spleen or MLN cells in 9 
ml CTL medium and cultured for 5 days at 37°C in 5% CO2 in air in a 
humidified incubator.
B) Restimulation of Popliteal Lymph Node Cells in vitro
CTL activity in popliteal lymph nodes was determined four 
days after footpad immunisation by in vitro restimulation with IL- 
2 as described previously (212). Aliquots of 2 x 106 popliteal lymph 
node (PLN) cells were cultured in vitro for 4 days in 1ml CTL 
medium containing lOU/ml recombinant human IL-2 (rhIL-2; Cetus 
Corporation, Emeryville, U.S.A.) in 24 well tissue culture plates 
(Costar) at 37°C in 5% CO2 in air in a humidified incubator.
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C) Measurement of OVA-Specific Cytotoxic T Cell Activity 
using Microcytotoxicity Assays
i) Labelling of Target Cells with 51Cr
Aliquots of 2.5 x 106 target cells were labelled with 51Cr by 
incubation in 1ml RPMI 1640/5% newborn calf serum (NCS, Gibco 
BRL) containing 2MBq Na251CrC>4 (West of Scotland Radionucleotide 
Dispensary, Western Infirmary), for 60min at 37°C. They were then 
washed 5 times in RPMI/5% NCS by centrifuging at 45Og for 5min 
and recounted before being used in the microcytotoxicity assay.
ii) Microcytotoxicity Assays
Effector cells which had been restimulated with EG7.0VA cells 
or IL-2 were washed twice in RPMI/5% NCS and recounted, before 
being incubated at different effector cell:target cell (E:T) ratios in 
quadruplicate with 51Cr-labelled target cells in a total volume of 
200|d in V-bottomed microtitre plates (Costar). For spleen and MLN 
effector cells, 2 x 104 target cells were added to each well, while 5 x 
103 target cells were used for CTL assays of PLN effector cells. After 
incubation for 4hr at 37°C in 5% CO2 in air in a humidified 
incubator, lOO^ il supernatant was removed from each well for 
analysis of 51Cr release in a 1282 Compugamma counter (LKB 
Wallac).
In assays in which OVA 111-122 and OVA 258-276 peptides 
were used to pulse target cells, peptides were added to the mixture 
of effector and target cells for the duration of the assay, at a final 
concentration of 2.3 \M.
In all assays, the percent OVA-specific CTL activity was 
calculated by the following formula:
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% specific lysis = (Experimental com - Spontaneous com) x 100%
(Total cpm - Spontaneous cpm)
Spontaneous release was obtained using cells taken from unprimed 
mice, which had been restimulated in vitro with EG7.0VA cells or 
rhIL-2, while total release was obtained using 10% Triton X-100 
(Sigma).
Measurement of Natural Killer Cell Activity
Splenic Natural Killer (NK) cell activity was assayed using a 
microcytotoxicity assay identical to that described above, except 
that in this case 51Cr-labelled YAC-1 cells were used as targets and 
spontaneous release was obtained using normal thymocytes.
Induction and M easurement of Cytokine Production in  
vitro
Cytokine production was induced and measured using 
techniques which were developed by Dr. Paul Garside in this 
laboratory.
i) Induction of Cytokine Production
Single cell suspensions from lymphoid organs were 
resuspended at a final concentration of 4 x 106 cells/ml and 
cultured in 1ml aliquots in 24 well tissue culture plates (Costar) in 
complete RPMI medium containing 5 x 10" 5M 2-ME, either alone or 
with lO^g/ml Con A or lmg/ml OVA. The supernatants were 
harvested after 2-6 days of culture, separated from contaminating
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cells by centrifuging at 13,000g for 5min and stored at -20°C until 
assayed.
ii) Measurement of Cytokine Levels using ELISA
Cytokine levels were quantified using sandwich ELISA 
techniques. Immunlon 4 96-well ELISA plates were coated 
overnight at 4°C with 50\d of monoclonal anti-cytokine antibody at 
predetermined optimal concentrations (Table 2.1) in 0.1M NaHCC>3 
buffer. The plates were then washed twice with PBS/0.05% Tween 
20, after which non-specific protein binding sites were blocked by 
incubation with 200^1 of PBS containing 10% FCS for lh r  at 37°C. 
Following blocking, the plates were washed twice in PBS/Tween 
and culture supernatants or standard preparations of recombinant 
murine cytokines (Table 2.2) diluted in culture medium, were 
added to individual wells in a volume of 50^1 and incubated at 
room temperature for 3 hr. The plates were then washed 4 times 
with PBS/Tween and 50^1 of predetermined concentrations of 
biotinylated anti-cytokine antibody (Table 2.1) diluted in PBS/10% 
FCS was added to each well. After incubation for lh r  at room 
temperature, the plates were washed 6 times with PBS/Tween and 
lOOjil of extravidin-peroxidase (2mg/ml in PBS/10% FCS) was 
added to each well. Following a final incubation for lh r  at room 
temperature, the plates were washed 8 times with PBS/Tween, 
before 100jxl TMB peroxidase substrate was added to each well. The 
plates were read at 630nm using an MR5000 automatic microplate 
reader and the concentrations of cytokines in test supernatants, 
assayed in quadruplicate, were determined with reference to a 
standard curve constructed using serial dilutions of the standard 
cytokines.
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M easurement of Respiratory Burst Enzyme Activity by
Chemiluminescence
i) Elicitation and Isolation of PEC
Peritoneal exudate cells (PEC) were used to examine the 
effects of ISCOMS on M<|> activity. PEC were elicited in BALB/c mice 
by i.p. injection of either 2ml thioglycollate broth (kindly provided 
by Dr. Jeremy Brock, Dept, of Immunology), lmg heat-killed 
Corynebacterium parvum (Wellcome Laboratories, Beckenham, 
Kent), 5ng ISCOMS-OVA or 0.5ng Quil A.
Four days after injection, mice were sacrificed and PEC 
isolated by injecting 2.5ml RPMI 1640 containing 25mM HEPES and 
10% FCS into the peritoneum, which was then massaged gently to 
dislodge PEC. A small incision was then made in the peritoneum and 
the cell suspension harvested with a Pasteur pipette.
ii) Chemiluminescence Assay
Respiratory burst activity was assayed by chemiluminescence 
using a slightly modified method of that described previously 
(213). In this assay, reactive O2 intermediates produced by 
activated M(|> interact with luminol causing it to emit photons that 
are detected using a luminometer.
107 PEC from each group were washed in Hank’s Balanced 
Salts Solution, without phenol red (HBSS, Gibco BRL) by centrifuging 
at 450g for 7min, resuspended at 5 x 106 cells/ml in HBSS and 
warmed to 37°C in a water bath. 2 x 106 PEC in 0.4ml were then 
added to 0.1ml of a 10-4M solution of 5-amino-2,3-dihydro-1,4- 
phthalazinedione solution (luminol; Sigma), before additon of 0.5ml
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of a 1 ng/ml solution of phorbol 12-myristate 13-acetate (PMA, 
Sigma). The suspensions were mixed at 37°C in a water bath and 
the resultant generation of chemiluminescence was measured every 
10 seconds for 5-10min using a 1250 Luminometer (LKB Wallac). 
The results were expressed in mV and measurement was 
terminated when five consecutive decreases in chemiluminescence 
occurred, indicating the decline of respiratory burst activity. Control 
samples were PEC incubated with luminol in the absence of PMA.
Statistics
Unless otherwise stated, results were expressed as means ± 
standard deviations (SD) and were compared by Student's t-test. In 
instances where the data were not normally distributed, the results 
were compared using Wilcoxon's Rank Sum test.
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Figure 2.1
Transmission electron m icrograph (TEM) of ISCOMS-OVA 
negatively stained with phosphotungstic acid, showing typical cage­
like structure. (x73000).
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Figure 2.2
Scanning electron m icrograph (SEM) of poly (lactide-co- 
glycolide) microparticles containing OVA (PLG-OVA). (Provided by 
Dr.D.T.O'Hagan).
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Figure 2.3
FACS analysis of OVA expression by EG7.0VA cells. Cells were 
stained with sheep-anti-OVA antiserum, followed by FITC-donkey- 
anti-sheep IgG. Non-OVA transfected EL4 cells were used as a 
negative control.
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Table 2.1: M onoclonal Antibodies used in  Cytokine
Sandwich ELISAs
i) Capture Antibodies
Specificity Clone Isotvoe Cone, (ug/ml)
Mouse IL-2 JES6-1A12 Rat IgG2a 2
Mouse IL-4 BVD4-1D11 Rat IgG2b 2
Mouse IL-5 TRFK5 Rat IgGi 4
Mouse IFN-y R4-6A2 Rat IgGi 2
ii) Biotinylated Detecting Antibodies
Specificity Clone Isotvpe Cone, (ug/ml)
Mouse IL-2 JES6-5H4 Rat IgG2b 1
Mouse IL-4 BVD6-24G2 Rat IgGi 1
Mouse IL-5 TRFK4 Rat IgG2a 4
Mouse IFN-y XMG1.2 Rat IgGi 1
All of the above monoclonal antibodies were purchased from 
Pharmingen, San Diego, CA, U.S.A.
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Table 2.2: Recombinant Murine Cytokine Standards used in
Sandwich ELISAs
Cvtokine Source
IL-2 Pharmingen
IL-4 Genzyme, West Mailing, Kent.
IL-5 Genzyme.
IFN-y Prof. F.Y. Liew, Dept, of Immunology
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CHAPTER 3: PRIMING OF IMMUNE RESPONSES in vivo  BY
ISCOMS-OVA
Introduction
The principal aim of my project was to investigate the 
immunological basis of the adjuvant properties of ISCOMS when 
used by the oral and parenteral routes. This had not been 
addressed in previous studies, partly because immunologically well 
characterised protein antigens had rarely been incorporated into 
ISCOMS. Furthermore the oral route had not been studied 
extensively using ISCOMS. My studies were therefore designed to 
exploit a recently established method for incorporating purified 
OVA into ISCOMS (165). Preliminary work in this laboratory had 
shown that ISCOMS-OVA were immunogenic in vivo and had 
indicated that these ISCOMS could induce class I MHC-restricted 
cytotoxic T lymphocyte responses and were immunogenic when 
given orally (165).
My first series of experiments aimed to repeat and extend 
these studies by examining in parallel the full range of immune 
responses induced by oral and parenteral immunisation with 
ISCOMS-OVA.
Experimental Protocol
To induce OVA-specific systemic antibody and CMI responses 
BALB/c mice were primed s.c. with a single dose of l(Vg ISCOMS- 
OVA into the right hind footpad. Primary antibody responses were 
measured 7 days after priming and mice were challenged with
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lOOpg of heat-aggregated OVA on dayl4 post-priming. Systemic 
DTH responses were measured 24-48hr later and secondary IgG
responses assayed one week later.
To induce systemic CTL responses C57B1/6 mice were primed 
with a single dose of 5ng ISCOMS-OVA i.p. and spleen cells taken 7- 
10 days later were restimulated in vitro for 5 days with EG7.0VA 
cells (202).
For oral immunisation, mice were fed 10-10(Vg doses of 
ISCOMS-OVA on one or more occasions over a ten day period. 
Systemic IgG, secretory IgA and CTL responses were assayed 7-10 
days after the final feed.
In all experiments control mice received identical priming 
doses of either soluble OVA, palmidfied OVA (palm-OVA), soluble 
OVA in complete Freund's adjuvant or saline only.
Results
i) Induction of Systemic Antibody and DTH Responses by 
Parenteral Immunisation with ISCOMS-OVA
Consistent with previous studies in our laboratory (165), I 
found that mice which had been immunised s.c. 14 days previously 
with l(Vg ISCOMS-OVA exhibited significant OVA-specific DTH 
responses when challenged in the opposite footpad with heat- 
aggregated OVA (Fig. 3.1). These DTH responses were comparable in 
magnitude to those elicited by immunisation with OVA in CFA 
(165).
In addition, measurement of OVA-specific IgG levels in the 
ISCOMS-OVA primed mice revealed that, while only modest 
primary antibody responses were observed 7 days after priming,
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highly significant levels of OVA-specific IgG antibodies were 
present in secondary sera taken after challenge with heat- 
aggregated OVA (Fig. 3.2). These results confirmed that ISCOMS 
containing small amounts of protein antigen primed both humoral 
and cell-mediated immune responses in vivo .
ii) Priming of Class I MHC-restricted CTL by Parenteral 
Immunisation with ISCOMS-OVA
I next attempted to confirm that ISCOMS were also able to 
induce antigen-specific CTL responses when adm inistered 
parenterally (165). Spleen cells from C57B1/6 mice primed seven 
days previously with 5^g ISCOMS-OVA i.p. showed marked OVA- 
specific CTL activity against OVA-transfected EG7.OVA target cells 
(Fig.3.3). The antigen specificity of the CTL was indicated by the 
fact that they did not lyse the non-transfected EL4 parental cell line 
(Fig. 3.3). Furthermore, spleen cells isolated from mice primed with 
saline showed no OVA-specific CTL activity after stimulation in 
vitro with EG7.0VA cells (Fig. 3.3).
In order to characterise the phenotype of the CTL induced by 
ISCOMS-OVA, I used monoclonal antibodies and complement 
treatment to remove CD4+or CD8+T cells from the effector spleen 
cell population. The absence of CD4+or CD8+ T cells was confirmed 
by FACS analysis (Fig. 3.4). Depletion ofCD4+T cells had no effect 
on the level of OVA-specific CTL activity, but removal of CD8+ T 
cells completely abrogated the cytotoxic response (Fig. 3.5) As the 
EG7.0VA cells do not express class II MHC antigens (202), these 
results confirm that incorporation of a protein antigen in ISCOMS 
leads to highly efficient priming of CD8+ class I MHC-restricted T 
cells in vivo.
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iii) Induction of Systemic Antibody and DTH Responses by 
Oral Immunisation with ISCOMS-OVA
I next investigated the immunogenicity of ISCOMS-OVA when 
administered orally. Previous work in our laboratory had shown 
that mice fed a single dose of lOO^g ISCOMS-OVA developed strong 
OVA-specific DTH responses, but had only low levels of OVA- 
specific IgG antibodies (165).
To attempt to improve the generation of serum antibody 
responses I decided to investigate the effects of multiple feeding, 
an immunisation strategy which had been employed effectively 
with other oral adjuvants, such as cholera toxin (143). When mice 
were fed ISCOMS-OVA on six occasions over a ten day period, they 
developed highly significant levels of OVA-specific IgG antibodies 
in serum (Fig. 3.6). These responses were maximal using an 
immunising dose of lOCVg ISCOMS-OVA, where the OVA-specific 
IgG levels were comparable to those found in mice immunised 
parenterally with lOO^g OVA in CFA, but significant responses were 
also elicited with doses containing as little as l(Vg ISCOMS-OVA 
(Fig. 3.6). Feeding palmitified OVA alone was not sufficient to 
induce a systemic IgG response (Fig. 3.6).
iv) Induction of Intestinal IgA Antibody Responses by 
Feeding ISCOMS-OVA
The ability of ISCOMS-OVA to induce such potent systemic 
immune responses when administered orally made it important to 
determine whether they could also stimulate local antibody 
responses in the intestine itself.
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Again, mice fed a single dose of lOOng ISCOMS-OVA had very 
low levels of OVA-specific IgA antibodies in intestinal washes, but 
those receiving three or six feeds had increasingly significant levels 
of OVA-specific IgA in the intestine (Fig. 3.7). The magnitude of the 
IgA response was primarily dependent on the number of feeds, 
rather than immunising dose, as mice receiving six feeds of l(Vg 
ISCOMS-OVA had similar levels to those fed lOOng on six occasions 
(Fig. 3.8). As before, feeding of palmitified OVA alone did not 
provoke OVA-specific IgA production (Fig. 3.8). Thus, repeated oral 
immunisation with ISCOMS provokes both strong systemic IgG 
responses and local secretory IgA responses to incorporated protein 
antigen.
v) Prim ing of OVA-specific CTL Responses by Oral 
Immunisation with ISCOMS-OVA
Lastly, I examined whether ISCOMS-OVA were able to prime 
class I MHC-restricted CTL responses when administered orally. 
Spleen cells from mice fed six times with lOOng ISCOMS-OVA had 
high levels of OVA-specific CTL activity (Fig. 3.9), comparable to 
that induced by a single parenteral immunisation with ISCOMS- 
OVA (Fig. 3.3). Marked OVA-specific CTL activity was also present 
in the mesenteric lymph node (MLN) cells taken from ISCOMS-OVA 
fed mice (Fig. 3.9), indicating that oral immunisation with ISCOMS 
primed both local and systemic CTL precursors. Feeding palmitified 
OVA alone did not induce any detectable CTL activity (Fig. 3.9). 
Hence ISCOMS allow incorporated protein antigen access to the 
endogenous pathway of antigen processing and presentation, even 
when adminstered orally.
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Conclusions
The results presented in this chapter confirm and extend 
previous findings (165) on the potent adjuvant effects of ISCOMS 
and indicate that ISCOMS have several unique properties as oral 
vaccine vectors.
A single parenteral immunisation with as little as 5-lCVg 
ISCOMS-OVA primed potent OVA-specific systemic DTH and IgG 
responses and high levels of class I MHC-restricted OVA-specific 
CTL were detected in the spleen. Together these findings indicate 
that ISCOMS allow presentation of incorporated protein to the class 
II MHC-restricted T cells required for antibody and DTH responses, 
while also permitting efficient entry of the protein into the 
endogenous antigen processing pathway required for stimulation of 
class I MHC-restricted CTL responses.
Perhaps the most novel adjuvant property of ISCOMS is their 
ability to induce a wide range of systemic and local immune 
responses when administered orally. These findings contrast with 
the profound immunological tolerance normally observed in 
animals given proteins orally (54) and highlight the potential of 
ISCOMS to form the basis of future oral vaccine development. As 
observed with other oral adjuvants (143), multiple feeds of ISCOMS 
were required to induce the same range of systemic immune 
responses as parenteral immunisation, including DTH, IgG and class 
I MHC-restricted CTL responses. In addition, oral immunisation 
with ISCOMS stimulated the production of secretory IgA antibodies 
in the intestine and local CTL precursors in MLN. These findings 
indicate that ISCOMS may allow protein antigen to subvert the
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regulatory mechanisms responsible for the induction of oral 
tolerance, which normally operate at mucosal surfaces.
In summary, this study has shown that ISCOMS possess a 
number of unique and potent adjuvant effects when administered 
either parenterally or orally and using ISCOMS-OVA as a model 
system it should be possible to analyse the mechanisms underlying 
the basis of their adjuvanticity.
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Figure 3.1.
Prim ary systemic DTH responses after paren teral 
immunisation with ISCOMS-OVA. DTH responses were measured 
24hr after footpad challenge with lOOpg heat-aggregated OVA in 
BALB/c mice which had been primed 14 days previously with lOjxg 
ISCOMS-OVA or saline only s.c. Results are means ± 1 S.D. for four to 
six mice per group.
*p<0.001v. CONTROL.
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Figure 3.2.
Priming of OVA-specific humoral immunity by parenteral 
immunisation with ISCOMS-OVA. Primary OVA-specific IgG 
responses of BALB/c mice were measured one week after priming 
with lO^g ISCOMS-OVA or saline only s.c., while secondary IgG 
responses were assayed one week after footpad challenge of 
primed mice with lOO^g heat-aggregated OVA. Mean O.D.(405nm) 
values ± 1S.D. are shown for six mice per group.
*p<0.001v. CONTROL.
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Figure 3.3.
Priming of OVA-specific CTL responses by parenteral 
immunisation with ISCOMS-OVA. Splenic CTL activity was assayed 
in C57B1/6 mice immunised one week before with 5pg ISCOMS-OVA 
or saline only i.p. after subsequent restimulation in vitro with 
EG7.0VA cells. Results shown are percent specific cytotoxicity using 
spleen cells pooled from four mice per group.
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Figure 3.4.
FACS analysis of effector spleen cells after depletion of CD4+ 
or CD8+ Tcells. After in vitro restim ulation with EG7.0VA cells, 
ISCOMS-OVA primed spleen cells from C57B1/6 mice were depleted 
of CD4+ or CD8+ T cells by monoclonal antibody plus complement 
treatm ent, before being stained with PE-anti-CD4 and FITC-anti- 
CD8 mAbs.
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Figure 3.5.
Phenotype of CTL primed by immunisation with ISCOMS-OVA. 
After in vitro restimulation with EG7.0VA cells, ISCOMS-OVA 
primed spleen cells from C57B1/6 mice were depleted of CD4+ or 
CD8+ T cells by monoclonal antibody plus complement treatment, 
before OVA-specific CTL activity was measured by 51 Cr release 
assay. The results shown are percent specific cytotoxicity against 
EG7.0VA target cells using spleen cells pooled from four immunised 
mice. There was no lysis of EL4 cells by any of the effector 
populations
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Figure 3.6.
Induction of systemic OVA-specific IgG responses by oral 
immunisation with ISCOMS-OVA. Sera were obtained 9 days after 
the last immunisation in BALB/c mice fed 10, 50 or lOO^g ISCOMS- 
OVA or lOOy-g palmitified OVA (Palm-OVA) or saline only on six 
occasions and in mice immunised s.c. with lOO^g OVA in CFA. 
Results shown are means ± 1S.D. from 4 or 5 mice per group. 
*p<0.05v. CONTROL.
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Figure 3.7.
Induction of OVA-specific secretory IgA responses by feeding 
ISCOMS-OVA. BALB/c mice were fed lOO^g ISCOMS-OVA on one or 
more occasions over a ten day period and intestinal washes were 
obtained one week after the final feed. Results shown represent 
means ± 1S.D. from six mice per group.
*p<0.05v. CONTROLS.
** p<0.001 v. CONTROLS.
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Figure 3.8.
Effect of antigen dose on the induction of secretory IgA 
responses by feeding ISCOMS-OVA. BALB/c mice were fed six times 
over a ten day period withl0-10(Vg ISCOMS-OVA, lOO^g 
palmitified OVA (Palm-OVA) or saline only and intestinal washes 
were obtained one week later. Results shown are means ± 1S.D. 
from six mice per group.
*p<0.05v. CONTROL.
**p<0.01v. CONTROL.
*** p<0.001 v. CONTROL.
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Figure 3.9.
Priming of OVA-specific CTL responses by oral immunisation 
with ISCOMS-OVA. Splenic or mesenteric lymph node (MLN) CTL 
activity was assayed in C57B1/6 mice 10 days after the last of six 
feeds of 100pg ISCOMS-OVA or 100pg palmitified OVA (Palm-OVA), 
after restimulation in vitro for 5 days with EG7.0VA cells. Results 
shown are percent specific cytotoxicity using spleen cells pooled 
from four mice per group.
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CHAPTER 4: IMMUNOBIOLOGY OF CLASS I MHC-RESTRICTED
CTL RESPONSES INDUCED BY ISCOMS-OVA 
In troduction
One of the most novel properties of ISCOMS highlighted in the 
previous chapter is their ability to stimulate potent class I MHC- 
restricted CTL responses to exogenous protein antigens in vivo. As 
this property would be important for a vaccine capable of 
stimulating protection against many viral infections, I thought it 
important to investigate the mechanisms involved.
Over the last few years it has become clear that class I MHC- 
restricted CD8+ T cells recognise small peptides of 8-10 amino acids 
in length, which are generated by intracellular degradation of 
cytosolic antigen and are presented in the binding cleft of class I 
MHC molecules (20, 33-35, 214). However, the cellular mechanisms 
involved in the induction of CTL responses in vivo are still not clear 
and different pathways may operate depending on the system 
under study. In particular, there is considerable variability in the 
nature of antigen presenting cells involved and in the dependency 
onCD4+ T cells in the induction of CTL responses (50, 215-219).
In this chapter, I have characterised the CTL responses 
primed by ISCOMS-OVA, by examining their phenotype, the nature 
of their recognition of antigen and the requirement for accessory 
cells and CD4+ T cells in their priming in vivo.
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Experimental Protocol
OVA-specific systemic CTL responses were assayed in spleen 
of C57B1/6 mice primed with a single dose of 5^g ISCOMS-OVA Lp. 
or with 3 to 6 feeds of 50-lOOpig ISCOMS-OVA, as described in 
chapter 3.
CTL responses were also assayed in the popliteal lymph node 
of C57B1/6 mice primed the hind footpad with l(Vg ISCOMS-OVA 4 
days previously. In this case primed cells were stimulated in vitro 
with lOU/ml rhIL-2 for 4 days before cytotoxicity was assayed.
M<J> were depleted or paralysed in vivo by injecting silica or 
liposomes containing Q2MDP (209), 24-48hr before priming with 
ISCOMS-OVA i.p.
CD4+ T cells were depleted in vivo by injecting 500ng anti-CD4 
mAb i.p. on day-7 and day-3 before priming with ISCOMS-OVA i.p. 
on dayO.
Results
i) Phenotype and Specificity of CTL Responses Primed by 
ISCOMS-OVA in vivo
The results in chapter 3 show that parenteral immunisation 
with ISCOMS-OVA primed OVA-specific CD8+ CTL which lysed the 
OVA-transfected EG7.0VA cell line, but not the parental EL4 cell 
line. I examined whether the antigen being recognised was derived 
from physiological processing of OVA by the endogenous route, or 
from exogenous OVA secreted by the cells (202). To distinguish 
: between these possibilities I tested the ability of ISCOMS-OVA
| primed CTL to lyse non-transfected EL4 cells in the presence of
iI
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native OVA, which was either added exogenously or which was 
introduced directly into the cytoplasm by osmotic lysis of 
pinosomes.
Pinocytic vesicles formed under hypertonic conditions lyse 
when the cells are returned to hypotonic medium, releasing their 
contents into the cytoplasm (202, 207). EL4 cells were cultured 
with hypertonic medium containing OVA, diluted to hypotonic 
medium and then washed and cultured overnight in normal culture 
medium before being used as target cells in a 51Cr release assay. As 
shown in Fig. 4.1, these cells were lysed very efficiently by 
ISCOMS-OVA primed CTL. In contrast, there was no lysis of EL4 
cells pulsed exogenously with soluble OVA (Fig. 4.1). Hence, the 
ISCOMS-OVA primed CTL recognise endogenously processed OVA.
The osmotic loading technique was exploited to examine the 
MHC-restriction of ISCOMS-OVA primed CTL. While syngeneic EL4 
(H-2b) cells endogenously loaded with OVA were efficiently lysed 
by ISCOMS-OVA primed CTL, there was no killing of allogeneic 
P815 (H-2d) cells either alone or after cytoplasmic loading with 
OVA (Fig. 4.2). That ISCOMS-OVA primed conventional CD8+ class I 
MHC-restricted CTL was further confirmed by the fact that they did 
not exhibit any cytotoxic activity against the NK-sensitive YAC-1 
cell line (Fig. 4.2).
Previous studies had shown that OVA-specific CTL elicited in 
H-2b mice by immunisation with EG7.0VA cells recognised a 
peptide epitope within residues 258-276 which was presented in 
association with the Kb class IMHC molecule (202). As shown in Fig. 
4.3, ISCOMS-OVA primed CTL showed substantial lysis of EL4 cells 
pulsed with the OVA peptide 258-276, but did not lyse EL4 cells 
pulsed with the OVA peptide 111-122. The latter peptide is
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recognised by OVA-specific H-2Db-restricted CTL induced by in 
vitro stimulation with trypsinised OVA, but is not presented by 
endogenous processing of OVA in vitro or in vivo (220).
Together, these results demonstrate that the OVA-specific CTL 
primed by ISCOMS-OVA in vivo are CD8+ T cells recognising an 
epitope within the OVA 258-276 peptide, which is derived from 
endogenously processing of OVA and which has been shown to 
contain the octamer motif (OVA 257-264) presented in association 
with Kb class IMHC molecules (33, 202, 221).
ii) Induction of Popliteal Lymph Node CTL Responses in  
vivo  by ISCOMS-OVA
All the CTL responses described thus far were assayed 
following restimulation with the OVA-expressing EG7.0VA in vitro. 
As it could be argued that this does not truly reflect a primary 
antigen-specific CTL response in vivo, I explored further the ability 
of ISCOMS-OVA to prime CTL using an alternative assay which did 
not involve in vitro restimulation with antigen. Following s.c. 
priming with ISCOMS-OVA, draining popliteal lymph node (PLN) 
cells were isolated and cultured with IL-2 in vitro, then assayed for 
OVA-specific CTL activity as before. As illustrated in Fig. 4.4, 
ISCOMS-OVA primed PLN cells exhibited substantial OVA-specific 
CTL activity in this assay, indicating that ISCOMS are indeed able to 
efficiently stimulate primary CTL responses in vivo.
iii) The Role of M<|> and CD4+ T Cells in ISCOMS-OVA 
induced CTL responses in vivo
It has been reported that the production of growth factors 
such as IL-2 is required for the initial induction of CTL responses
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under many conditions (222, 223). In addition, recent evidence 
suggests that phagocytic cells such as M<|> may play a critical role in 
priming CTL (215, 224, 225). I therefore examined the effects of 
depletion of phagocytic cells or of CD4+ T cells on the priming of CTL 
by ISCOMS-OVA.
a) Role of Phagocytic Cells
Mice treated with silica in order to paralyse M<j> in vivo 
showed markedly reduced OVA-specific CTL activity after priming 
with ISCOMS-OVA, to around one third of the level of lysis achieved 
in the ISCOMS-OVA primed group (Fig. 4.5). As not all CTL activity 
was abolished injecting silica, I decided to try and confirm these 
findings using another method to deplete M<|> in vivo. Mice were 
therefore treated with liposomes containing dichloromethylene 
diphosphonate (CI2MDP) which are ingested selectively by M<j> and 
degraded by phospholipases, releasing the toxic CI2MDP into the 
cytosol (209, 210). Mice depleted of M<j> in this manner also showed 
reduced OVA-specific CTL activity (Fig. 4.6), confirming that a 
substantial proportion of ISCOMS primed CTL are dependent on the 
presence of M<|>.
b) Role of CD4+ T cells
I next determined whether CD4+ Th cells were necessary for 
in vivo priming of CTL by ISCOMS. Mice depleted of CD4+ T cells, by 
treatment with anti-CD4 mAb, had markedly reduced numbers of 
CD4+ T cells in the spleen as assayed by FACS (Fig. 4.7) and were 
unable to generate any OVA-specific CTL when primed with 
ISCOMS-OVA (Fig. 4.8). Thus ISCOMS prime CTL responses in vivo 
via a CD4+ T cell-dependent pathway.
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iv) Characteristics of CTL Primed by Oral Imm unisation 
with ISCOMS-OVA
The preceding experiments explored the CTL responses 
primed by parenteral immunisation with ISCOMS-OVA and I went 
on to determine whether the OVA-specific CTL primed in vivo by 
o ra l im munisation with ISCOMS-OVA exhibited similar 
characteristics.
As shown in the previous chapter, mice which had been fed 
six times with ISCOMS-OVA developed good splenic CTL responses. 
These were ablated by in vitro depletion of CD8+ T cells from the 
effector population, while removal of CD4+ T cells had no effect (Fig. 
4.9). In addition, orally primed CTL were also able to lyse EL4 cells 
pulsed with OVA peptide 258-276, but not EL4 cells pulsed with 
exogenous intact OVA or with the OVA 111-122 peptide (Fig. 4.10). 
These results indicate that the systemic CTL responses primed by 
oral administration of ISCOMS are also CD8+ T cells recognising an 
epitope within the OVA 258-276 peptide.
Conclusions
These results have confirmed that ISCOMS elicit conventional 
class I MHC-restricted CTL responses when administered either 
parenterally or orally. The CTL primed by ISCOMS-OVA were CD8+ 
T cells which recognised endogenously processed OVA, the 
immunodominant epitope contained within the peptide OVA 258- 
276. Several studies have shown that this peptide contains an 
octamer (OVA 257-264) which comprises the minimal motif for 
binding the H-2Kb class I MHC molecule and is the dominant
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epitope recognised by OVA-specific CTL in H-2b mice following 
physiological processing of OVA (33, 202, 221, 226). Orally primed 
CTL appeared identical to parenterally primed CTL in all of the 
above aspects.
Shortly after s.c. immunisation with ISCOMS-OVA, OVA- 
specific precursor CTL were present in the draining lymph node. 
These pCTL differentiated into effector cells when cultured in the 
absence of antigen, but in the presence of IL-2, confirming that 
these cells had already been primed in vivo by the ISCOMS-OVA.
Phagocytic accessory cells (M<|>) were required for the priming 
of a large proportion of OVA-specific CTL, as paralysis or depletion 
of these cells produced a marked decrease in the priming of OVA- 
specific CTL in vivo. However, detectable CTL activity remained in 
the absence of M<j>, suggesting that there may be more than one 
pathway of CTL induction utilised by ISCOMS in vivo.
The CTL responses were also dependent on helper T cells, as 
depletion of CD4+ T cells completely abolished priming of CTL 
responses by ISCOMS-OVA. Thus, concomitant activation of CD4+ T 
cells plays a key role in the in vivo priming of CD8+ CTL by ISCOMS- 
OVA, possibly reflecting production of IL-2.
These findings suggest that the induction of CTL by ISCOMS is 
a complicated process, involving both phagocytic accessory cells and 
CD4+ T helper cells. The helper-dependence of the CTL responses, 
together with the potent humoral responses described in chapter 3, 
suggested that the activation of CD4+Th cells was a critical event in 
the induction of immune responses by ISCOMS and this topic is 
addressed in the following chapter.
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Figure 4.1.
ISCOMS-OVA induced CTL recognise endogenously processed 
OVA. Splenic CTL induced in C57B1/6 mice by immunisation with 
ISCOMS-OVA i.p. and restimulated in vitro with EG7.0VA cells, were 
tested for their ability to lyse EG7.0VA cells, or EL4 cells pulsed 
with exogenous OVA (EL4 + OVA) or osmotically loaded with OVA 
(EL4-OVA). The results shown are percent specific cytotoxicity 
using pooled spleen cells from four immunised mice.
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Figure 4.2.
ISCOMS-OVA primed CTL are MHC-restricted. Splenic CTL 
induced in C57B1/6 mice by immunisation with ISCOMS-OVA i.p. 
and restimulated in vitro with EG7.0VA cells, were tested for their 
ability to lyse either EL4 (H-2b) or allogeneic P815 (H-2d) cells 
which had been osmotically loaded with OVA (EL4-OVA and P815- 
OVA). Control targets which had not been loaded with antigen were 
also included, as were EG7.0VA cells and NK-sensitive YAC-1 cells. 
The results shown are specific cytotoxicity using pooled spleen cells 
from four immunised mice.
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Figure 4.3.
ISCOMS-OVA primed CTL recognise an epitope within the OVA 
258-276 peptide. Splenic CTL induced in C57B1/6 mice by 
immunisation with ISCOMS-OVA i.p. and restimulated in vitro with 
EG7.0VA cells, were tested for their ability to lyse EL4 cells in the 
presence of the peptide OVA 258-276 or OVA 111-122. Peptides, 
which were added to the target cells before the start of the assay, 
remained present at a final concentration of 2.3pM throughout the 
51Cr release assay. The results shown are specific cytotoxicity using 
pooled spleen cells from four immunised mice.
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Figure 4.4.
Induction of OVA-specific CTL activity in popliteal lymph 
node (PLN) cells. PLN cells from C57B1/6 mice were isolated 4 days 
after footpad priming with ISCOMS-OVA or saline only and cultured 
in vitro for 4 days with rhIL-2, before OVA-specific CTL activity 
was assayed by 51Cr release assay. The results shown are specific 
cytotoxicity using pooled PLN cells from six mice.
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Figure 4.5.
Effect of M<j> paralysis on the priming of CTL responses by 
ISCOMS-OVA. C57B1/6 mice were injected with silica on two 
consecutive days, before immunisation with ISCOMS-OVA i.p. The 
results shown are percent specific cytotoxicity against EG7.0VA 
target cells using spleen cells pooled from four mice per group. 
There was no lysis of EL4 cells by any of the effector populations 
(data not shown).
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Figure 4.6.
Effect of M<|> depletion on priming of CTL responses by 
ISCOMS-OVA. C57B1/6 mice were given 0.2ml liposomes containing 
Q2MDP i.v. 24hr prior to immunisation with ISCOMS-OVA i.p. and 
spleen cells removed 7 days later for restimulation with EG7.OVA 
cells in vitro. The results shown are percent specific cytotoxicity 
against EG7.0VA target cells using spleen cells pooled from four 
mice per group. There was no lysis of EL4 cells by any of the 
effector populations.
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Figure 4.7.
FACS analysis of spleen cells from anti-CD4 mAb treated mice. 
Prior to immunisation with ISCOMS-OVA, two mice were sacrificed 
from the anti-CD4 mAb treated and untreated groups, spleen cells 
isolated and the proportion of CD4+ T cells determ ined using FACS 
analysis as described in the Materials and Methods.
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Figure 4.8
CTL responses primed by ISCOMS-OVA in vivo are CD4+ T 
cell-dependent. C57B1/6 mice were injected with anti-CD4 mAb 
(YTS 191.1) on two occasions, prior to immunisation with ISCOMS- 
OVA i.p. The results shown are percent specific cytotoxicity against 
EG7.0VA target cells using spleen cells pooled from four mice per 
group. There was no lysis of EL4 cells by any of the effector 
populations.
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Figure 4.9.
Phenotype of OVA-specific CTL primed by feeding ISCOMS- 
OVA. Spleen cells isolated from C57B1/6 mice which had been fed 
six times with ISCOMS-OVA were restimulated in vitro  with 
EG7.0VA cells, and then depleted of CD4+ or CD8+ T cells by 
monoclonal antibody plus complement treatment, before OVA- 
specific CTL activity was measured by 51Cr release assay. The 
results shown are percent specific cytotoxicity against EG7.0VA 
target cells using spleen cells pooled from four immunised mice. 
There was no lysis of EL4 cells by any of the effector populations.
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Figure 4.10.
Epitope specificity of OVA-specific CTL induced by feeding 
ISCOMS-OVA. Spleen cells isolated from C57B1/6 mice which had 
been fed six times with ISCOMS-OVA were restimulated in vitro 
with EG7.0VA cells and tested for their ability to lyse EL4 cells in 
the presence of the peptide OVA 258-276 or OVA 111-122. 
Peptides, which were added to the target cells before the start of 
the assay, remained present at a final concentration of 2.3pM 
throughout the 51Cr release assay. The results shown are specific 
cytotoxicity using pooled spleen cells from four immunised mice.
100
CHAPTER 5: PRIMING OF in vitro  PROLIFERATIVE AND
CYTOKINE RESPONSES BY ISCOMS 
Introduction
The experiments I have described thus far have shown that 
ISCOMS induce a wide range of both humoral and cell mediated 
immune effector responses in vivo. Many of these responses, such 
as IgA, IgG and DTH responses are classically dependent on CD4+ T 
cells. In addition, the induction of class I MHC-restricted CTL by 
ISCOMS also required CD4+ T cells. It was therefore important to 
examine directly the priming of antigen-specific CD4+ T cells by 
ISCOMS-OVA. Furthermore, I wished to determine if there was any 
preferential induction of the Th subsets which have been described 
in mice, based on the pattern of cytokines which they produce (27, 
45). This area had not been previously addressed following 
immunisation with ISCOMS and in general, there had been little 
investigation of ISCOMS-primed T cell functions in vitro.
To do this, I established the protocols necessary for inducing 
and assaying antigen-specific T cell proliferative responses in vitro 
in mice primed parenterally and orally with ISCOMS-OVA. In 
addition, I utilised ELISA techniques developed in this laboratory to 
assess the pattern of CD4+ T cell-dependent cytokines produced by 
ISCOMS-OVA primed cells when restimulated in vitro with soluble 
OVA.
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Experimental Protocol
Proliferative and cytokine responses were assayed in BALB/c 
or C57B1/6 mice which had been immunised s.c. with lO^g ISCOMS- 
OVA into the rear footpad or with S\ig ISCOMS-OVA i.p. or which 
had been fed 50-lOOjig ISCOMS-OVA on 3-6 occasions. Control mice 
received equivalent priming volumes of saline only.
Lymphoid organs were removed at various timepoints after 
immunisation and proliferative and cytokine responses of pooled 
lymphoid cells assayed in vitro.
OVA-specific serum IgG isotypes were assayed in BALB/c 
mice primed s.c. with a single dose of 10*ig ISCOMS-OVA into the 
right hind footpad. Primary antibody responses were measured 7 
days after priming and mice were challenged with lOOng of heat- 
aggregated OVA on dayl4  post-priming and secondary IgG 
responses assayed one week later.
Results
A) Proliferative Responses of ISCOMS Primed Lymphocytes
i) ISCOMS Prim e for A ntigen-Specific P ro life ra tive  
Responses in  vitro
In the first experiments, I examined the proliferative 
responses of draining popliteal lymph node cells from BALB/c mice 
which had been immunised s.c. 7 or 14 days previously. One week 
after immunisation, strong OVA-specific proliferative responses 
were observed in ISCOMS-OVA primed PLN cells harvested after 7
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days of in vitro culture with soluble OVA (Fig. 5.1 A), even when 
concentrations as low as l-10^g/m l OVA were used for 
restimulation. In contrast, saline-primed control PLN cells showed 
no proliferation in the presence of OVA (Fig. 5.1 A). Both populations 
had strong proliferative responses to mitogenic stimulation with 
Con A (Fig. 5.IB). Similar antigen-specific proliferative responses 
were obtained using PLN cells isolated 14 days after immunisation 
(Fig. 5.2), confirming the ability of ISCOMS to prime potent antigen- 
specific proliferative responses in the draining lymph node after s.c. 
immunisation.
ii) Kinetics of OVA-Specific Proliferative Responses in  
vi tro
The proliferative responses of ISCOMS-OVA primed PLN cells 
to restimulation with soluble OVA peaked between 4 and 6 days of 
culture in vitro, although significant responses remained detectable 
even after 8 days of culture (Fig. 5.3). At the earliest stage of the 
response, the level of proliferation was proportional to the 
concentration of OVA, but as the period of culture increased, the 
peak proliferative responses were observed at progressively lower 
concentrations of OVA (Fig. 5.3C).
Repeat experiments showed that this pattern of response was 
reproducible and in most subsequent studies I assayed 
proliferative responses 14 days after immunisation and after 6 
days culture in vitro.
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iii) Phenotype of ISCOMS-Primed Cells Proliferating in 
Response to Antigen in vitro
As ISCOMS stimulated a wide range of different T cell 
responses in vivo, I thought it important to examine the phenotype 
of the cells which were primed by ISCOMS-OVA to proliferate in 
vitro. PLN cells were depleted of either CD4+ T cells or CD8+ T cells 
using mAb plus complement treatment, before being cultured in 
vitro with OVA. As shown in Fig. 5.4, depletion of CD8+ T cells had 
no effect on the subsequent proliferative response, whereas 
depletion of CD4+ T cells completely ablated the proliferative 
response to OVA. Similar results were obtained irrespective of 
whether PLN cells were isolated 7 or 14 days after immunisation 
(Fig. 5.4), indicating that the proliferative responses to soluble OVA 
were entirely dependent on CD4+ T cells.
As the soluble OVA used to restimulate in vitro was likely to 
be processed only via the exogenous antigen processing pathway, it 
was perhaps not surprising that the responses induced by this 
challenge were dependent on CD4+ T cells. However, as ISCOMS 
induced such strong class I MHC-restricted T cell responses in vivo, 
I thought it important to examine more directly whether antigen- 
specific proliferation of CD8+ T cells could be observed during 
restimulation in vitro.
To do this, I determined whether primed CD8+ PLN cells from 
C57B1/6 mice could proliferate in response to the class I MHC- 
restricted peptide epitope OVA 257-264, which had previously 
been shown to be recognised by ISCOMS-primed CTL in this strain 
(33, 221, 226). As in BALB/c mice, intact ISCOMS-OVA primed PLN 
cells from B6 mice showed significant proliferative responses to 
soluble OVA in vitro, and these were abolished by removal of CD4+
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T cells (Fig. 5.5). However, there was no detectable proliferative 
response to the peptide OVA 257-264, using either intact PLN cells 
or cells enriched for CD8+ T cells by depletion with anti-CD4 mAb 
and complement (Fig. 5.5).
Addition of IL-2 to cultures containing peptide did induce 
significant proliferation, but this was the same in wells containing 
either primed or control PLN cells and occurred when cells were 
cultured with IL-2 in the absence of peptide (Fig. 5.5). Of particular 
note, CD4-depleted primed PLN cells showed no significant specific 
response to peptide, even when exogenous IL-2 was added. These 
results strongly suggest that the in vitro proliferative responses 
primed by ISCOMS are mediated entirely by CD4+ T cells, even 
under conditions where CD8+ T cells are provided with appropriate 
sources of antigen and IL-2.
iv) Proliferative Responses of ISCOMS Primed Spleen Cells
I next attempted to examine whether i.p. priming could also 
prime for antigen-specific proliferative responses in spleen cells.
As shown in Fig. 5.6, ISCOMS-OVA primed spleen cells, taken 
from BALB/c mice 7 days after immunisation, showed somewhat 
higher proliferation than control spleen cells when cultured with 
OVA in vitro. However, this was not antigen-specific, as the 
ISCOMS-OVA primed spleen cells showed identical incorporation of 
3H-thymidine when cultured in medium alone. The viability of the 
ISCOMS-primed spleen cells was shown by their ability to 
proliferate normally in response to the T cell mitogen Con A (Fig. 
5.6C). Similar results were obtained using spleen cells taken 14 
days after priming (data not shown) and I made identical findings 
in two futher experiments, indicating the absence of priming of
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antigen-specific proliferative responses in the spleen of ISCOMS 
primed mice.
v) Priming of in vitro  Proliferative Responses by Feeding 
ISCOMS
The results above demonstrated that ISCOMS were capable of 
inducing antigen-specific proliferative responses when 
administered parenterally. I next examined whether ISCOMS also 
primed similar antigen-specific proliferative responses when given 
by the oral route. Thus, mice were fed three times with lOO^g 
ISCOMS-OVA, their spleen and MLN cells isolated 7 days later and 
in vitro proliferative responses assayed as before.
MLN cells isolated from ISCOMS-OVA fed BALB/c mice 
showed strong proliferative responses when restimulated with high 
concentrations of OVA in vitro (Fig. 5.7). However, in contrast to the 
PLN responses, no antigen-specific proliferation occurred with MLN 
cells cultured with concentrations of OVA lower than lmg/ml. The 
kinetics of the proliferative responses of MLN cells were similar to 
those observed with PLN cells, being maximal after 6 days of 
culture in vitro, and a small, but marked, response still being 
detectable after 8 days (Fig. 5.7).
In contrast, spleen cells from mice primed orally with 
ISCOMS-OVA mounted no antigen-specific proliferative responses 
when restimulated with OVA in vitro (Fig. 5.8), with control spleen 
cells showing equivalent incorporation of 3H-thymidine when 
cultured with OVA. Similar results were obtained when cultures 
were harvested after 4, 6 or 8 days of restimulation in vitro (Fig. 
5.8) and were consistent with the failure of parenteral
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immunisation to prime detectable proliferative responses in the 
spleen.
Thus, ISCOMS were able to prime antigen-specific in vitro 
proliferative responses in the draining lymph node following either 
oral or systemic immunisation.
vi) A bility  of ISCOMS to Restim ulate P ro life ra tive  
Responses in vitro
The proliferation assays discussed thus far used native 
antigen to recall the responses of ISCOMS primed cells in vitro. It 
was also of interest to determine whether ISCOMS primed cells 
would be able to proliferate in response to restimulation with 
ISCOMS themselves, as this would indicate that ISCOMS could be 
processed and presented in vitro. As shown in Fig. 5.9, PLN cells 
isolated from BALB/c mice primed s.c. with ISCOMS-OVA exhibited 
strong proliferative responses when restimulated with ISCOMS- 
OVA in vitro. These responses were present in PLN cells taken 7 or 
14 days after priming and were maximal using concentrations 
equivalent to l-lO^g/ml OVA incorporated in ISCOMS (Fig. 5.9). 
These results show that very low amounts of protein in ISCOMS can 
be processed and presented for recognition by T cells in vitro. I 
planned to make use of this finding to study whether ISCOMS could 
directly prime immune responses in vitrot but unfortunately there 
was not enough time for me to do this.
B) Cytokine Production by ISCOMS Primed Lymphocytes
As CD4+ T cells appeared to be central to the in vivo and in 
vitro responses induced by ISCOMS-OVA and as the action of these
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cells is determined by their production of cytokines, I next 
examined the pattern of antigen-specific cytokine production by 
ISCOMS primed cells. I chose to examine IL-2 and IFN-y production 
as indicators of the Th 1 subset of CD4+ T cells and IL-4 and IL-5 as 
markers of Th2 cells (27, 45).
i) Cytokine Production by Parenterally Primed Popliteal 
Lymph Node Cells
My first experiments concentrated on PLN cells from s.c. 
primed mice, as this protocol had provided the strongest 
proliferative responses to OVA in vitro. In addition, the PLN cells 
were restimulated in vitro with the concentration of OVA found to 
be optimal for inducing proliferative responses (lmg/ml). Parallel 
cultures were performed using the T cell mitogen Con A as a 
positive control and with medium only to measure spontaneous 
cytokine production. After varying periods of culture, supernatants 
were harvested and their cytokine content assayed by ELISA.
a) IL-2
PLN cells isolated from mice 7 days after immunisation with 
ISCOMS-OVA produced a small, but significant, amount of IL-2 after 
restimulation with OVA in vitro (Fig. 5.10A). In contrast, PLN cells 
from control mice did not produce any IL-2 in the presence of OVA 
and immunised cells produced no IL-2 when cultured without OVA. 
The IL-2 response was transient, as IL-2 was only detected in 
supernatants collected after 2 days of culture and was not present 
at later timepoints (Fig. 5.10A). This pattern of IL-2 production 
probably reflects early activation of antigen-specific T cells, 
followed by its subsequent utilisation as they proliferate.
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An identical pattern of IL-2 production was observed using 
ISCOMS-OVA primed PLN cells isolated 14 days after immunisation 
(Fig. 5.11A).
b) IFN-y
In parallel, ISCOMS primed PLN cells produced IFN-y when 
cultured with OVA in vitro (Fig. 5.10B). In contrast to IL-2, the IFN- 
Y response was persistent and increasing amounts of this cytokine 
were detected over the culture period, with the highest levels being 
found after 6 days.
Small amounts of IFN-y were produced spontaneously by both 
ISCOMS primed and control PLN cells during culture (Fig. 5.10B), 
but these were much lower than the antigen-specific IFN-y 
responses of ISCOMS-OVA primed PLN cells at all times (Fig. 
5.1 OB).In addition, control cells showed no enhancement of IFN-y 
production when cultured with OVA.
Similar findings were made using PLN cells isolated 14 days 
after immunisation, with large amounts of OVA-specific IFN-y being 
produced only when ISCOMS primed cells were restimulated with 
OVA (Fig. 5.1 IB).
c) IL-4
Little or no IL-4 production could be detected at any time 
during culture of ISCOMS primed or control PLN cells in the 
presence or absence of OVA in vitro, either 7 or 14 days after 
immunisation (Table 5.1). Although these results suggest that 
ISCOMS do not prime antigen-specific IL-4 production in the 
draining lymph node, it should be noted that stimulation of both 
primed and control PLN cells with Con A also induced only very low
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amounts of IL-4 (Table 5.1). A similar lack of IL-4 production has 
been observed by others in the laboratory using mice from our 
animal facility.
d) IL-5
In contrast to their poor production of IL-4, PLN cells isolated 
one week after priming with ISCOMS-OVA produced IL-5 when 
restimulated with OVA in vitro (Fig. 5.IOC). The kinetics of IL-5 
production were different from those found with IL-2 and IFN-y, as 
IL-5 did not appear until after 4 days of culture and the highest 
levels were found after 6 days (Fig. 5.IOC). An identical pattern of 
IL-5 production was found using PLN cells isolated 14 days after 
immunisation (Fig. 5.11C).
Together, these results indicate that a single subcutaneous 
immunisation with ISCOMS can prime for the production of both 
Th 1 and Th2 cytokines by draining lymph node cells .
ii) Subcutaneous Immunisation with ISCOMS Primes for 
Splenic Cytokine Production
I next examined the ability of s.c. immunisation to prime 
disseminated cytokine production, by measuring the production of 
cytokines by spleen cells from mice primed s.c. with ISCOMS-OVA.
a) IL-2
Spleen cells isolated one week after s.c. priming with ISCOMS- 
OVA showed no antigen-specific IL-2 response when restimulated 
in vitro with OVA, despite the fact that spleen cells from both 
control and immunised mice showed marked production of IL-2 in 
response to Con A (Table 5.2). There was no difference in the
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magnitude of the mitogen-induced IL-2 responses between the 
groups (Table 5.2).
In contrast, spleen cells isolated 14 days after priming with 
ISCOMS-OVA produced small amounts of IL-2 when restimulated in 
vitro with OVA, whereas control spleen cells did not (Fig. 5.13A). 
Again the IL-2 response was observed only at the earliest 
timepoint, indicating that IL-2 production was rapidly triggered in 
primed cells upon restimulation with antigen.
b ) IFN-y
As with PLN cells, spleen cells isolated one week after s.c. 
priming with ISCOMS-OVA produced high amounts of IFN-y when 
restimulated with OVA in vitro (Fig. 5.12A). The kinetics of this 
response were similar to those observed for PLN cells, with the 
level of IFN-y increasing progressively during the culture period 
(Fig. 5.12A).
Although some IFN-y was also produced by control spleen 
cells, particularly when cultured with OVA in vitro (Fig. 5.12B), the 
amount was markedly less than that produced by the ISCOMS-OVA 
primed cells. As with PLN cells, spleen cells from both naive and 
primed mice produced small amounts of IFN-y when cultured in the 
absence of OVA.
A similar pattern of IFN-y production was observed using 
spleen cells isolated 14 days post-immunisation, with high antigen- 
specific IFN-y production by ISCOMS primed spleen cells and very 
little produced by control spleen cells (Fig. 5.13B). At this time, 
spontaneous IFN-y production by both primed and control spleen 
cells was very low (Fig. 5.13B).
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c) IL-4
As with the PLN cells, little or no IL-4 was produced by 
spleen cells restimulated with OVA (Table 5.3). Both control and 
ISCOMS-OVA primed spleen cells produced small amounts of IL-4 
following stimulation with Con A and there was no difference 
between the groups (Table 5.3).
d) IL-5
Spleen cells taken one week after s.c. priming with ISCOMS- 
OVA produced IL-5 when restimulated with OVA in vitro (Fig. 
5.12B). The pattern of IL-5 production was similar to that observed 
for PLN cells, first appearing after 4 days of culture and increasing 
thereafter (Fig. 5.12B). Control spleen cells produced little 
detectable IL-5 at any timepoint, when cultured in either the 
presence or absence of OVA (Fig. 5.12B).
A similar pattern of antigen-specific IL-5 production was 
observed with spleen cells isolated 14 days post-immunisation (Fig. 
5.13C), except that in this case a small amount of IL-5 was 
produced by ISCOMS primed spleen cells after 2 days of culture 
with OVA. Again, naive spleen cells showed little production of IL-5 
in vitro, regardless of the culture conditions (Fig. 5.13C).
Taken together, these results confirm that the priming of Th 1 
and Th2 cytokine responses was not restricted to the draining 
lymph node following s.c. immunisation, but was also disseminated 
to more distant lymphoid organs.
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iii) Cytokine Production by Spleen Cells From Mice Primed 
Orally with ISCOMS
I next investigated whether oral administration of ISCOMS 
also primed for antigen-specific cytokine production. Mice were fed 
six times with 50ng ISCOMS-OVA and, 7 days after the last feed, 
spleen cells were assayed for OVA-specific cytokine production in 
vitro.
In contrast to naive spleen cells, those taken from mice fed 
ISCOMS-OVA produced a marked am ount of IL-2 when 
restimulated with OVA in vitro (Fig. 5.14A). As in previous 
experiments on parenterally primed primed mice, the OVA-specific 
IL-2 was present only after 2 days of culture and not thereafter.
Also consistent with my previous observations, orally primed 
spleen cells did not produce any IL-4 in response to in vitro 
restimulation with OVA (Table 5.4). However, significant quantities 
of IL-4 were produced by orally primed and control spleen cells 
when cultured with Con A and there were no differences between 
the groups (Table 5.4).
Orally primed spleen cells produced large amounts of both 
IFN-y and IL-5 when restimulated in vitro with OVA (Fig. 5.14B,C). 
The kinetics of these responses were similar, with the greatest 
amounts present in supernatants isolated after 6 days of culture 
(Fig. 5.14). As in some previous experiments, naive spleen cells also 
produced significant amounts of IFN-y after 6 days of culture in the 
presence of OVA, although these were markedly lower than the 
IFN-y levels produced by spleen cells from mice fed ISCOMS-OVA 
(Fig. 5.14B).
Together, these results indicate that oral immunisation with 
ISCOMS primes an identical pattern of systemic cytokine production
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to that observed following parenteral immunisation, suggesting 
that ISCOMS are able to prime both Thl and Th2 type responses 
regardless of their route of administration.
C) Priming of Antigen-Specific IgGl and IgG2a Production 
by ISCOMS
To examine whether the pattern of cytokine production I 
observed in vitro was reflected by immune function in vivo, I 
measured the priming of OVA-specific IgG isotypes by parenteral 
immunisation with ISCOMS-OVA (227, 228). No OVA-specific IgG 
isotype responses could be detected after primary immunisation 
with ISCOMS-OVA (data not shown), but one week after challenge 
with heat-aggregated OVA, ISCOMS-OVA primed mice produced 
high titres of OVA-specific IgGl and IgG2a antibodies (Fig. 5.15). In 
contrast, control mice challenged with OVA alone produced very 
little OVA-specific IgGl or IgG2a antibody (Fig. 5.15).
Conclusions
The results of these in vitro studies show that ISCOMS prime 
strong antigen-specific proliferative responses in the draining 
lymph node after parenteral immunisation. These were entirely 
dependent on CD4+ T cells as they were ablated by depletion of this 
subset and I was unable to obtain any evidence that CD8+ T cells 
played any role in the proliferative responses. Removal of CD8+ T 
cells had no effect on the responses of primed lymph node cells and 
there was no proliferative response to the H-2Kb-restricted peptide 
epitope OVA 257-264, even in the presence of exogenous IL-2.
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These findings correlate well with my earlier observations on the 
induction of CD8+ CTL by ISCOMS in vivo, which also required the 
presence of CD4+ T cells, but do raise the question of how these CTL 
are generated in vivo.
In con trast to the PLN responses, antigen-specific 
proliferative responses could not be detected in ISCOMS primed 
spleen cell populations after either oral or parenteral immunisation. 
However, parenteral immunisation with ISCOMS primed for 
substantial amounts of antigen-specific cytokine production by both 
PLN and spleen cells following restimulation with antigen in vitro. 
Thus, efficient dissemination of the initially localised response must 
occur after immunisation with low amounts of protein antigen in 
ISCOMS (lO^g OVA).
The pattern of cytokine production by ISCOMS primed 
lymphoid cells restimulated with antigen in vitro was characterised 
by a transient IL-2 response, followed by the later accumulation of 
both IFN-y and IL-5. This indicates that both Thl and Th2 type 
CD4+ T cells were activated by immunisation with ISCOMS. This is 
supported by the wide range of both humoral and cell-mediated 
immune responses primed by ISCOMS in vivo, and was confirmed 
in the present study by the priming of both IgGl and IgG2a serum 
antibody responses.
Priming of both proliferative and cytokine responses also 
occurred after oral immunisation with ISCOMS. Strong antigen- 
specific proliferative responses were detected in draining MLN cells 
isolated from orally primed mice, while spleen cells from these 
mice produced IL-2, IFN-y and IL-5 when restimulated with 
antigen in vitro. The proliferative and cytokine responses induced 
by feeding ISCOMS showed the same characteristics as those
I
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primed by parenteral immunisation, indicating that ISCOMS were 
able to prime these local and systemic responses in a similar 
manner, regardless of the route of immunisation.
Together, the findings presented in this chapter emphasise 
the range, strength and dissemination of the immune responses 
induced by oral and parenteral immunisation with ISCOMS. In 
particular, the efficient generation of CD4+ T cell dependent 
proliferative responses and both Thl and Th2 cytokine responses, 
indicates the potent adjuvant effect of ISCOMS on this cell 
population, which is central to the development of effector immune 
responses. The biological and physico-chemical basis of these 
adjuvant properties will be explored further in chapters 7 and 8.
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Figure 5,1.
Proliferative responses of popliteal lymph node cells isolated 
7 days after priming with 10pg ISCOMS-OVA or saline s.c., after 
restimulation with OVA (A) or Con A (B) in vitro. The data 
represent mean cpm values ± 1S.D. from quadruplicate cultures 
harvested after 3 (B) or 6 days (A) of culture.
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Figure 5.2.
Proliferative responses of popliteal lymph node cells isolated 
14 days after priming with 10pg ISCOMS-OVA or saline s.c., after 
restimulation with OVA (A) or Con A (B) in vitro. The data 
represent mean cpm ± 1S.D. from quadruplicate cultures harvested 
after 3 (B) or 6 days (A) of culture.
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Figure 5.3.
Kinetics of in vitro OVA-specific proliferative responses of 
primed popliteal lymph node cells isolated 14 days after 
immunisation with 10pg ISCOMS-OVA or saline s.c. The data 
represent mean cpm ± 1S.D. from quadruplicate cultures harvested 
after 4 (A), 6 (B) or 8 days (C) of culture.
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Figure 5.4.
Role of CD4+ and CD8+ T cells in OVA-specific proliferative 
responses of ISCOMS primed LN cells. Popliteal lymph node cells 
were isolated 7 (A) or 14 days (B) after priming with 10pg ISCOMS- 
OVA s.c. and depleted of CD4+ or CD8+ T cells using mAbs plus 
complement, before restimulation with OVA in vitro. The data 
represent mean cpm ± 1S.D. from quadruplicate cultures of PLN 
harvested after 6 days of in vitro culture.
120
cpm/well 
2 0 0 0 0  1
10000 -
a
■  CONTROL 
□  INTACT 
CD4 DEPL.
OVA Con A PEP PEP + IL-2 IL-2 MED
STIMULUS
Figure 5.5.
Proliferative responses of ISCOMS-OVA primed cells and 
control cells to the OVA peptide 257-264. Popliteal lymph node 
cells were isolated from C57B1/6 mice 7 days after priming and 
used intact or after depletion of CD4+ T cells. Cells were cultured 
with soluble OVA (lmg/ml), Con A (10pg/ml) or OVA 257-264 
(200nM) ± rh IL-2 (lOU/ml). The data represent mean cpm ± 1S.D. 
from quadruplicate cultures harvested after 6 days of culture.
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Figure 5.6.
Proliferative responses of spleen cells from mice primed with 
5pg ISCOMS-OVA or saline i.p. to stimulation with OVA (A,B) or Con 
A (C) in vitro. The data represent mean cpm ± 1S.D. from
quadruplicate cultures harvested after 4 (A and C) or 6 days (B) of 
culture.
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Figure 5.7.
Proliferative responses to OVA of mesenteric lymph node 
(MLN) cells isolated from mice primed orally with ISCOMS-OVA. 
Mice were fed three times with 50*ig ISCOMS-OVA or saline and 
MLN cells taken 7 days after the last feed. The data represent mean 
cpm values ± 1S.D. from quadruplicate cultures harvested after 4 
(A),  6 (B) or  8 d a y s  (C) of  culture.
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Figure 5.8.
Proliferative responses of spleen cells isolated from mice 
primed orally with ISCOMS-OVA and stimulated with OVA in vitro. 
Mice were fed three times with 50pg ISCOMS-OVA or saline and 
spleen cells isolated 7 days after the last feed. The data represent 
mean cpm ± 1S.D. from quadruplicate cultures harvested after 4 
(A), 6 (B) or 8 days (C) of culture.
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Figure 5.9.
Stimulation of proliferative responses using ISCOMS-OVA as 
recall antigen in vitro. Popliteal lymph node cells were isolated 7 
(A) or 14 days (B) after priming with 10pg ISCOMS-OVA or saline 
s.c. The data represent mean cpm ± 1S.D. from quadruplicate 
cultures harvested after 6 days of culture.
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Figure 5.10.
Cytokine production by popliteal lymph node cells isolated 7 
days after priming of BALB/c mice with lO^g ISCOMS-OVA or 
saline s.c. PLN cells were cultured for 2-6 days in the presence 
(+OVA) or absence (+MED) of lmg/ml OVA and the supernatants 
assayed for IL-2 (A), IFN-y (B) and IL-5 (C) using sandwich ELISAs. 
The data represent mean cytokine concentrations ± 1S.D. of 
supernatants assayed in quadruplicate.
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Figure 5.11.
Cytokine production by popliteal lymph node cells isolated 14 
days after priming of BALB/c mice with 10^g ISCOMS-OVA or 
saline s.c. PLN cells were cultured for 2-6 days in the presence 
(+OVA) or absence (+MED) of lmg/ml OVA and the supernatants 
assayed for IL-2 (A), IFN-y (B) and IL-5 (C) using sandwich ELISAs. 
The data represent mean cytokine concentrations ± 1S.D. of 
supernatants assayed in quadruplicate.
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Figure 5.12.
Cytokine production by spleen cells isolated 7 days after 
priming of BALB/c mice with l(Vg ISCOMS-OVA or saline s.c. 
Spleen cells were cultured for 2-6 days in the presence (+OVA) or 
absence (+MED) of lmg/ml OVA and the supernatants assayed for 
IFN-y (A) and IL-5 (B) using sandwich ELISAs. The data represent 
mean cytokine concentrations ± 1S.D. of supernatants assayed in 
quadruplicate.
(U/ml)
IFN-y B)  
(U/ml) 300 i
200  -
100  -
IL-5 c)
O.D. 630nm ' 
0.8  -
0.6  ~
0 .4  "
0 .2  -
0 .0
DAY 2
DAY 2
DAY 4
DAY 4
□  CONTROL+MED 
■  CONTROL+OYA
□  ISCOMS+MED 
B  ISCOMS+OVA
 ___,___I'T- T
DAY 6
DAY 6
DAY 2 DAY 4 DAY 6
DAY OF CULTURE
Figure 5.13.
Cytokine production by spleen cells isolated 14 days after 
priming of BALB/c mice with lO^ ig ISCOMS-OVA or saline s.c. 
Spleen cells were cultured for 2-6 days in the presence (+OVA) or 
absence (+MED) of lmg/ml OVA and the supernatants assayed for 
IL-2 (A), IFN-y (B) and IL-5 (C) using sandwich ELISAs. The data 
represent mean cytokine concentrations ± 1S.D. of supernatants 
assayed in quadruplicate.
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Figure 5.14.
Cytokine production by spleen cells from BALB/c mice fed 
three times with 50\ig ISCOMS-OVA. Spleen cells isolated 7 days 
after the last feed were cultured for 2-6 days in the presence 
(+OVA) or absence (+MED) of lmg/ml OVA and the supernatants 
assayed for IL-2 (A), IFN-y (B) and IL-5 (C) using sandwich ELISAs. 
The data represent mean cytokine concentrations ± 1S.D. of 
s u p e r n a t a n t s  a s s a y e d  i n  quadruplicate.
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Figure 5.15.
Priming of OVA-specific serum IgG isotypes by parenteral 
immunisation with ISCOMS-OVA. Secondary antibody levels in 
BALB/c mice primed 14 days previously with lOgg ISCOMS-OVA or 
saline only s.c., were assayed one week after footpad challenge with 
lOOgg heat-aggregated OVA. Each symbol represents the titres 
from an individual mouse.
*p<0.05v. CONTROL.
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Table 5.1: Production of IL-4 by Popliteal Lymph Node
Cells After Priming with ISCOMS-OVA s.c. 
i) Day 7 Post-Immunisation_____________
CELLS STIMULUS Day 2 Dav 4 Dav 6
Medium 0.7±0.2 0.2±0.1 0.2±0.2
Control: Con A 2,1 ±03 1.8±0.5 0.5 ±0.2
OVA 0.2±0.2 0.3±0.2 0.2±0.2
Medium 0.1±0.1 0.1±0.1 0.1±0.1
ISCOMS: Con A 1.8±0.4 1.7±0.5 0.2±0.1
OVA 0.3 ±0.3 0.2±0.1 0.2±0.1
ii) Day 14 Post-Immunisation
CELLS STIMULUS Dav 2 Dav 4 Dav 6
Medium 0.1±0.1 0.2±0.1 0.1±0.1
Control: Con A 1.1±0.2 2.2±0.3 0.4±0.1
OVA 0.1±01 0.1±0.1 0.1±0.1
Medium 0.1±0.1 0.2±0.1 0.1±0.1
ISCOMS: Con A 0.8±0.2 1.5 ±0.4 0.2±0.1
OVA 0.1±01 0.1±0.1 0.1±0.1
Popliteal lymph node cells isolated 7 or 14 days after priming 
of BALB/c mice with lO^g ISCOMS-OVA or saline s.c. were cultured 
for 2-6 days in the presence of lmg/ml OVA, lO^ig/ml Con A or 
medium only. The supernatants were assayed for the presence of 
IL-4 using a sandwich ELISA and the results represent mean IL-4 
concentrations (U/ml) ± 1S.D. of supernatants assayed in 
quadruplicate.
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Table 5.2: Production of IL-2 by Spleen Cells After
Priming with ISCOMS-OVA s.c.
CELLS STIMULUS Dav 2 Dav 4 Dav 6
Medium 1.9±0.2 12.6±0.5 0.9±0.1
Control: Con A >200 >200 51.2±4.4
OVA 1.1±0.4 5.5±0.2 0.1±0.1
Medium 2.5±0.2 13.8±0.6 1.6±0.4
ISCOMS: Con A >200 >200 62.1±8.4
OVA 1.1±0.3 0.9±0.5 0.2±0.2
Spleen cells isolated 7 days after priming of BALB/c mice with 
l(Vg ISCOMS-OVA or saline s.c. were cultured for 2-6 days in the 
presence of lmg/ml OVA, 10^g/ml Con A or medium only. The 
supernatants were assayed for the presence of IL-Z using a 
sandwich ELISA and the results represen t m ean IL-2. 
concentrations (U/ml) ± 1S.D. of supernatants assayed in 
quadruplicate.
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Table 5.3: Production of IL-4 by Spleen Cells After
Priming with ISCOMS-OVA s.c. 
i) Day 7 Post-Immunisation
CELLS STIMULUS Dav 2 Dav 4 Dav 6
Medium 0.1±0.1 0.1±0.1 0.1±0.1
Control: Con A 8.7±0.6 7.3±0.7 5.4±2.3
OVA 0.1±0.1 0.1±0.1 0.1±0.1
Medium 0.1±0.1 0.1±0.1 0.1±0.1
ISCOMS: Con A 8.5±1.8 6.2±0.7 2.2±1.1
OVA 0.1±0.1 0.1±0.1 0.1±0.1
ii) Day 14 Post-Immunisation
CELLS STIMULUS Dav 2 Dav 4 Dav 6
Medium 0.1±0.1 0.1±0.1 0.1±0.1
Control: Con A 14.0±0.9 9.8±0.5 2.3±1.8
OVA 0.1±01 0.1±0.1 0.1±0.1
Medium 0.1±0.1 0.1±0.1 0.1+D.l
ISCOMS: Con A 11.3±0.9 8.4±1.5 4.4±1.2
OVA 0.1±01 0.1±0.1 0.1±0.1
Spleen cells isolated 7 or 14 days after priming of BALB/c 
mice with 10ng ISCOMS-OVA or saline s.c. were cultured for 2-6 
days in the presence of lmg/ml OVA, l(Vg/ml Con A or medium 
only. The supernatants were assayed for the presence of IL-4 using 
a sandwich ELISA and the results represent m ean IL-4 
concentrations (U/ml) ± 1S.D. of supernatants assayed in 
quadruplicate.
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Table 5.4: Production of IL-4 by Spleen Cells After Oral
Immunisation with ISCOMS-OVA
CELLS STIMULUS Dav 2 Dav 6
Medium 0.2±0.1 4.5±0.5
Control: Con A 15.7±0.9 37.0±0.8
OVA 0.2±0.1 0.2±0.1
Medium 0.2±0.1 3.1±0.3
ISCOMS: Con A 14.5 ±0.8 39.3±4.1
OVA 0.2±0.1 0.2±0.1
BALB/c mice were fed three times with 50^g ISCOMS-OVA or 
saline and spleen cells isolated 7 days after the last feed were 
cultured for 2-6 days in the presence of lmg/ml OVA, 10ng/ml Con 
A or medium only. The supernatants were assayed for the presence 
of IL-4 using a sandwich ELISA and the results represent mean IL- 
4 concentrations (U/ml) ± 1S.D. of supernatants assayed in 
quadruplicate.
135
CHAPTER 6: PRIMING OF LONG-TERM MEMORY RESPONSES
BY ISCOMS 
Introduction
A vital attribute of any potential vaccine vector is the ability 
to elicit long-lasting specific immunological memory without the 
need for repeated booster inoculations. As many current vaccines 
have to be administered as multiple doses, the identification of 
vectors which promote long-lasting protection by single 
immunisation would be of great practical and economical benefit.
The experiments I have described thus far have illustrated 
that ISCOMS are potent stimulators of primary immune responses 
in vivo. Earlier studies in the laboratory had shown that the 
primary DTH and CTL responses induced by ISCOMS-OVA in vivo 
were relatively short-lived, usually undetectable one month after 
priming (165, 229). However, this did not exclude the possibility 
that the immune system was still primed beyond this time, as it 
might be anticipated that relatively high numbers of antigen- 
specific T cells would be required to maintain primary immunity in 
vivo, whereas a few specific memory cells may remain for longer 
periods.
In this chapter, I therefore compared the persistence of 
primary immune responses for up to one year after a single 
parenteral immunisation with ISCOMS-OVA and the ability of these 
animals to generate secondary immunity after challenge in vivo 
with OVA.
136
Experimental Protocol
BALB/c mice were immunised s.c. with lO i^g ISCOMS-OVA 
into one footpad, while control mice received an equivalent volume 
of saline. At four-monthly intervals up to one year thereafter, 
groups of primed or control mice were bled for the measurement of 
primary IgG responses and were challenged in the opposite footpad 
with lOOng heat-aggregated OVA to assess the primary DTH 
response. One week after challenge, the mice were bled again to 
measure the secondary IgG response.
At the same timepoints after priming, additional groups of 
primed and control mice were sacrificed without challenge in vivo 
and the proliferative and cytokine responses of their pooled 
popliteal lymph node cells or spleen cells assayed after 
restimulation with OVA in vitro.
Results
i) Persistence of Prim ary DTH Responses Prim ed by 
ISCOMS
The first parameter I examined was the longevity of the 
primary DTH responses induced by ISCOMS-OVA. In contrast to 
earlier experience in the laboratory (165), I found that mice primed 
with a single dose of 10ng ISCOMS-OVA s.c. exhibited primary OVA- 
specific DTH when challenged with OVA for up to 8 months after 
immunisation (Fig. 6.1). At this time, the footpad response of 
ISCOMS-primed mice remained significantly greater than that in 
control mice. Four months after immunisation, ISCOMS-primed mice 
also had footpad increments around twice those observed in the
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control group, but this was not statistically significant, perhaps 
reflecting the generally small magnitude of the DTH responses in all 
groups in this experiment. One year after immunisation, no 
detectable OVA-specific DTH response remained in the ISCOMS- 
primed group (Fig. 6.1).
These results indicate that the DTH responses primed by 
ISCOMS may be more long-lived than previously reported.
ii) Persistence of Primary OVA-Specific IgG Responses 
Induced by ISCOMS-OVA
I next examined the longevity of OVA-specific IgG responses 
primed by ISCOMS-OVA. Four months after immunisation, 
significant levels of primary OVA-specific IgG antibodies were 
present in all mice immunised with ISCOMS-OVA (Fig. 6.2A). 
Similar findings were made 8 months after immunisation and even 
one year after immunisation, a small primary OVA-specific IgG 
response persisted in all ISCOMS-OVA primed mice. As anticipated, 
there was a gradual decrease in the levels of primary OVA-specific 
IgG antibodies over the period of the experiment.
The challenge protocol used to determine primary DTH 
responses allowed me to examine the secondary IgG antibody 
responses in the same mice in which primary IgG responses had 
been assessed. Unfortunately, the serum samples obtained from 
mice challenged with heat-aggregated OVA four months after 
priming were lost and I was unable to determine their secondary 
responses. However, all mice challenged with heat-aggregated OVA 
8 months after immunisation mounted a potent secondary OVA- 
specfic IgG response to heat-aggregated OVA (Fig. 6.2B). All mice 
challenged one year after immunisation also made secondary OVA-
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specific IgG responses (Fig. 6.2B), although these were of a much 
lower magnitude than those observed 8 months after priming. 
Unprimed control mice challenged with heat-aggregated OVA made 
no detectable primary IgG responses, indicating the poor 
immunogenicity of the challenge immunisation itself.
These results demonstrate that ISCOMS induced primary 
antigen-specific systemic IgG responses which persisted for at least 
12 months after a single immunisation and that these were 
accompanied by potent priming of secondary humoral immunity to 
challenge with sub-optimal dose of antigen.
iii) Persistence of In Vitro Proliferative Responses Primed 
by ISCOMS-OVA
I next examined whether the long-term persistence of 
primary DTH and antibody responses induced by ISCOMS-OVA was 
accompanied by other T cell dependent responses, as measured by 
proliferation and cytokine production in vitro.
Popliteal lymph node cells taken four months after priming 
with ISCOMS-OVA showed no antigen-specific proliferative 
response when cultured with OVA in vitro (Fig. 6.3). However, there 
was an unusually low background level of 3H-thymidine 
incorporation in this assay indicating there may have been a 
general problem with this culture assay, rather than a specific 
absence of T cell responsiveness.
This was supported by the fact that when popliteal lymph node 
cells were isolated from the same group of mice 8 months after 
priming with ISCOMS-OVA, they showed a marked OVA-specific 
proliferative response when cultured with OVA in vitro (Fig. 6.4). 
As described in earlier chapters, these responses were detectable
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after either 4 (Fig. 6.4A) or 6 days (Fig. 6.4B) of culture in vitro. 
Control lymph node cells showed no proliferative response when 
cultured with OVA in vitro.
Popliteal lymph node cells taken one year after immunisation 
also showed specific proliferative responses to soluble OVA in vitro 
(Fig. 6.5). However, these responses were of a much lower 
magnitude than those observed 8 months after priming and were 
significant only after 4 days of culture in vitro (Fig. 6.5A).
Together, these results confirm that ISCOMS primed long- 
lived T cell responses which could be restimulated by in vitro 
challenge for at least 8 months after immunisation and gradually 
waned after this time.
iv) Persistence of Cytokine Responses Primed by ISCOMS- 
OVA
It was also of interest to determine whether the pattern of 
proliferative responses observed over time after immunisation with 
ISCOMS-OVA was reflected in the production of antigen-specific 
cytokines. In these experiments, spleen cells were isolated from the 
mice used to examine the longevity of popliteal lymph node 
proliferative responses. By using spleen cells in this case, I was able 
both to obtain sufficient cells to examine the full range of cytokine 
responses and to explore the ability of local immunisation with 
ISCOMS to promote long-term disseminated immunity in other 
lymphoid tissues.
Spleen cells isolated four months after priming with ISCOMS- 
OVA produced both IL-2 and IL-5 in response to in vitro 
restimulation with OVA (Fig. 6.6). The kinetics of these responses 
were similar to those observed previously, with IL-2 only present
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on days 2 and 4 of culture in vitro and IL-5 peaking after 6 days 
(Fig. 6.6). Control spleen cells made no IL-2 or IL-5 in response to 
OVA, nor did ISCOMS-OVA primed spleen cells when cultured in the 
absence of OVA. No OVA-specific IL-4 or IFN^ was produced by 
spleen cells taken four months after immunisation, despite the fact 
that both control and ISCOMS-OVA primed cells produced 
comparable amounts of these cytokines when stimulated with Con 
A in vitro (Table 6.1).
An almost identical pattern of cytokine production was 
observed when spleen cells were isolated 8 months after 
immunisation and restimulated with OVA in vitro , with early 
production of IL-2 and later accumulation of IL-5 (Fig. 6.7). Small 
amounts of IL-5 were produced by control cells early in culture 
when restimulated with OVA, but this response was not present at 
the later timepoints. ISCOMS-OVA primed cells also produced some 
IL-5 in the absence of OVA after 6 days of culture in vitro, but this 
was much lower than the antigen-specific IL-5 response and its 
significance unclear. Again, no significant antigen-specific IL-4 or 
IFN-y production could be detected from ISCOMS-OVA primed 
spleen cells or naive control cells cultured with OVA (Table 6.2). 
Both control and ISCOMS-primed spleen cells produced IL-4 and 
IFN-y in response to in vitro culture with Con A (Table 6.2).
One year after immunisation, primed spleen cells showed 
little or no production of any cytokines when restimulated in vitro 
with OVA. The IL-2 responses observed at earlier timepoints were 
now absent (Fig. 6.8A) and the magnitude of the IL-5 response was 
greatly diminished, with only very small amounts found after 6 
days of culture in vitro (Fig. 6.8B). As before, no OVA-specific 
production of IL-4 or IFN-y was observed, although mitogenic
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stimulation induced production of these cytokines by both control 
and ISCOMS primed spleen cells (Table 6.3).
These results indicate that the priming of Thl and Th2 
dependent cytokine responses by ISCOMS shows similar kinetics to 
the other T cell dependent responses assayed above, with strong 
IL-2 and IL-5 responses persisting for at least 8 months after 
immunisation and a decline thereafter.
Conclusions
The results described in this chapter demonstrate that a 
single immunisation with 10ng protein antigen in ISCOMS primes 
long-lasting memory responses, which include all aspects of the 
immune response in vivo and in vitro.
Long-term priming of memory T cell responses was 
demonstrated by the persistence of antigen-specific DTH responses 
in vivo, as well as antigen-specific proliferation and cytokine 
production in vitro, for at least 8 months after immunisation. These 
T cell responses included both Thl andTh2 type responses, as IL-2 
and IL-5 responses were both present.
The kinetics of all these responses were similar, with a 
marked reduction in magnitude observed 12 months after priming. 
However this may have been partly attributable to the effects of 
ageing on immune responsiveness (230), as approximately 25% of 
both immunised and control mice had died prior to the conclusion 
of this experiment.
In addition to effector T cell responses, primary antigen- 
specific systemic IgG responses remained detectable even one year 
after immunisation, supporting the persistence of priming of Th2
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dependent responses. That memory B cells were also present was 
suggested by the potent secondary IgG responses found after in 
vivo challenge with OVA. Again, these immune responses decreased 
gradually over the course of the study.
In summary, these results highlight that ISCOMS are potent 
inducers of long-lasting immunity, encompassing both humoral and 
cell-mediated immune responses and activation of both Th 1 and 
Th2 memory responses. These responses can be recalled both in 
vivo and in vitro even when primary immune responses are no 
longer evident. These observations on the longevity of ISCOMS- 
primed immune responses further underline their potential use as 
future vaccine vectors.
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Figure 6.1.
Persistence of prim ary DTH responses after paren teral 
immunisation with ISCOMS. DTH responses were m easured 24hr 
a fte r challenge with lOOpg heat-aggregated  OVA of mice 
immunised at the timepoints indicated with 10pg ISCOMS-OVA or 
saline into the opposite rear footpad. The results shown are means 
± 1 S.D. for six mice per group.
* p<0.05 v. Control.
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Figure 6.2.
ISCOMS prime long-term primary and secondary OVA-specific 
serum IgG responses. Primary IgG responses (A) were assayed at 
the timepoints indicated after immunisation with 10[.ig ISCOMS- 
OVA (filled circles) or saline (open squares) into the rear footpad. 
Secondary IgG responses (B) were assayed in the same mice one 
week after challenge with lOOng heat-aggregated OVA into the 
opposite rear footpad. Results from individual mice (six mice per 
group) are expressed as the % of hyperimmune standard. * p<0.02 
v. Control.
** p<0.02 v. Control, 12 months.
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Figure 6.3.
Proliferative responses of popliteal lymph node cells isolated 
4 months after immunisation with ISCOMS-OVA. Draining PLN cells 
were taken from mice primed with 10pg ISCOMS-OVA or saline s.c. 
and restimulated with OVA in vitro. The data represent mean cpm 
values ± 1S.D. from quadruplicate cultures harvested after 4 (A) or 
6 days (B) of culture.
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Figure 6.4.
Proliferative responses of popliteal lymph node cells isolated 
8 months after immunisation with ISCOMS-OVA. Draining PLN cells 
were taken from mice primed with 10pg ISCOMS-OVA or saline s.c. 
and restimulated with OVA in vitro. The data represent mean cpm 
values ± 1S.D. from quadruplicate cultures harvested after 4 (A) or 
6 days (B) of culture.
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Figure 6.5.
Proliferative responses of popliteal lymph node cells isolated 
12 m onths after immunisation with ISCOMS-OVA. Draining PLN 
cells were taken from mice prim ed with 10pg ISCOMS-OVA or 
saline s.c. and restimulated with OVA in vitro. The data represent 
m ean cpm values ± 1S.D. from quadruplicate cultures harvested 
after 4 (A) or 6 days (B) of culture.
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Figure 6.6.
Cytokine production by spleen cells isolated 4 m onths after 
im m unisation with 10ng ISCOMS-OVA or saline s.c. Spleen cells 
were cultured for 2-6 days in the presence (+OVA) or absence 
(+MED) of 1 m g/m l OVA and the supernatants assayed for the 
presence of IL-2 (A) and IL-5 (B) using sandwich ELISAs. The data 
represent mean cytokine concentrations ± 1S.D. of supernatants 
assayed in quadruplicate.
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Figure 6.7.
Cytokine production by spleen cells isolated 8 m onths after 
im munisation with lOfxg ISCOMS-OVA or saline s.c. Spleen cells 
were cultured for 2-6 days in the presence (+OVA) or absence 
(+MED) of 1 m g/m l OVA and the supernatants assayed for the 
presence of IL-2 (A) and IL-5 (B) using sandwich ELISAs. The data 
represent mean cytokine concentrations ± 1S.D. of supernatants 
assayed in quadruplicate.
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Figure 6.8.
Cytokine production by spleen cells isolated 12 months after 
immunisation with lOjig ISCOMS-OVA or saline s.c. Spleen cells 
were cultured for 2-6 days in the presence (+OVA) or absence 
(+MED) of 1 m g/m l OVA and the supernatants assayed for the 
presence of IL-2 (A) and IL-5 (B) using sandwich ELISAs. The data 
represent mean cytokine concentrations ± 1S.D. of supernatants 
assayed in quadruplicate.
151
Table 6.1: Cytokine production by spleen cells isolated 4 
months after parenteral immunisation with ISCOMS-OVA
i) IL-4 Production (U/ml):
CELLS STIMULUS Day 2 Dav 4 Dav 6
Medium 32.5±11.2 39.9±6.5 36.5±11.0
Control: Con A 115.2±5.0 85.2±5.2 47.1±8.8
OVA 20.4±4.1 25.3±5.8 0.4±0.1
Medium 34.3±9.9 42.3±4.7 21.9±11.4
ISCOMS: Con A 63.7±17.2 50.2±14.0 47.7±8.1
OVA 22.5±3.5 15.7±7.8 0.4±0.1
ii) IFN-y Production (ng/ml):
CELLS STIMULUS Dav 2 Dav 4 Dav 6
Medium 0.1±0.1 0.1±0.1 0.1±0.1
Control: Con A >20.0 >20.0 >20.0
OVA 0.1±01 0.1±0.1 0.1±0.1
Medium 0.1±0.1 0.1±0.1 0.110.1
ISCOMS: Con A >20.0 >20.0 >20.0
OVA 0.1±01 0.1±0.1 0.1±0.1
Spleen cells isolated 4 months after immunisation with lO^ ig 
ISCOMS-OVA or saline s.c. were cultured for 2-6 days and the 
supernatants assayed for the presence of IL-4 (A) and IFN-y (B) 
using sandwich ELISAs. The data represent mean cytokine 
concentrations ± 1S.D. of supernatants assayed in quadruplicate.
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Table 6.2: Cytokine production by spleen cells isolated 8
months after parenteral immunisation with ISCOMS-OVA
i) IL-4 Production (U/ml):
CELLS STIMULUS Dav 2 Dav 4 Dav 6
Medium 0.2±0.1 0.2±0.1 0.2±0.1
Control: Con A 26.7±1.4 41.2±8.2 37.8±0.6
OVA 0.2+0.1 0.2±0.1 0.2±0.1
Medium 0.2±0.1 0.2±0.1 0.2±0.1
ISCOMS: Con A 57.2±1.2 31.7±2.6 75.3±1.6
OVA 0.2±0.1 0.2±0.1 0.2±0.1
ii) IFN-y Production (ng/ml):
CELLS STIMULUS Dav 2 Dav 4 Dav 6
Medium 0.1±0.1 0.1±0.1 4.9±0.4
Control: Con A >20.0 >20.0 >20.0
OVA 0.1±01 4.1±0.5 6.8±0.2
Medium 0.1±0.1 0.1±0.1 4.7±0.3
ISCOMS: Con A >20.0 >20.0 >20.0
OVA 0.1±01 6.2±0.3 6.4±0.3
Spleen cells isolated 8 months after immunisation with lO^g 
ISCOMS-OVA or saline s.c. were cultured for 2-6 days and the 
supernatants assayed for the presence of IL-4 (A) and IFN-y (B) 
using sandwich ELISAs. The data represent mean cytokine 
concentrations ± 1S.D. of supernatants assayed in quadruplicate.
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Table 6.3: Cytokine production by spleen cells isolated 12
months after parenteral immunisation with ISCOMS-OVA
i) IL-4 Production (U/ml):
CELLS STIMULUS Dav 2 Dav 4 Dav 6
Medium 0.2±0.1 0.2±0.1 0.2±0.1
Control: Con A 0.2±0.1 19.6±2.0 15.4±1.6
OVA 0.2±0.1 0.2±0.1 0.2±0.1
Medium 0.2±0.1 0.2±0.1 0.2±0.1
ISCOMS: Con A 0.2±0.1 17.4±2.3 20.2±1.3
OVA 0.2±0.1 0.2±0.1 0.2±0.1
ii) IFN-y Production (ng/ml):
CELLS STIMULUS Dav 2 Dav 4 Dav 6
Medium 0.1±0.1 0.1±0.1 0.1±0.1
Control: Con A 17.6±0.6 18.7±0.7 17.3±0.6
OVA 0.1±01 0.1±0.1 0.1±0.1
Medium 0.1±0.1 0.1±0.1 0.1±0.1
ISCOMS: Con A 13.7±0.7 13.5 ±0.4 11.8±0.5
OVA 0.1±01 0.1±0.1 0.1±0.1
Spleen cells isolated 12 months after immunisation with lO^g 
ISCOMS-OVA or saline s.c. were cultured for 2-6 days and the 
supernatants assayed for the presence of IL-4 (A) and IFN-y (B) 
using sandwich ELISAs. The data represent mean cytokine 
concentrations ± 1S.D. of supernatants assayed in quadruplicate.
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CHAPTER 7: THE ROLE OF QUIL A IN THE ADTUVANTICITY
OF ISCOMS 
Introduction
The results presented in previous chapters have described 
some of the host factors involved in the unusual adjuvant effects of 
ISCOMS. I next went on to examine the properties of the ISCOMS 
themselves which contribute to their adjuvanticity.
The adjuvant properties of saponins have been known for 
some time (194) and it therefore seemed likely that Quil A played a 
crucial role in the activity of ISCOMS. Quil A itself enhances both 
humoral and cell-mediated immune responses when administered 
either parenterally or orally (194, 199, 200). However, a very 
narrow range of responses have been measured and there have 
been no comparative studies of Quil A and intact ISCOMS. Thus, the 
exact contribution of Quil A to the actions of ISCOMS is unknown.
In this chapter, I therefore compared directly the adjuvant 
effects of Qpil A and ISCOMS on the range of local and systemic 
OVA-specific immune responses described previously. In addition, I 
examined the effects of Qij.il A on aspects of innate immunity, which 
may be important in the induction of cell-mediated immune 
responses. These were the ability to activate macrophages (M<t>) and 
NK cell activity.
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Experimental Protocol
Systemic IgG, DTH, proliferative and cytokine responses were 
measured in BALB/c mice which had been immunised s.c. with 
lO^ ig OVA, either as a soluble protein mixed with free Quil A, or 
incorporated in ISCOMS. Primary antibody responses were 
measured 7 days after priming and mice were challenged with 
lOOpg of heat-aggregated OVA on day 14 post-priming. Systemic 
DTH responses were measured 48hr later and secondary IgG 
responses and in vitro proliferation and cytokine production 
assayed one week later.
Splenic CTL responses were assayed in C57B1/6 mice 
immunised i.p. with lO^g OVA mixed with free Quil A or 
incorporated in ISCOMS.
Intestinal IgA reponses were assayed in BALB/c mice which 
received 6 feeds of 50*ig OVA mixed with Qjiil A or incorporated in 
ISCOMS. The ability of oral immunisation to induce systemic CTL 
activity was measured using spleen cells from C57B1/6 mice which 
had been fed 6 times with 50ng OVA plus Quil A or in ISCOMS.
To assess the effects of ISCOMS and Quil A on non-specific 
immunity, BALB/c mice were injected i.p. with Quil A or ISCOMS, 
together with 5-10ng OVA. Splenic NK cell activity was measured 
using a standard 51Cr release assay with the YAC-1 target cell line, 
while macrophage activation was measured in peritoneal exudate 
cells by assessing respiratory enzyme burst activity using a 
chemiluminescence assay (213).
In all experiments control mice received identical priming 
doses of either soluble OVA, free Quil A or saline only.
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Results
A) Parenteral Immunisation With Quil A
i) Parenteral Administration of OVA and Quil A Primes for 
Antigen-Specific IgG and DTH Responses
My first experiments compared the adjuvant activity of free 
Quil A and Quil A incorporated in ISCOMS for parenteral 
immunisation with OVA.
Although virtually no primary IgG antibody response was 
observed in the serum of BALB/c mice immunised s.c. with either 
OVA mixed with l-20^g Quil A or ISCOMS-OVA 7 days after 
immunisation, both Quil A and ISCOMS primed mice to develop 
secondary OVA-specific IgG responses when challenged with heat- 
aggregated OVA (Fig. 7.1). The secondary IgG responses in mice 
immunised with OVA and free Quil A were dependent on the dose 
of Quil A given, with significant responses only occurring when 10- 
20jig Quil A was used. Although these optimal responses were 
comparable to the secondary IgG responses obtained after 
immunisation with ISCOMS-OVA, lower doses of Quil A, including 
that equivalent to the amount given in ISCOMS (l^ig Quil A), did not 
prime mice to develop significant secondary IgG responses (Fig. 
7.1).
Both free Quil A and ISCOMS also induced significant primary 
DTH responses and again the responses elicited by free Quil A were 
dependent on the dose used (Fig. 7.2). The highest dose of Quil A 
(2CVg) provoked very potent primary DTH responses, which were 
greater than those elicited by the same amount of OVA in ISCOMS 
(Fig. 7.2). Mice receiving 5-10ng free Quil A had similar DIH
|
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responses to the ISCOMS primed group, but mice primed with lug 
Quil A, the amount present in the ISCOMS, did not mount any 
significant DTH responses (Fig. 7.2).
Thus, a single parenteral immunisation of antigen with Qjiil A 
primes both humoral and cell-mediated immunity in a dose- 
dependent manner, but Quil A is more efficient when incorporated 
within ISCOMS.
ii) Priming of Antigen-Specific Proliferative Responses by 
Parenteral Immunisation with Quil A
I next examined the ability of free Quil A to prime for 
antigen-specific proliferative responses in vitro.
Popliteal lymph node cells from BALB/c mice primed with 
either OVA plus l-20|xg Qjnil A or ISCOMS-OVA exhibited marked 
proliferative responses when restimulated with lOO-lOOO^g/ml 
soluble OVA in vitro (Fig. 7.3). In contrast to the responses in vivoy 
the level of the proliferative response induced by free Quil A did 
not show a clear dependence on the dose of Quil A used. In fact the 
highest dose of Qjail A (20^g) induced the poorest proliferative 
responses (Fig. 7.3). In addition, even the lower doses of Quil A, 
including the equivalent of that contained in ISCOMS (lug), elicited 
proliferative responses similar to those primed by ISCOMS 
themselves (Fig. 7.3).
Thus, free Quil A is able to prime local antigen-specific 
proliferative T-cell responses, with equivalent efficacy to those 
induced by ISCOMS.
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iii) Induction of Antigen-Specific Cytokine Production by 
Parenteral Immunisation with Quil A
As the proliferative responses suggested that Quil A primed 
antigen-specific T cell responses very efficiently, I examined the 
pattern of cytokines produced by spleen cells isolated from mice 
primed with different amounts of free Quil A and OVA.
a) IL-2
Spleen cells isolated from BALB/c mice 14 days after footpad 
immunisation with OVA and Quil A or in ISCOMS produced marked 
amounts of IL-2 when restimulated in vitro with soluble OVA (Fig. 
7.4). Spleen cells from control mice did not produce any IL-2 in the 
presence of OVA and immunised cells produced no IL-2 when 
cultured without OVA (Fig. 7.4). Consistent with my previous 
observations in chapter 5, the IL-2 responses were transient, being 
detected only after 2 days of culture and not at 6 days (Fig. 7.4). In 
contrast to the proliferative responses, the IL-2 responses induced 
by all doses of free Quil A were lower than those of the ISCOMS 
primed cells. The amount of IL-2 produced was directly dependent 
on the priming dose of free Quil A, with the spleen cells from mice 
primed with the dose present in ISCOMS (lug) producing very little 
IL-2 in response to OVA in vitro (Fig. 7.4).
b )  IFN-y
In addition to IL-2, spleen cells from mice primed with OVA 
plus free Quil A also produced large amounts of IFN-y when 
restimulated with OVA in vitro (Fig. 7.5). These responses were 
first detectable after 2 days of culture, but persisted until day 6. In 
contrast to the IL-2 response, there did not appear to be any clear
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correlation between the amount of IFN-y produced and the dose of 
Quil A used for priming. In general however, none of the doses of 
free Quil A induced equivalent levels of IFN-y to those produced by
ISCOMS primed cells, especially early in culture (Fig. 7.5).
In these studies, Quil A or ISCOMS primed spleen cells also 
produced significant amounts of IFN-y when cultured for 6 days in 
the absence of OVA (Fig. 7.5B), although these responses were 
markedly lower than those found after restimulation with OVA.
c) IL-4
In agreement with my earlier observations, little or no IL-4 
was produced by Quil A or ISCOMS primed spleen cells restimulated 
with OVA in vitro (Table 7.1). However, all groups produced similar 
amounts of this cytokine after restimulation with Con A (Table 7.1).
d) IL-5
Spleen cells from mice primed with OVA plus free Quil A 
produced IL-5 in response to restimulation with OVA (Fig. 7.6). 
ISCOMS primed spleen cells generally produced the highest levels 
of IL-5 and these showed a similar pattern to the responses 
described in chapter 5, with increasing amounts of IL-5 detected as 
the time of culture increased (Fig. 7.6). In the Quil A primed groups, 
the amount of IL-5 produced was dependent on the dose of Quil A, 
with cells from mice immunised with 20^g Quil A producing the 
most IL-5 and those from mice which received l i^g Quil A making 
very little IL-5 upon restimulation with OVA in vitro (Fig 7.6).
These results demonstrate that free Quil A is capable of 
priming the same range of antigen-specific Thl and Th2 cytokine
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responses as intact ISCOMS, but incorporation of Quil A into ISCOMS 
increases the efficiency of these responses.
iv) Induction of Antigen-Specific CTL Responses by 
Parenteral Immunisation with Quil A
The above findings suggested that free Qjail A was capable of 
priming CD4+ T cell dependent responses to co-administered 
protein antigen. I next compared the ability of free Quil A and Quil 
A in ISCOMS to induce OVA-specific CTL responses, as this is one of 
the most novel adjuvant properties of ISCOMS and has important 
implications for the development of vaccine vectors.
Spleen cells from mice primed with OVA either with l-20jig 
free Quil A or incorporated within ISCOMS (containing l^g Quil A) 
i.p. 7 days before and restimulated with EG7.0VA cells in vitro 
exhibited potent OVA-specific CTL activity (Fig. 7.7). The priming of 
these responses by free Qpil A was dose-dependent, with 20\ig Quil 
A producing the highest levels of OVA-specific CTL activity and 
lOjig Qjuil A inducing CTL responses comparable in magnitude to 
those elicited by ISCOMS-OVA (Fig. 7.7). There was a slight decrease 
in the OVA-specific CTL activity in mice primed with S\ig free Quil 
A, but when only l^g was used, the equivalent dose of Quil A 
contained in ISCOMS, much less CTL activity was observed (Fig. 7.7).
Unexpectedly, cells from mice given free Quil A and OVA also 
showed some non-specific cytotoxicity, as evidenced by the lysis of 
the the non-OVA expressing EL4 cell line (Fig. 7.7B). This non­
specific cytotoxicity was present even with the lowest dose of free 
Quil A (lug), but was not observed using ISCOMS primed spleen 
cells, confirming my previous findings in chapter 4. Thus, the OVA- 
specific cytotoxic response induced by free Quil A is considerably
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less than that induced by ISCOMS. This ability of free Quil A to 
induce non-specific cytotoxicity is discussed further below.
These results show that free Quil A can prime antigen-specific 
CTL responses when administered parenterally, but this is of lower 
efficiency and specificity when compared with ISCOMS.
B) Oral Immunisation With Quil A
i) Induction of Intestinal IgA and Systemic IgG Responses 
by Feeding OVA and Quil A
I next examined whether orally administered Quil A could 
stimulate the primary intestinal IgA and systemic IgG responses 
found in mice fed ISCOMS. Mice fed six times with 5(Vg OVA and 
free Quil A had significant OVA-specific IgA antibodies in intestinal 
secretions and again the magnitude of the response was dependent 
on the dose of Quil A used (Fig. 7.8). High doses of Quil A (20-4(Vg) 
induced potent OVA-specific IgA responses, while lower doses of 
Quil A, including that equivalent to the amount given in ISCOMS 
(5ng), were unable to prime significant IgA production (Fig. 7.8).
A similar pattern of OVA-specific IgG production was 
observed in the serum of mice fed Quil A plus OVA (Fig. 7.9). The 
responses were again dose-dependent, with mice fed with 20-40^g 
Quil A having equivalent OVA-specific IgG responses 
ISCOMS, while lower doses of Quil A (5-10ng) failed to prime 
significant primary IgG responses (Fig. 7.9).
Thus, Quil A is capable of inducing both local and systemic 
antigen-specific antibody responses when administered orally, but 
does so more efficiently when incorporated within ISCOMS.
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ii) Induction  of Antigen-Specific CTL following Oral 
Immunisation with Quil A
As Quil A was capable of adjuvant activity when administered 
orally and ISCOMS can prime CTL responses by this route, I 
compared the ability of Quil A and ISCOMS to induce antigen- 
specific CTL responses in mice fed OVA.
As I have described in previous chapters, mice fed 50\ig 
ISCOMS-OVA on 6 occasions over a 10 day period developed high 
levels of OVA-specific CTL in the spleen (Fig. 7.10). Mice fed the 
same amount of OVA with free Quil A also generated strong OVA- 
specific CTL responses (Fig. 7.10A). However, as with systemic 
immunisation, the CTL responses primed by oral administration of 
Quil A and OVA were highly dose-dependent, with doses in excess 
of 2(Vg Quil A necessary for optimal priming. The 5^g Qjiil A dose, 
equivalent to that found in ISCOMS-OVA, elicited only low levels of 
OVA-specific systemic CTL (Fig. 7.10A).
As found after parenteral immunisation, there was also a 
significant non-specific cytotoxic component to the responses 
induced by free Quil A, as evidenced by the lysis of non-OVA 
expressing EL4 (Fig. 7.10B). This non-specific cytotoxicity was not 
observed following immunisation with ISCOMS-OVA and again 
appeared to be associated with the presence of free Quil A (Fig. 
7.10B).
Thus, Quil A is able to prime potent CTL responses when 
administered orally, but again, ISCOMS induce more efficient and 
specific responses by this route.
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C) Activation of Innate Immunity bv Quil A
The results described above indicate that both Quil A and 
ISCOMS are potent adjuvants, especially for T cell dependent 
immunity. One factor which has been suggested to be involved in 
the activity of many adjuvants is the stimulation of non-specific 
inflammatory mechanisms important in the initial stages of 
activation of antigen-specific T lymphocytes (231, 232). I examined 
this by investigating the ability of ISCOMS and Quil A to activate 
macrophages and natural killer (NK) cells.
i) Chemiluminescence of Peritoneal Macrophages Induced 
by Q.uil A
To examine macrophage activation, I employed a 
chemiluminescence assay that can be used to discriminate between 
macrophage populations which have been elicited by an 
inflammatory or immunological stimulus, the la tter being 
characterised by their enhanced oxidative metabolic capacity (213).
In this assay, peritoneal exudate cells (PEC) were obtained 
from BALB/c mice which had been injected i.p. with lO^g OVA plus 
l i^g Quil A or incorporated in ISCOMS-OVA, 4 days before. Adherent 
M<|> were then stimulated with PMA in the presence of luminol and 
oxidative metabolism measured in a luminometer (213). Heat-killed 
Corynebacterium parvum was used as a stimulus which induces 
immunologically activated M<J>, while thioglycollate broth was used 
as an example of a non-specific inflammatory agent (213).
As shown in Figure 7.11, PEC elicited by C. parvum exhibited a 
rapid oxidative burst after stimulation with PMA, which peaked 
after 3-4 mins and gradually declined thereafter. In contrast,
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thioglycollate induced PEC did not make any significant oxidative 
response upon stimulation with PMA, confirming the entirely 
inflammatory nature of these cells (Fig. 7.11). PEC from ISCOMS- 
OVA primed mice produced a small, but marked, oxidative burst in 
response to PMA stimulation, although this was of much lower 
magnitude than the response of the C. parvum elicited cells (Fig.
7.11). Similarly, PEC primed by Quil A plus OVA also mounted a 
small oxidative response after PMA stimulation, which was only 
slightly lower than that obtained from ISCOMS primed cells (Fig.
7.11).
These results suggest that ISCOMS and free Quil A may 
activate M<|> in an immunological manner, albeit to a lesser degree 
than strong immunoJcgictti stimuli such as heat-killed C.parvum.
ii) Enhancement of Natural Killer Cell Activity by Quil A
As my previous results showed that parenteral immunisation 
with free Quil A, but not ISCOMS, induced non-specific cytotoxicity 
in the spleen, I investigated whether natural killer (NK) cell activity 
was enhanced by Quil A.
Spleen cells isolated one day after injection of l-20^g free 
Quil A showed a small but consistent enhancement of NK cell 
activity against YAC-1 cells, compared with control cells (Fig. 
7.12A). This augmentation was dependent on the dose of Qpil A 
adminstered, with 20ng Quil A producing the greatest increase and 
lug Quil A having very little effect on NK activity (Fig 7.12A).
The enhancement of NK activity was more pronounced when 
spleen cells were isolated 3 days after injection and again directly 
correlated with the dose of Quil A administered (Fig. 7.12B). The 
increase in NK activity appeared to be a transient phenomenon
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however, as spleen cells isolated 7 days after injection did not 
exhibit enhanced NK cell activity, compared with controls (Fig. 
7.12C).
These results demonstrate that free Quil A induces a dose- 
dependent but transient increase in splenic NK cell activity.
Conclusions
The results in this chapter demonstrate that Quil A acts as an 
adjuvant for the same range of humoral and cell-mediated immune 
responses induced by oral or parenteral immunisation with ISCOMS. 
However, by directly comparing equivalent doses of free Quil A and 
Quil A in ISCOMS, I have been able to show that free Qpil A is less 
efficient than the intact vector.
Parenteral immunisation with OVA and Quil A primed 
systemic antigen-specific DTH , CTL and IgG antibody responses in 
vivo, as well as T cell proliferative activity and Thl and Th2-type 
cytokine production in vitro. In addition, oral immunisation with 
OVA and Quil A induced local antigen-specific intestinal IgA 
production, together with systemic IgG and CTL responses. These 
findings indicate that, like intact ISCOMS, free Quil A allows antigen 
to gain access to both the exogenous and endogenous pathways of 
antigen processing and presentation in vivo. In addition to its 
effects on the presentation of exogenous protein antigen to specific 
lymphocytes, Quil A also had marked effects on innate immune 
responses including the activation of M<J> and NK cells, as well as the 
non-specific stimulation of regulatory cytokines such as IFN-y.
In summary, my results indicate that the oral and parenteral 
adjuvant properties of ISCOMS are shared by Quil A itself. However,
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my findings that equivalent doses of Quil A were generally much 
more efficient when incorporated into ISCOMS, show that additional 
factors must be important for the potent adjuvanticity of intact 
ISCOMS.
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Anti-OVA antibody
O.D. (405nm) I  1° Sera 
□  2° Sera
0 . 8  -
0 .4  -
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CONTROL ISCOMS QA20 QA10 QA5 QA1
Figure 7.1.
Priming of OVA-specific serum IgG responses by parenteral 
immunisation with Quil A and OVA. Primary IgG responses were 
measured 14 days after immunisation with lO^g OVA plus l-20^ig 
Quil A (QA), 10ng ISCOMS-OVA or saline only s.c., while secondary 
IgG responses were assayed one week after footpad challenge of 
primed mice with lOOjig heat-aggregated OVA. The data represent 
mean O.D. (405nm) values ± 1 S.D. from six mice per group.
* p<0.05 v. Control.
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0 .4  ~
0 .3  -
0 . 2 -
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CONTROL ISCOMS QA20 QA10 QA5 QA1
Figure 7.2.
Priming of OVA-specific DTH responses by parenteral 
immunisation with Quil A and OVA. DTH responses were measured 
24hr after challenge with lOO^g heat-aggregated OVA in mice 
immunised 14 days previously with lO^g OVA plus l-20pg Quil A 
(QA), 10fig ISCOMS-OVA or saline only s.c. Results shown are means 
± 1S.D. for six mice per group.
* p<0.05 v. Control.
** p<0.002 v. Control and QA1; p<0.02 v. all other groups.
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F igu re  7.3.
Priming of antigen-specific pro liferative responses by 
paren tera l im m unisation with Quil A and OVA. Proliferative 
responses of draining popliteal lymph node cells isolated 14 days 
after immunisation with lCVg OVA plus l-2(Vg Quil A (QA), lOpg 
ISCOMS-OVA or saline only s.c., were assayed to stimulation with 
OVA in vitro. The data represent mean cpm values ± 1S.D. from 
quadruplicate cultures harvested after 6 days of culture.
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Figure 7.4.
IL-2 production by spleen cells from mice primed with Quil A 
and OVA. Spleen cells taken 14 days after immunisation with lO i^g 
OVA plus l-2(Vg Quil A (QA), lO i^g ISCOMS-OVA or saline only s.c., 
were cultured for 2 days (A) or 6 days (B) in the presence or 
absence of lm g/m l OVA and the supernatants assayed for IL-2 by 
ELISA. The data represent mean cytokine concentrations ± 1S.D. of 
supernatants assayed in quadruplicate.
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Figure 7.5.
IFN-y production by spleen cells from mice primed with Quil 
A and OVA. Spleen cells taken 14 days after immunisation with 
l(Vg OVA plus l-20^ig Quil A (QA), 10(.ig ISCOMS-OVA or saline 
only s.c., were cultured for 2 days (A) or 6 days (B) in the presence 
or absence of lm g/m l OVA and the supernatants assayed for IFN-y 
by ELISA. The data represent mean O.D. 630nm values ± 1S.D. of 
supernatants assayed in quadruplicate.
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Figure 7.6.
IL-5 production by spleen cells from mice primed with Quil A 
and OVA. Spleen cells taken 14 days after immunisation with lOpig 
OVA plus l-20^ig Quil A (QA), 10^g ISCOMS-OVA or saline only s.c., 
were cultured for 2 days (A) or 6 days (B) in the presence or 
absence of lm g/m l OVA and the supernatants assayed for IL-5 by 
ELISA. The data represent mean cytokine concentrations ± 1S.D. of 
supernatants assayed in quadruplicate.
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Figure 7.7.
Induction of OVA-specific CTL responses by paren tera l 
im munisation with Quil A and OVA. Splenic CTL activity was 
assayed in C57B1/6 mice immunised 7 days before with lCVg OVA 
plus l-20(Ltg Quil A (QA), 10|Lig ISCOMS-OVA or saline only i.p., after 
restimulation in vitro for 5 days with EG7.0VA cells. Results shown 
are percent specific cytotoxicity using spleen cells pooled from four 
mice per group.
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Intestinal anti-OVA IgA (OD 405nm)
Figure 7.8.
Induction of OVA-specific intestinal IgA responses by oral 
im m unisation with Quil A and OVA. Intestinal washes were 
obtained from BALB/c mice 7 days after the last of six feeds of 
50fig OVA plus 5-40|xg Quil A (QA)> 50|.ig ISCOMS-OVA or saline 
only. Results shown represent mean O.D. 405nm values ± 1S.D. from 
six mice per group.
*p<0.05 v. CONTROL.
**p<0.02 v. CONTROL.
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Figure 7.9.
Induction of OVA-specific serum  IgG responses by oral 
immunisation with Quil A and OVA. Sera were obtained from 
BALB/c mice 7 days after the last of six feeds of 5(Vg OVA plus 5- 
40^ig Quil A (QA), 5CVg ISCOMS-OVA or saline only. Results shown 
represent mean O.D. 405nm values ± 1S.D. from six mice per group. 
*p<0.05 v. CONTROL.
176
% Specific
Cytotox ic ity
A) EG7.QVA TARGETS
ISCOMS
QA40
QA20
QA10
QA5
30  "
2 0  "
100:1 50:1 25:1
E:T RATIO
% Specific
Cytotoxicity 
30 i B) EL4 TARGETS
20  ~
100:1 50:1 25:1
E:T RATIO
Figure 7.10.
Indu c tio n  of OVA-specific CTL re sp o n ses  by ora l 
im munisation with Quil A and OVA. Splenic CTL activity was 
assayed in C57B1/6 mice 7 days after the last of six feeds of 50pg 
OVA plus 5-40ng Quil A (QA), 5(Vg ISCOMS-OVA or saline only, 
after restimulation in vitro for 5 days with EG7.0VA cells. Results 
shown are percent specific cytotoxicity using spleen cells pooled 
from four mice per group.
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Figure 7,11.
Respiratory burst activity of peritoneal exudate cells (PEC) 
after adm inistration of Quil A or ISCOMS. A dherent PEC were 
isolated from mice 4 days after i.p. administration of Uig free Quil 
A, ISCOMS-OVA containing lpg Quil A, lm g  h ea t-k illed  
Corynebacterium parvum or 2mls thioglycollate broth and their 
oxidative m etabolic capacity assayed by chemiluminescence 
following stimulation with 0.5^ig/ml PMA in vitro.
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Figure 7.12.
Enhancement of splenic natural killer (NK) cell activity by Quil 
A. Splenic NK cell activity was assayed in BALB/c mice 1 day (A), 3 
days (B) or 7 days (C) after injection of l-20ng Quil A (QA) or saline 
only i.p. Results shown are percent specific cytotoxicity against 
YAC-1 target cells using spleen cells pooled from two mice per 
group.
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Table 7.1: IL-4 production  bv spleen cells from  mice
primed with Quil A and OVA
CELLS STIMULUS Dav 2 Dav 6
Medium O.liO.l 0.6±0.3
Control: Con A 14.5 ±4.9 6.7±3.5
OVA 0.1±0.1 0.3 ±0.2
Medium 0.1±0.1 O.liO.l
ISCOMS: Con A 28.7H.3 31.2±2.6
OVA 1.8±1.0 O.liO.l
Medium 0.1±0.1 1.7±0.6
QA20: Con A 34.9±2.3 21.4±7.1
OVA 0.6±0.6 0.3±0.3
Medium 0.1±0.1 2.1±0.8
QA10: Con A 23.4±1.0 19.7±2.7
OVA 0.3±0.2 0.7±0.4
Medium 0.1±0.1 1.3±1.0
QA5: Con A 33.9±2.1 21.3±2.1
OVA 0.1±0.1 0.7±0.6
Medium O.liO.l 2.7±2.0
QA1: Con A 30.2±2.2 39.3±7.6
OVA O.liO.l 0.8±0.6
Spleen cells taken 14 days after immunisation with lOng OVA
plus l-2(Vg Quil A (QA), l(Vg ISCOMS-OVA or saline only s.c., were 
cultured for 2 or 6 days in the presence or absence of lmg/ml OVA 
and the supernatants assayed for IL-4 by ELISA. The data 
represent mean IL-4 concentrations (U/ml) ± 1S.D. of supernatants 
assayed in quadruplicate.
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CHAPTER 8: INDUCTION OF MUCOSAL AND SYSTEMIC
IMMUNE RESPONSES BY IMMUNISATION WITH OVA 
E NT RAP P E D IN POLY( LACTI DE-CO-GLYCOLIDE) 
MICROPARTICLES
Introduction
The results described in previous chapters have shown that 
ISCOMS are potent adjuvants when administered either orally or 
parenterally and a substantial part of this activity is due to the 
saponin component Qjiil A. However, Quil A itself was not as potent 
as when incorporated into ISCOMS and in this chapter, I have 
attempted to define how the particulate nature of the ISCOMS 
contributes to their adjuvant effects by comparing them with 
another particulate vaccine vector which lacked Qpil A.
Biodegradable microparticles composed of poly(lactide-co- 
glycolides) (PLG) release antigen over a long period after in vivo 
administration (233). Parenteral or oral immunisation with antigen 
entrapped in microparticles induces systemic and mucosal antibody 
responses, indicating the potential usefulness of this approach for 
the induction of mucosal and systemic immune responses (108, 
234). The availability of PLG microparticles containing OVA thus 
allowed me to compare the mucosal adjuvanticity of ISCOMS 
directly with another particulate vector.
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Experimental Protocol
OVA-containing PLG microparticles, prepared as described in 
the Materials and Methods, were provided by Dr. D.T. O'Hagan 
(University of Nottingham).
Systemic IgG and DTH responses were measured in BALB/c 
mice immunised s.c. into the rear footpad with either lOO^g OVA 
entrapped in PLG microparticles or with KVg ISCOMS-OVA. For the 
induction of antigen-specific proliferative responses, BALB/c mice 
were immunised s.c. into the rear footpad with either 50^g OVA in 
microparticles or 5^g ISCOMS-OVA and the draining popliteal 
lymph node cells were isolated 14 days later.
Splenic CTL responses were assayed in C57B1/6 mice which 
had been immunised 7 days before with S\ig orlOOpg or OVA in 
microparticles or 5^g ISCOMS-OVA i.p. To induce popliteal lymph 
node CTL responses, C57B1/6 mice were primed s.c. with 50\ig OVA 
in microparticles or 5^g ISCOMS-OVA and the draining popliteal 
lymph node cells were isolated 4 days later.
To assess mucosal immunogenicity, intestinal IgA responses 
were assayed in BALB/c mice one week after the last of 6 feeds of 
lOO^ ig OVA in PLG microparticles. Splenic CTL responses were 
measured in C57B1/6 mice one week after the last of 3 or 6 feeds of 
either 100 f ig  OVA in PLG microparticles or 50^g ISCOMS-OVA.
In all experiments, control mice received identical priming 
doses of saline only.
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Results
i) OVA Entrapped in PLG M icroparticles or in ISCOMS 
Primes for OVA-Specific IgG and DTH Responses
My first experiments set out to confirm the adjuvant activity 
of PLG microparticles for parenteral immunisation and to compare 
this with the responses induced with OVA in ISCOMS. Virtually no 
primary IgG antibody response was observed in mice immunised 
into the rear footpad with either OVA in PLG microparticles or 
ISCOMS-OVA 7 days after immunisation (Fig. 8.1). However, both 
PLG-OVA and ISCOMS-OVA primed mice to develop highly 
significant OVA-specific IgG responses when challenged with heat- 
aggregated OVA (Fig. 8.1). The responses of the ISCOMS-OVA 
primed group were significantly higher than those of the 
microparticle primed group, despite the fact that the ISCOMS 
contained 10-fold less antigen.
Both adjuvants induced significant primary DTH responses 
and there was no significant difference between the ISCOMS and 
PLG primed groups (Fig. 8.2).
These results confirm previous findings that a single 
parenteral immunisation of antigen in PLG microparticles or 
ISCOMS can prime systemic humoral and cell mediated responses 
and indicate that they are of generally comparable magnitude.
ii) Priming of Antigen-Specific Proliferative Responses by 
OVA in PLG Microparticles or ISCOMS
As there had been little previous examination of the priming 
of T cells by PLG microparticles, I next compared the abilities of 
PLG entrapped OVA and ISCOMS-OVA to prime for antigen-specific
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proliferative responses in vitro. Popliteal lymph node cells isolated 
two weeks after s.c. immunisation with either ISCOMS-OVA or OVA 
in PLG microparticles exhibited marked proliferative responses to 
restimulation with exogenous soluble OVA (Fig. 8.3A). However, 
these responses were only evident at the highest concentrations of 
OVA when microparticle primed cells were used. In contrast, as I 
have shown before, ISCOMS primed cells responded at 
concentrations of as little as l-10^g OVA/ml. Unprimed cells 
showed no response to OVA in vitro and both responded strongly to 
stimulation with Con A (Fig. 8.3B)
Thus, while these findings clearly show tha t PLG 
microparticles can prime local proliferative T cell responses, 
ISCOMS appear to be more potent for this purpose.
iii)  Induction  of OVA-Specific CTL by P a re n te ra l 
Immunisation with OVA Entrapped in Microparticles or in 
ISCOMS
As PLG microparticles shared the ability of ISCOMS to induce 
peripheral T cell responses, I went on to examine whether PLG 
microparticles were also capable of generating OVA-specific CTL 
responses.
As expected, spleen cells from mice primed with 5^g ISCOMS- 
OVA i.p. exhibited very high levels of OVA-specific CTL activity, 
even at E:T ratios as low as 6.25:1 (Fig. 8.4A). In contrast, mice 
immunised with the same amount of OVA in PLG microparticles had 
no OVA-specific CTL activity in the spleen (Fig. 8.4A). Mice 
immunised with a much larger dose of OVA (lOOjig) in PLG 
microparticles did generate OVA-specific CTL responses, but these 
were much reduced at lower E:T ratios when compared with those
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found using ISCOMS-OVA primed cells (Fig. 8.4A). These results 
show for the first time that PLG microparticles can prime CTL in 
vivo, but they are less efficient than ISCOMS in this respect.
To confirm this finding, I examined for the presence of CTL 
precursors in the draining lymph node following footpad 
immunisation with 5(Vg OVA in microparticles or 5^g ISCOMS-OVA, 
without further restimulation with antigen. As shown in Fig. 8.4B, 
ISCOMS-OVA primed cells showed substantial OVA-specific CTL 
activity in this assay, whereas no CTL activity could be detected in 
the PLG microparticle primed group.
These results confirm that PLG microparticles are less 
efficient at priming antigen-specific CTL responses than ISCOMS, 
when administered parenterally.
iv) Induction of OVA-Specific CTL by Oral Immunisation 
with OVA in PLG Microparticles or ISCOMS
To explore further the ability of PLG microparticles to induce 
CTL activity, I next compared the ability of PLG and ISCOMS to 
induce systemic CTL responses when administered orally. As in 
previous experiments, mice fed lOO^g OVA in ISCOMS six times
over a 10 day period developed high levels of OVA-specific CTL in 
the spleen (Fig. 8.5A). Comparable levels of OVA-specific CTL were 
found in mice fed the same amount of OVA in PLG microparticles 
(Fig. 8.5A). However, mice fed ISCOMS-OVA on only 3 occasions still 
exhibited strong splenic CTL responses, whereas those receiving 3 
oral immunisations with OVA in PLG microparticles had only very 
low levels of OVA-specific CTL activity (Fig. 8.5B).
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Thus, PLG microparticles are also able to prime CTL responses 
when administered orally, but again, ISCOMS are more efficient by 
this route.
v) Induction of Intestinal IgA Responses by Feeding OVA 
in PLG Microparticles
As previous studies had indicated that feeding antigen 
entrapped in PLG microparticles could induce systemic and salivary 
antibody responses, I also examined the induction of OVA-specifc 
intestinal IgA responses by oral immunisation with OVA in PLG 
microparticles. Mice fed 6 times with HXVg OVA in PLG 
microparticles had significant OVA-specific IgA in intestinal 
secretions (Fig. 8.6), confirming that PLG microparticles are potent 
inducers of local and systemic antibody responses when 
administered orally.
Conclusions
These studies show that oral or parenteral immunisation with 
antigen entrapped in PLG microparticles primes a wide range of 
humoral and cell-mediated immune responses, both locally and 
systemically. This extends previous reports of the adjuvant activity 
of PLG microparticles, by demonstrating the stimulation of T cell 
responses, particularly antigen-specific CTL activity after either 
parenteral or oral administration. However, the CTL responses 
induced by ISCOMS were usually higher than those induced by PLG 
microparticles, requiring fewer or lower doses of antigen. It was 
also impossible to detect CTL activity in PLG-OVA immunised mice 
without in vitro restimulation with antigen.
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Interestingly, PLG seemed relatively more efficient when 
given by the oral route a finding supported by the fact that oral 
immunisation with OVA in PLG induced antigen-specific IgA 
responses in the small intestine itself. This extends previous studies 
which showed serum IgG and salivary IgA antibody responses in 
mice fed PLG-OVA (108, 234).
These preliminary findings indicate that only part of the 
adjuvant effect of ISCOMS can be ascribed to their particulate 
nature, supporting evidence from the previous chapter on the 
adjuvant properties of free Qtxil A.
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Figure 8.1.
Priming of OVA-specific serum IgG responses by parenteral 
immunisation with OVA in PLG microparticles. Primary sera were 
obtained one week after priming of BALB/c mice with either 10(Vg 
OVA in PLG microparticles, 10|ig ISCOMS-OVA or saline only s.c., 
while secondary IgG responses were assayed one week after 
footpad challenge of primed mice with lOO i^g heat-aggregated OVA. 
Mean O.D. values ± 1S.D. are shown for 6 mice per group.
* pcO.OOl v. Control.
** pcO.OOl v. Control; p<0.005 v. PLG-OVA.
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Figure 8.2.
Priming of OVA-specific system ic DTH responses by 
paren teral immunisation with OVA in PLG microparticles. DTH 
responses were measured 24hr after footpad challenge with lOOpg 
heat-aggregated OVA in BALB/c mice which had been prim ed 14 
days previously with either lOOpg OVA in PLG microparticles, 10pg 
in ISCOMS-OVA or saline only s.c. Results shown are means ± 1S.D. 
for 6 mice per group.
* p<0.05 v. Control.
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Figure 8.3.
Priming of antigen-specific proliferative responses by OVA in 
PLG microparticles. Proliferative responses of draining popliteal 
lymph node cells were assayed 14 days after priming with either 
50pg OVA in PLG microparticles, 5pg ISCOMS-OVA or saline only 
s.c., to in vitro restimulation with (A) OVA or (B) Con A. The data 
represent mean cpm values ± 1S.D. from quadruplicate cultures 
harvested after 4 days (B) or 6 days (A) of culture.
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Figure 8.4.
Induction of OVA-specific CTL responses by paren tera l 
immunisation with OVA in PLG microparticles. (A) Splenic CTL 
responses were assayed one week after priming with either 5pg 
ISCOMS-OVA or 5pg or 100pg OVA in PLG microparticles i.p., after 
restimulation in vitro with EG7.0VA cells. (B) PLN CTL responses 
were assayed 4 days after priming with either 50pg OVA in PLG 
microparticles or 5pg ISCOMS-OVA s.c., after in vitro restimulation 
with rhIL-2. Results shown are specific cytotoxicity against 
EG7.0VA cells using cells pooled from 4 mice per group. There was 
no lysis of EL4 cells by any of the effector populations
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Figure 8.5.
Induction of OVA-specific systemic CTL responses by oral 
im m unisation with OVA in PLG m icroparticles. Splenic CTL 
responses were assayed one week after the last of 6 feeds (A) or 3 
feeds (B) of either lOO i^g OVA in PLG m icroparticles or 5CVg 
ISCOMS-OVA, after restim ulation in vitro with EG7.0VA cells. 
Results shown are specific cytotoxicity against EG7.0VA cells using 
cells pooled from 4 mice per group. There was no lysis of EL4 cells 
by any of the effector populations.
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Figure 8.6.
Oral immunisation with OVA in PLG microparticles induces 
OVA-specific intestinal IgA. BALB/c mice were fed six times over a 
ten day period with lOCVg OVA in PLG microparticles or saline only 
and intestinal washes obtained one week later. Results shown are 
mean O.D. (405nm) values +1S.D. from six mice per group.
* p<0.05 v. Control.
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CHAPTER 9: DISCUSSION
Introduction
The results presented in this thesis have confirmed and 
extended previous findings on the induction of immune responses 
by ISCOMS. In addition, they have highlighted several important 
features of the host immune response, and of ISCOMS themselves, 
which contribute to their adjuvant properties. These results have 
implications not only for oral vaccine development, but also for 
understanding the regulation of immune responses to protein 
antigens in vivo.
Nature of the Immune Responses Induced by Oral and 
Parenteral Administration of ISCOMS
The results in chapter 3 showed that ISCOMS primed a wide 
range of humoral and cell-mediated immune responses when 
administered either orally or parenterally. These included systemic 
IgG and secretory IgA antibodies, systemic DTH responses, and 
antigen-specific CTL responses. Although the ability of ISCOMS to 
induce both humoral and cell-mediated immunity has been 
demonstrated with a wide variety of protein antigens, this study 
was the first to assess the parallel induction of such a wide range of 
immune responses in vivo.
The first important finding was that a single parenteral 
immunisation with as little as 5-10fig of a soluble protein antigen in 
ISCOMS primed antigen-specific IgG responses, confirming what we 
and others had shown previously (159, 165, 169, 170, 172, 173,
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179, 181). I also confirmed that this immunisation regime elicited 
potent antigen-specific DTH responses (165), indicating efficient 
priming of both B and T cells by antigen incorporated in ISCOMS.
Parenteral immunisation with ISCOMS-OVA also elicited high 
levels of antigen-specific CTL activity in the spleen, which was 
entirely mediated by CD8+ T cells. These results suggest that, in 
addition to processing and presentation of antigen by the exogenous 
route to class II MHC-restricted CD4+ T cells, incorporation within 
ISCOMS allowed soluble protein antigen access to the endogenous 
processing pathway for recognition by CD8+ T cells. This unusual 
ability of ISCOMS to induce potent CTL responses has been 
confirmed in a number of other systems (184, 212, 235, 236) and 
may be of vital importance for protecting against many viral 
infections.
The most impressive property of ISCOMS to be demonstrated 
in chapter 3 was their ability to elicit a wide range of local and 
systemic immune responses when administered orally. This 
required repeated oral immunisation, with optimal immune 
responses occurring when ISCOMS were fed six times over a 10 day 
period. The responses induced included the induction of secretory 
IgA in the intestine, as well as systemic IgG, DTH and CTL 
responses. These observations are in contrast to the systemic 
immunological tolerance normally induced by feeding soluble 
protein antigen (54), but are consistent with the findings that local 
and systemic immunity can be induced by in tranasal 
administration of ISCOMS (173, 183, 235). This suggests that 
presentation in ISCOMS allows protein antigens to avoid the 
regulatory mechanisms which normally operate at mucosal 
surfaces. This may be due in part to their ability to withstand the
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harsh environments of the stomach and small intestine (166) and 
may also reflect the particulate nature of antigen in ISCOMS, which 
may alter both uptake and immunogenicity of orally administered 
antigen (128). Evidence for this hypothesis has come from recent 
studies showing that prior administration ISCOMS enhances the 
uptake of orally administered protein into the systemic circulation 
(237). In parallel, serum from these mice does not contain the 
tolerogenic material normally found in animals fed soluble proteins 
(Furrie E, Mowat AMcI; manuscript in preparation). The exact 
reasons for this are unclear, but cholera toxin, one of the most well 
studied oral adjuvants, has many effects on the intestinal 
environment, including increasing intestinal permeability and 
antigen uptake (238), altering epithelial cell function (152, 239) 
and activation of local and systemic APC (148, 151), a process 
known to interfere with oral tolerance (240). Further studies on the 
effects of ISCOMS on these parameters are necessary in order to 
elucidate the mechanisms responsible for their oral adjuvant 
properties.
The fact that multiple oral immunisations of 10-20 fold more 
antigen than that used for systemic immunisation were required to 
efficiently prime via the oral route, suggests that some degradation 
of either the ISCOMS or of the incorporated antigen did occur after 
feeding. Nevertheless, effective immunisation with other oral 
adjuvants such as cholera toxin also requires repeated feeding 
(143), indicating the general difficulty in stimulating solid 
immunity at mucosal sufaces. The fact that the most important 
factor governing the induction of immune responses to orally 
administered ISCOMS and CT is the frequency of antigen 
administration, rather than the total dose of antigen given, may
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reflect the need for repeated stimulation of a relatively small 
number of antigen specific precursors in the gut-associated 
lymphoid tissues (GALT). The site of priming of the immune system 
by orally administered ISCOMS is unknown, but the presence of 
secretory IgA responses and CTL responses in the MLN suggests 
that priming occurs locally in the GALT. In addition, it must be 
emphasised that feeding ISCOMS simultaneously primed systemic 
immune responses, although whether this is due to recirculation of 
primed lymphocytes from the GALT or to systemic dissemination of 
antigen is not yet clear. Studies using fluorescently labelled ISCOMS 
have reported that they are preferentially taken up into the PeyerTs 
patches after oral administration (241), but their subsequent fate is 
not known. Time-course studies looking for the appearance of 
antigen-specific B and T cells in mucosal and systemic lymphoid 
tissues following oral administration of ISCOMS could help clarify 
this issue.
Having illustrated the nature and range of immune responses 
induced by parenteral or oral immunisation with ISCOMS, I went on 
to characterise the host immunological mechanisms involved in the 
generation of immunity against ISCOMS.
Induction of Class I MHC-Restricted CTL Responses by 
ISCOMS
The novel ability of ISCOMS to stimulate potent antigen- 
specific CTL responses against exogenous protein antigens make 
them ideal candidates for vaccines against many viral infections. 
However, to confirm that these CTL responses were relevant to 
those induced by endogenous processing of naturally occurring
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viral antigens, it was important for me to fully characterise the CTL 
elicited by ISCOMS and to explore the mechanisms involved in their 
generation.
i) Phenotype and Specificity of CTL Induced by ISCOMS
My results showed that the CTL primed by ISCOMS-OVA were 
CD8+T cells, which efficiently lysed OVA-transfected EG7.0VA cells 
but not parental non-transfected EL4 cells. As the EG7.0VA cells do 
not express class II MHC molecules (202) and there was no lysis of 
OVA-pulsed P815 cells, the ISCOMS primed CTL were conventional 
class I MHC-restricted T cells. The CTL recognised an endogenously 
processed form of OVA, as osmotic loading of EL4 cells with OVA 
sensitised them for lysis, while exogenously added native OVA did 
not. There was also no component of NK cell activity, as ISCOMS- 
OVA primed CTL did not lyse the NK-sensitive YAC-1 cell line. I also 
showed that oral administration of ISCOMS-OVA elicited CTL with 
an identical phenotype and specificity to those induced after 
parenteral immunisation, indicating that ISCOMS retained the 
ability to elicit conventional CD8+ class I MHC-restricted T cells 
when administered orally.
The ISCOMS-OVA primed CTL recognised an epitope within 
the OVA 258-276 peptide, as EL4 cells were sensitised for lysis 
when pulsed with this peptide. Others have shown that this peptide 
contains an octamer (OVA 257-264) which binds the YP class I MHC 
molecule and is the dominant epitope recognised by OVA-specific 
CTL in H-2b mice following normal endogenous processing of OVA 
(33, 221, 242, 243). Notably, the ISCOMS-OVA primed CTL did not 
recognise EL4 cells pulsed with the peptide OVA 111-122, which 
contains a H-2Db-restricted epitope that can be recognised by OVA-
198
specific CTL generated by in vitro stimulation with enzymatically 
cleaved OVA, but is not generated by endogenous processing of 
OVA in vitro or in vivo (220). Taken together, these findings 
further support the hypothesis that ISCOMS faciltate the entry of 
incorporated protein antigen into the natural endogenous antigen 
processing and presentation pathway for recognition by CD8+ class I 
MHC-restricted T cells in vivo. My findings are supported by other 
reports that CD8+ class I MHC-restricted CTL are primed by ISCOMS 
containing HIV gpl60 or influenza haemagglutinin (184) or OVA 
(212), in which the class I MHC-restriction of OVA-specific CTL was 
shown formally using RMA-S target cells (212).
The lysis of OVA 258-276 pulsed EL4 cells by ISCOMS-OVA 
primed CTL was always lower than the lysis of EG7.0VA cells. This 
could reflect a higher epitope density of the naturally occurring 
octamer on the surface of the EG7.0VA cells, compared with 
fragments of exogenous OVA 258-276 which will need processed. 
Alternatively, the bulk CTL population may contain T cells which 
recognise class I MHC binding peptides derived from OVA other 
than the 257-264 epitope. Others have reported  similar 
observations on the recognition of peptide pulsed EL4 cells by 
ISCOMS-OVA primed CTL (212) and it has recently been shown that 
these CTL may recognise at least two Kb-restricted OVA peptides, 
OVA 257-264 and OVA 176-183 (244). These CTL were 
heterogeneoos^as some clones were specific for the individual 
epitopes, while others recognised both epitopes (244). Thus, 
ISCOMS-OVA primes a diverse population of CTL in vivo, capable of 
recognising a range of endogenously processed OVA peptides.
In confirmation of other observations (212), ISCOMS-OVA 
primed CTL did not require in vitro restimulation with antigen, as
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pCTL in the PLN differentiated when cultured with IL-2 in vitro. 
This indicates that ISCOMS prime a high frequency of precursor CTL 
in vivo and this assay emphasises the potency of this property of 
ISCOMS.
The induction of class I MHC-restricted CTL responses by 
ISCOMS-OVA is of particular interest, as exogenous soluble protein 
generally does not prime CD8+ CTL responses (202, 245). However, 
recent studies have indicated that soluble protein antigens can 
induce CTL responses when injected in association with detergents 
(246, 247) adjuvants such as CFA (248), or cellular debris (215, 
245, 249). Furthermore, as will be discussed more fully below, 
there is increasing evidence that particulate antigens may 
effectively stimulate class I MHC-restricted CTL responses against 
associated protein antigens (224, 250-252).
ii) The Uptake, Processing and Presentation of ISCOMS to 
Class I MHC-Restricted T Cells
The mechanisms underlying the ability of exogenous antigen 
to prime CTL responses are controversial and I therefore examined 
some of the factors involved in the induction of these responses by 
ISCOMS-OVA. I firstly examined the role of macrophages in the 
induction of CTL, using silica or liposomes containing the toxic 
compound ChMDP, to paralyse or deplete M<|> in vivo. These 
procedures resulted in a marked reduction in the magnitude of the 
CTL responses primed by ISCOMS, to around one third of the level 
of cytotoxicity achieved in the ISCOMS primed group. Thus, efficient 
priming of CTL by ISCOMS is dependent on the presence of 
functional phagocytic accessory cells. These observations are 
consistent with a number of reports documenting a role for
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phagocytic cells in the induction of CTL responses in vivo (215, 251, 
253-255). In addition, they concur with findings that exogenous 
particulate forms of antigen, such as antigen conjugated to beads 
(252) or encapsulated within liposomes (224, 250, 251), can 
efficiently prime class I MHC-restricted T cells in vivo and that 
phagocytic cells are of central importance in the uptake, processing 
and presentation of such particulate antigens to T cells (131, 132, 
251, 256-258).
More recently, direct evidence for the involvement of M<|> in 
the uptake and processing of ISCOMS has been provided by the 
finding that rabies virus antigen presented in ISCOMS was taken up 
mainly by the marginal metallophilic macrophages in the spleen, a 
subset of macrophages distinct from those that take up free 
inactivated rabies virus antigen (241). Depletion of M<|> with 
liposomes containing Q2MDP also inhibits the development of CTL 
responses against OVA encapsulated in liposomes, but only for a 
peroid of about 30 days after injection of C^MDP-containing 
liposomes (251). The return of CTL priming coincides exactly with 
the repopulation of marginal metallophilic macrophages in the 
spleen, while marginal zone macrophages are not repleted until 
more than 2 months later (209). Taken together, these results 
suggest that marginal metallophilic macrophages in the spleen play 
a key role in the induction of class I MHC-restricted CTL responses 
against exogenous protein antigens presented in ISCOMS or in other 
particulate vectors. Interestingly, o ther studies have also 
highlighted the ability of a subset of splenic macrophages to process 
and present exogenous protein antigen in association with class I 
MHC molecules, although the anatomical location of these cells was 
not identified (259).
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It should be noted that some CTL activity was retained in 
ISCOMS primed mice, even after depletion or paralysis of M<t>, 
suggesting that ISCOMS utilise more than one pathway of CTL 
induction in vivo. One candidate APC for this activity are DC, which 
are also potent inducers of antigen-specific CTL responses (218, 
260, 261). Although doubts have been raised over the ability of DC 
to take up and process particulate antigens (16), recent studies 
show that they are able to induce antigen-specific CTL responses 
when pulsed with liposome-encapsulated OVA in vitro or in vivo 
(216). EBV-transformed B lymphoblastoid cell lines (B-LCL) can also 
process and present ISCOMS containing the transmembrane fusion 
protein of measles virus (MV-F-ISCOMS), or the envelope 
glycoprotein gp340 of EBV (gp340 ISCOMS), for recogntion by both 
class I MHC-restricted and class II MHC-restricted CTL clones in 
vitro (236, 262). Whether this presentation pathway operates in 
vivo and occurs for all types of protein antigens incorporated in 
ISCOMS is not clear, but together with my own observations and the 
evidence discussed above, they emphasise the possibility that 
protein antigens in ISCOMS may be processed and presented by a 
range of different APC types in vivo.
The precise intracellular processing route by which protein 
antigens incorporated in ISCOMS gain entry into the endogenous 
pathway of antigen processing for presentation in association with 
class I MHC molecules is also unclear. Recent evidence that 
presentation of OVA-coated particles by M<|> for recognition by class 
I MHC-restricted T cells requires functional TAP proteins and 
involves processing by proteasomes (263), suggests that the 
associated antigen gains access to the cytosol. Similarly, the 
presentation of MV-F-ISCOMS to CD8+T cells by B-LCL is also TAP-
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dependent, indicating that ISCOMS do allow protein antigens to 
enter the cytosolic pathway of antigen processing (236). This could 
occur because the lipophilic nature of ISCOMS may allow them to 
fuse with cellular or endosomal membranes and thus release 
incorporated antigen directly into the cytosol. This hypothesis is 
consistent with the ability of other hydrophilic complexes such as 
lipopeptides (253, 264) and liposomes (224, 250, 251) to induce 
CTL responses. However, as I shall discuss below, the detergent 
properties of Qjuil A may also play a role in allowing antigens access 
to the endogenous pathway of antigen processing and presentation. 
Therefore, at present it remains uncertain as to how ISCOMS enter 
the endogenous pathway of antigen processing and presentation.
iii) The Role of CD4+ T Cells in the Priming of CTL by 
ISCOMS
I next investigated whether the concomitant activation of 
CD4+ T cells was involved in the priming of such potent CTL 
responses by ISCOMS in vivo. Mice depleted of CD4+ T cells failed to 
exhibit any OVA-specific CTL activity after priming with ISCOMS- 
OVA, indicating that CD4+ T cells play a crucial role in the priming 
of CTL by ISCOMS. Although these findings are in agreement with a 
number of other studies showing that CD4+T cells are necessary for 
the priming of CD8+ CTL responses (49-51, 265-269), there is 
conflicting evidence on this subject, as other workers have reported 
that CTL responses can be efficiently primed in the absence of CD4+ 
T cells (217, 219, 260, 270).
It is likely that the requirement for CD4+ T cells in the 
induction of CTL responses is influenced both by the nature of the 
immunological stimulus and by the strength of non-specific
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inflammatory signals present at the time of antigen recognition. 
Thus, viruses which replicate at high levels in host cells which 
express class I MHC molecules, but not class II MHC molecules, are 
likely to elicit CTL responses in the absence of CD4+ T cells (217, 
270). Similarly, allospecific CTL responses can be induced in the 
absence of CD4+ T cells (260, 271), because the frequency of 
responding CD8+T cells is unusually high, allowing enough IL-2 to 
be produced to provide autocrine help (271, 272).
The position with the induction of CD8+ CTL responses by 
soluble protein antigens is less clear, but most reports support the 
view that concomitant activation of CD4+ T cells may be required 
(215, 245-248). Similar findings have been reported with purified 
peptides, where direct induction of CD8+ T cell responses in vivo 
with free peptide appears difficult and usually requires conjugation 
to lipid moieities (253, 264), activation of CD4+T cells (267, 273), or 
co-administration with inflammatory stimuli such as IFA (219, 267, 
274). The induction of CTL responses by influenza-infected or 
peptide-pulsed DC in vitro also requires the presence of CD4+T cells 
or their lymphokine products (218). Thus, the ability to present 
antigen to both CD4+ T cells and CTL is usually essential for the 
effective induction of CTL responses by DC. Similarly, although CD8+ 
CTL primed in vivo by OVA in liposomes can be restimulated in 
vitro in the absence of CD4+ T cells, this is enhanced by the 
presence of CD4+ T cells (251). Furthermore, studies in IL-2 
deficient mice have indicated that although these mice can make 
anti-viral CTL responses, their magnitude is reduced by 70-90%, 
confirming the important role of this cytokine in the expansion of 
CTL (275, 276).
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Taken together with the evidence discussed above, my results 
suggest that after in vivo administration, ISCOMS are taken up by 
professional APC populations, which process and present antigen to 
both class I MHC- and class II MHC-restricted T cells. This could 
create a three-cell cluster providing the antigenic signal and local 
IL-2 production required for the efficient induction of CD8+ CTL, as 
has been suggested by other in vitro studies of helper-dependent 
CTL responses (269).
Priming of CD4+ T Cell Responses by ISCOMS
The induction of potent local and systemic antibody responses 
and systemic DTH responses by ISCOMS, together with requirement 
forCD4+T cells in the priming of CTL responses, suggested that the 
priming of CD4+ T cells was the key event in the induction of 
immune responses by ISCOMS. To assess this issue more closely, I 
examined the antigen-specific T cell proliferative responses and the 
pattern of cytokines produced by ISCOMS-OVA primed cells 
restimulated in vitro with soluble OVA.
I found that parenteral immunisation with ISCOMS primed 
strong antigen-specific proliferative responses in the draining 
lymph node, which were entirely mediated by CD4+ T cells. I could 
find no evidence of CD8+ T cell proliferation in vitroy even when 
primed cells were cultured with the immunodominant CTL epitope 
in the presence of exogenous IL-2. Although these findings support 
my earlier observations on the CD4-dependence of CTL responses 
induced by ISCOMS, they are somewhat paradoxical in view of the 
potent ability of ISCOMS-OVA to prime class I MHC-restricted CTL 
which can be restimulated by endogenously processed OVA
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epitopes or IL-2 in vitro (212). This discrepancy may be explained 
by the fact that as peptide-specific CTL are present only in a low 
frequency, it is difficult to detect their proliferation in vitro. 
Alternatively, the kinetics of CTL proliferation in vitro could differ 
from those of CD4+ T cells and by this late timepoint in culture the 
pCTL in the primed PLN cells may have already fully differentiated 
into effector CTL. In support of the latter hypothesis, others have 
noted that CD8+ T cells undergo blastogenesis in vivo after priming 
with ISCOMS-OVA (212). Thus, the in vitro proliferative assay I 
used may not be sensitive enough to detect the proliferation of 
small numbers of CD8+ T cells. Nevertheless, the results emphasise 
that relatively more CD4+ T cells must be primed by in vivo 
immunisation with ISCOMS.
My experiments showed for the first time that oral 
administration of ISCOMS-OVA also primed antigen-specific 
proliferative responses in the draining lymph nodes (MLN), but 
these required higher concentrations of antigen for restimulation 
(lmg/ml vs. l-10ng/ml for PLN cells). This difference may reflect 
differences in the proliferative capacity of the different cell 
populations and/or differences in the proportion of antigen- 
reactive cells. However, I believe it is more likely that ISCOMS are 
simply less efficient at priming a high frequency of T cells by the 
oral route. This would be consistent with my earlier findings on the 
induction of local and systemic immunity by feeding ISCOMS, where 
much higher amounts of antigen were required to prime equivalent 
responses by the oral rather than parenteral route. It would be 
helpful to investigate this hypothesis using ISCOMS containing 
radio- or fluorescently-labelled antigen to examine the
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concentration of antigen achieved in local lymphoid tissues after 
oral or parenteral immunisation.
One feature of my studies was the consistent inability to 
prime detectable antigen-specific proliferative responses in the 
spleen after either oral or parenteral immunisation with ISCOMS. 
Although this finding could reflect the lower proportion of T cells in 
spleen compared with lymph node, ISCOMS primed spleen cells 
produced cytokines when restimulated with antigen in vitro (see 
below), suggesting that T cell priming may have occurred in the 
spleen and again indicating the limited sensitivity of the 
proliferative assay. In this respect, it is notable that others have 
reported a degree of non-specific proliferation in the spleen for up 
to 2 weeks after parenteral administration of ISCOMS (182), which 
could mask the smaller antigen-specific component. In support of 
this hypothesis, I also observed elevated spontaneous proliferative 
responses of spleen cells from mice primed parenterally with 
ISCOMS.
ISCOMS-OVA primed PLN cells also proliferated in response to 
restimulation with ISCOMS-OVA, showing that ISCOMS themselves 
can be processed and presented to T cells in vitro. Similar findings 
have been reported using ISCOMS containing influenza virus 
glycoproteins (182) and these observations are consistent with 
studies showing that EBV-transformed B cells can process and 
present ISCOMS associated antigen for recognition by both CD4+ and 
CD8+clones in vitro (236, 262). Importantly, in agreement with the 
other reports (182, 236, 262), I found that very low concentrations 
of antigen in ISCOMS (lug/ml) could stimulate T cell proliferation in 
vitro, suggesting that when incorporated in ISCOMS antigen is 
processed and presented very efficiently for recognition by T cells.
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This property may prove useful in terms of understanding the 
mechanisms which are involved in the processing and presentation 
of ISCOMS to CD4+ andCD8+ T cells in vivo, but unfortunately I did 
not have time to explore this issue during this study.
The strong priming of CD4+ T cells by ISCOMS was emphasised 
by the substantial amounts of antigen-specific cytokine production 
by ISCOMS primed lymphoid cells. This included production of the 
Thl cytokines, IL-2 and IFN-y, as well as production of the Th2 
cytokine, IL-5. In addition, these cytokines were found after both 
oral and parenteral priming with ISCOMS. The cytokines were 
produced in a distinctive pattern during in vitro culture with 
antigen, characterised by an early, transient IL-2 response, which 
peaked on day 2 of culture, whereas IL-5 and IFN-y accumulated 
later, with the highest levels of these cytokines being found on day 
6 of culture. This pattern may reflect the initial activation of 
antigen-specific cells in vitro, followed by their subsequent 
proliferation and maturation to express effector functions.
The simultaneous production of IL-2, IL-5 and IFN-y indicated 
that both Thl and Th2 subsets of CD4+ T cells were activated by 
immunisation with ISCOMS, supporting the wide range of humoral 
and cell-mediated immune responses primed by ISCOMS in vivo. 
Furthermore, ISCOMS-OVA primed mice to produce high titres of 
antigen-specific IgGl and IgG2a antibodies, indicative of Th2 and 
Thl cell activation respectively (227, 228, 277). Others have also 
reported the secretion of both these immunoglobulin isotypes after 
immunisation with ISCOMS containing influenza virus proteins 
(179, 278) and although one of these studies reported the 
preferential production of IL-2 and IFN-y (278), subsequent work
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showed that IL-4 was also produced (279). Together, these findings 
confirm that ISCOMS stimulate both subsets of CD4+ T cells in vivo.
Surprisingly in view of the marked IgGl antibody and IL-5 
production I observed, I could detect no antigen-specific IL-4 
production in any of the tissues after either oral or parenteral 
immunisation, even when this cytokine was produced when the 
same cells were stimulated with mitogen. Although it remains 
possible that the levels of IL-4 produced in responses to antigen 
were below the sensitivity of the ELISA, or that any IL-4 produced 
was being utilised rapidly during culture, my findings could 
represent a true dichotomy in the regulation of IL-4 and IL-5 
production during the stimulation of CD4+ T cells by ISCOMS- 
associated antigen in vivo. This idea needs confirmation by direct 
examination of IL-4 production in vivot using ELISPOT or PCR 
assays.
In addition to the range of cytokines primed by ISCOMS, oral 
and parenteral immunisation induced disseminated systemic 
immunity. Local immunisation in the footpad induced identical 
profiles of cytokine production in both the draining lymph node 
and more distantly in the spleen, consistent with the induction of 
systemic IgG and DTH responses which I observed after s.c. priming 
with ISCOMS. A similar pattern of cytokine production was obtained 
with spleen cells from mice primed orally with ISCOMS-OVA. Thus, 
ISCOMS promote a full range of local and systemic antigen-specific 
immune responses when administered by mucosal or parenteral 
routes. This contrasts with the restricted nature of Thl or Th2 
responses induced by conventional parenteral adjuvants such as 
CFA and alum which predominantly stimulate Thl and Th2 
responses respectively (53). In addition, existing mucosal adjuvants
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such as Salmonella (115) or cholera toxin (154,155) are believed to 
stimulate similarly restricted patterns of CD4+T cell responses (see 
below). These results emphasise the potential of ISCOMS as vaccine 
vectors and show that the mucosal immune system is perfectly 
capable of inducing a variety of different effector responses against 
a single protein antigen if presented in an appropriate manner.
Priming of Long-Term Memory Responses by ISCOMS
The next part of my thesis addressed some aspects of ISCOMS 
which were not directly concerned with the host mechanisms 
involved in the induction of immune responses by ISCOMS, but 
which were important for evaluating their potential as vaccine 
vectors. The first area that I examined was whether immunisation 
with ISCOMS stimulated long-lasting immune priming.
A single parenteral immunisation with lO^g OVA in ISCOMS 
primed T and B cell memory responses for several months after 
immunisation. Systemic DTH responses could be recalled for up to 8 
months after priming, a much longer period than was suggested by 
previous studies (165). The presence of memory T cells was 
confirmed by the fact that proliferative responses of ISCOMS 
primed PLN cells could be restimulated in vitro for at least 8 
months after immunisation and gradually waned thereafter. Similar 
findings were made with cytokine production by spleen cells from 
these mice, with strong IL-2 and IL-5 responses persisting for at 
least 8 months after priming and subsequently declining. This 
suggests that memory T cells of both Thl and Th2 phenotypes 
persisted after priming with ISCOMS. However, it was noteworthy 
that there was no antigen-specific production of IFN-y by ISCOMS
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primed cells at any of the timepoints examined, a finding that was 
surprising in view of the long-term DTH response I observed. This 
was not due to any inherent defect in the cells, as both primed and 
control cells produced high amounts of IFN-y when stimulated with 
mitogen. Unfortunately, I was not able to measure the isotypes of 
the persisting primary or memory IgG responses (see below), as 
these would have provided further evidence on whether both 
memory Thl and Th2 cells persisted in vivo after priming.
Immunisation with ISCOMS induced a small but significant 
primary IgG response which persisted for one year after priming. 
Although this primary IgG response was not found in my earlier 
experiments described in chapter 3, these responses were 
measured 7 days after priming, which may be too early for the 
development of an IgG response. Indeed previous work in this 
laboratory showed that mice immunised with 10|ig ISCOMS-OVA 
did not develop primary IgG antibodies until 21 days after priming 
(165). Other studies using influenza virus antigens in ISCOMS have 
also demonstrated the persistence of antigen-specific IgG responses 
for at least 5 months after a single parenteral immunisation (280, 
281). The potent secondary IgG responses I found after challenge 
with antigen in vivo are consistent with the presence of long-lived 
memory B cells, as well as the memory T cells I described above. As 
with the T cell responses, both the primary and secondary IgG 
responses decreased in magnitude over time, but persisted for a 
full year after immunisation. I did not examine the IgG isotype of 
the persisting IgG responses, but it has been reported that all IgG 
subclasses, particularly IgG2a, remained elevated for at least 5 
months after priming with ISCOMS (281). Furthermore, multiple 
parenteral immunisation of macaque monkeys with purified HIV-2
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proteins in ISCOMS induced protective immunity which persisted 
for up to 18 months after the final immunisation (282). Thus, 
ISCOMS appear capable of inducing long-term immunity in both 
rodents and primates.
The secondary T and B cell responses declined markedly 
between 8 and 12 months post-immunisation. This could reflect 
loss of antigen reactive cells, but may also have been partly due to 
the effects of ageing. This is known to influence immunological 
responsiveness (230) and, as around 25% of both primed and 
control mice had died by the end of my experiments, this clearly 
could have been an important factor.
I did not directly examine the persistence of the OVA-specific 
CTL responses primed by ISCOMS-OVA, as previous experiments in 
our laboratory had shown that these were relatively short lived, 
being virtually undetectable one month after priming (165, 229). 
However, other workers have reported the presence of antigen- 
specific CTL responses for up to 3-4 months after parenteral 
immunisation with viral proteins in ISCOMS (184, 235) and recent 
studies have shown that CTL responses primed by live virus persist 
for extremely long periods in vivo, even after adoptive transfer of 
primed cells into class I MHC-deficient recipients (283, 284). Thus, 
it seems surprising that ISCOMS-OVA did not induce CTL responses 
of longer duration in our earlier work and a more detailed re­
examination of this issue would be useful. In addition, the use of 
alternative assays, such as precursor frequency analysis, may give 
a more accurate estimation of the longevity of the CTL responses 
primed by ISCOMS.
An important area which I did not have time to investigate 
was the longevity of immune responses prim ed by oral
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administration of ISCOMS. With the exception of our earlier findings 
that the secretory IgA and systemic CTL responses were both 
transient (229), there is no information on the persistence of 
memory after mucosal immunisation with ISCOMS. Long-lasting 
priming of local and systemic KLH-specific B and T lymphocytes 
persisted for at least 8 months after oral immunisation with CT 
administered with KLH, indicating that solid memory can be 
achieved by this route (146, 285). Therefore, it would be important 
to study this directly after oral immunisation with ISCOMS.
While my results showed that ISCOMS primed for long-term 
memory responses, an investigation of the mechanisms responsible 
for the maintenance of immunological memory was beyond the 
scope of this study. However, it would be interesting to examine the 
phenotype of T cells primed by antigen in ISCOMS to assess their 
expression of molecules such as MEL-14 (L-selectin) and CD44 
which are differentially expressed on naive and memory T cells 
(286, 287). It would also be interesting to employ the 
bromodeoxyuridine (BrdU) labelling technique, which allows cells 
which proliferate at the time of priming to be tracked in vivo (288), 
to explore the longevity of the different lymphocyte subpopulations 
primed by ISCOMS. Such studies would be assisted by the use of 
mice transgenic for an OVA-specific TcR, which provide a 
population of antigen-specific cells that can be adoptively 
transferred and monitored before and after priming in vivo (289). 
Experiments of this kind are now being established in the 
laboratory.
In summary, my results clearly demonstrated that a single 
parenteral immunisation with a small amount (lO i^g) of protein 
antigen in ISCOMS primed long-term B cell and T cell memory
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responses, which persisted for a full year after priming. Although 
further work will be required to confirm and extend these 
findings, they enhance the potential of ISCOMS as future vaccine 
vectors.
Quil A Plays a Key Role in the Adiuvanticitv of ISCOMS
In the latter part of this study, I investigated some of the 
aspects of the ISCOMS themselves which I thought might be 
important for their adjuvant activity. The class of compounds 
extracted from plant sources, termed collectively as saponins 
because of the detergent properties associated with them, have long 
been known to possess adjuvant activity (194). Qpil A is a saponin 
fraction prepared from an aqueous extract of the South American 
soap tree, Quillaja saponaria molina (290). It is the adjuvant 
component of ISCOMS (159, 161) and therefore I thought it 
important to examine how much of the adjuvant properties of 
ISCOMS were attributable to the presence of Quil A, or whether the 
particulate structure of the ISCOM was also required for 
adjuvanticity.
i) Adjuvant Effects of Free Quil A
I first compared the adjuvant properties of free Quil A with 
that of Quil A incorporated in ISCOMS. Free Quil A induced the same 
range of immune responses as ISCOMS, but it was generally less 
efficient in this form than in intact ISCOMS. These responses 
included the priming of systemic IgG, DTH and class I MHC- 
restricted CTL responses, demonstrating that free Quil A has the 
ability to facilitate the entry of exogenous protein antigen into both
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the endogenous and exogenous pathways of antigen processing in 
vivo. Free Quil A also primed for proliferative responses and the 
production of bothThl and Th2 cytokines in vitro, indicating that it 
is a potent activator of both subsets of CD4+ T cells in vivo. Free Quil 
A exhibited a similar range of adjuvant properties when 
administered orally, with the induction of local and systemic 
antigen-specific antibody responses and the priming of class I MHC- 
restricted CTL.
Others have reported similar findings on the adjuvanticity of 
parenterally administered Quil A, although direct comparison with 
ISCOMS in such a wide range of responses has not been performed 
previously. Many studies have demonstrated that Qjiil A augments 
humoral immune responses to both T-dependent and T- 
independent antigens (199, 200, 291-293). Although I did not 
examine the isotype distribution after immunisation with OVA plus 
free Q,uil A, it has been shown that this effect encompasses both 
IgGl and IgG2a isotypes (294, 295). This is consistent with my 
observations that Quil A primed both Thl and Th2 cytokine 
production in vitro.
The oral adjuvant properties of saponins have also been 
reported in a number of other studies and this route has the 
advantage that much higher amounts of saponins can be tolerated 
when administered orally (194). Co-administration of saponin and 
inactivated rabies vaccine led to 10-fold higher serum neutralizing 
antibody responses than elicited when the vaccine was fed alone 
(296) and led to enhanced lymphocyte proliferation in both the 
spleen and MLN in vivo (192), suggesting that saponins elicit local 
and systemic immunity. Unfortunately, I was not able to examine 
the priming of DTH, proliferative and cytokine responses induced
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by feeding Quil A. However, subsequent work in the laboratory has 
shown that Quil A does indeed stimulate both subsets of CD4+ T 
cells when administered orally.
My findings that Quil A allows priming of CMI responses, 
including proliferative responses and CTL responses, has been 
confirmed by other workers using both intact Quil A (192, 292) and 
an HPLC-purified fraction designated QS-21 (201, 297, 298). 
Furthermore, recent studies using liposomes containing the 
immunodominant Kb-restricted CTL epitope, OVA 257-264, showed 
that this peptide was unable to prime CTL when given in liposomes, 
unless the liposomes also contained Quil A (299). The antigen- 
specific CTL primed by co-administration of QS-21 and OVA exhibit 
an identical phenotype and specificity to those primed by ISCOMS- 
OVA, suggesting that the saponin alone is able to allow protein 
antigen to enter into the endogenous pathway of antigen processing 
and presentation (297). This may be related to the ability of 
saponins to bind cholesterol and create pores in cellular membranes 
(162, 196), which could facilitate the delivery of protein antigen 
into the cytosol. These findings suggest that the induction of 
antigen-specific CTL responses by ISCOMS may be largely due to 
the detergent properties of Quil A and are consistent with recent 
reports that detergents can promote the priming of CTL by soluble 
protein antigens (246, 247). An alternative explanation for the 
effects of saponin on CTL is that it may create a local inflammatory 
reaction, leading to uptake of cellular debris together with 
exogenous protein antigen by APC, which can result in CTL priming 
(215). This would be consistent with the findings that the priming 
of CTL responses by QS-21 requires the presence of phagocytic cells 
in vivo (300). Although similar to ISCOMS, the QS-21 induced
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responses were not dependent on CD4+ T cells (300) and therefore 
the precise pathway of CTL induction requires further study.
In my studies, incorporation within ISCOMS particles greatly 
augmented the adjuvant properties of Quil A. When compared with 
parenteral immunisation with ISCOMS containing l^g of Qpil A, 
around 5-10 fold more free Quil A was required to achieve the 
same levels of priming of antibody, DTH and CTL responses in vivo, 
as well as cytokine production in vitro. In addition, other workers 
have shown that multiple immunisations with QS-21 were required 
for the efficient induction of CTL (297), confirming my findings 
that, although not essential, incorporation within ISCOMS particles 
greatly increased the efficacy of CTL induction when compared with 
free saponin preparations. Similarly, oral immunisation with 25- 
50ng doses of free Quil A was required to provoke antibody and 
CTL responses equivalent to those obtained after immunisation 
with ISCOMS containing 5*ig Quil A, confirming that the particulate 
nature of ISCOMS enhances the induction of immune responses at 
mucosal surfaces.
One exception to the general dose dependency of the effects of 
free Quil A was that in vitro proliferative responses were 
effectively primed by as little as lug of free Quil A and the highest 
dose (2(Vg) actually inhibited the priming of this response. The 
reasons for this paradox are not clear, but they may reflect 
differences in the kinetics of the in vitro proliferative responses 
and/or toxicity associated with higher doses of saponins (194). 
Alternatively, the high dose of Quil A may have induced unusually 
high levels of an inhibitory mediator such as IFN-y. This idea is 
supported by the very large DTH responses seen in these mice and 
by the fact that mice immunised with free Quil A produced higher
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levels of spontaneous IFN-y than mice which received ISCOMS. As 
high concentrations of IFN-y are known to be cytostatic in vitro 
(301, 302), this could have contributed to the low proliferative 
responses in mice given high doses of free Quil A.
ii) Activation of Innate Immune Responses by Quil A
Stimulation of non-specific inflammatory mechanisms has 
been suggested to be an important property of many adjuvants 
(231, 303) and this prompted me to examine the ability of free Quil 
A to activate macrophages and NK cells.
I found that M<|> populations obtained from PEC elicited with 
either ISCOMS or free Quil A produced a small, but marked 
oxidative burst when stimulated with PMA in vitro. Although the 
magnitude of this response did not compare with that obtained 
using M<|> elicited with a strong immunological stimulus (C.parvum), 
my results suggested that ISCOMS and free Qpil A may activate at 
least some M<j> in an immunological manner. In addition, others 
have demonstrated that ISCOMS and free saponin can enhance the 
expression of class IIMHC molecules in an IFN-y dependent manner 
(304, 305) and also that ISCOMS themselves induce the production 
of inflammatory cytokines such as IL-1 and IL-6 by macrophages 
(279, 306). It would be interesting to extend these studies by 
examining the expression of co-stimulatory molecules by ISCOMS 
and Quil A primed macrophages and also their production of 
cytokines, such as IL-12, which can influence the nature of the 
subsequent immune response (307, 308).
One difference between ISCOMS and free Quil A that emerged 
from my studies, was the ability of orally or parenterally 
administered free Quil A to stimulate non-specific cytotoxicity, as
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evidenced by the marked lysis of EL4 cells. This effect was 
dependent on the dose of free Quil A administered and was 
associated with enhanced NK cell activity, as I also found that 
parenteral administration of free Quil A produced a small, transient 
increase in NK cell activity, which peaked around 3 days after 
injection. Importantly, neither enhanced NK cell activity or non­
specific cytotoxicity were observed after oral or parenteral 
immunisation with protein antigen in ISCOMS. As with the non­
specific cytotoxic responses, the NK cell activity was dependent on 
the dose of Quil A administered and was most marked when 10- 
20\ig  Qjiil A was injected. Similar findings on the induction of NK 
cells and non-specific cytotoxicity by saponin have been reported 
by others (192) and this could again be partly explained by the 
stimulation of IFN-y release.
In this respect, it is notable that mice fed saponin alone 
showed a significant level of protection against intracerebral 
challenge with rabies (191, 309) and feeding saponin greatly 
potentiated the efficiency of parenterally administered rabies 
vaccine (309). Thus, oral administration of saponin appears to 
activate non-specific systemic immune mechanisms. Others have 
also noted the similarities in lymphocyte traffic and enhanced class 
II MHC expression after parenteral injection of saponin or IFN-y, 
suggesting that the adjuvant activities of saponin are partly due to 
the induction of IFN-y release (305).
Although they clearly have adjuvant effects on specific and 
non-specific immune responses, the precise mode of action and 
cellular targets of saponins remains unclear. As Quil A augments 
antibody responses to T-independent antigens and is effective in 
athymic mice, it seems likely that some of the adjuvant effects of
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Quil A may be mediated directly through B cells (200). There is also 
evidence that saponins can increase the permeability of mucosal 
cells and infleunce macromolecular transport in vitro (310), an 
attribute that is also possessed by CT (238). Studies using 
radiolabelled antigens co-administered with Quil A could help to 
define the effects of saponins on the uptake and processing of 
soluble protein antigens at mucosal surfaces after oral 
immunisation and by systemic professional APC after parenteral 
administration.
When taken together, my studies indicate that although free 
Quil A shares many of their adjuvant properties, ISCOMS have a 
number of potential advantages for use as vaccine vectors. 
Incorporation within ISCOMS decreases the amount of Quil A 
required for effective priming, thus limiting any problems with 
toxicity. In addition, as antigen and adjuvant are physically linked 
in the ISCOM particle, the induction of potentially harmful non­
specific immune responses is avoided. In contrast, the non-specific 
responses elicited by free Quil A suggest that caution must be used 
to avoid the possiblity that priming may occur to soluble self or 
dietary proteins which may be present at the time of 
administration of free Qjiil A.
Induction of Immune Responses with PLG Microparticles
The results described above showed that although Quil A was 
important for the adjuvant effects of ISCOMS, the structure of the 
ISCOM itself also played a role in enhancing the efficiency and 
specificity of immune priming. To investigate if this related to their 
particulate nature, I compared the oral and parenteral adjuvant
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effects of ISCOMS with those of an inert particulate vaccine vector 
which did not contain a built-in adjuvant. These were PLG 
m icroparticles composed of the biodegradable polymer 
poly(lactide-co-glycolide).
I found that OVA entrapped in PLG microparticles could 
induce the same range of local and systemic immune responses as 
OVA incorporated in ISCOMS, but that higher amounts of antigen 
were required when the PLG microparticle vector was used. A 
single s.c immunisation with OVA in PLG microparticles primed for 
strong antigen-specific DTH responses and serum IgG responses in 
vivo, as well as for excellent OVA-specific proliferative responses in 
vitro, indicating that PLG microparticles can prime antigen-specific 
T and B cells in vivo. Although others had reported similar findings 
on the priming of humoral immune responses by PLG 
microparticles (108, 136, 311, 312), there had been little prior 
investigation of their effects on T cell priming. The proliferative 
responses indicated that PLG microparticles could prime CD4+ T 
cells and the induction of IgG and DTH responses in vivo suggested 
that they primed both Thl and Th2 subsets. However, an 
assessment of the IgG isotypes present and cytokines produced by 
PLG primed mice would be necessary in order to confirm this 
hypothesis.
I also observed that that PLG microparticles primed both 
humoral and cell-mediated immune responses when administered 
orally. My findings are consistent with other reports on the 
induction of antigen-specific salivary IgA and serum IgG antibodies 
after oral administration of protein antigens entrapped in PLG 
microparticles (137, 234) and underline the potential of PLG
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microparticles for stimulating local and systemic immunity by the 
oral route.
A novel finding of my experiments was that PLG-OVA primed 
antigen-specific class I MHC-restricted CTL responses after either 
parenteral or oral adm inistration. This had never been 
demonstrated previously using PLG microparticles and although I 
did not fully characterise the CTL in this study, they appear very 
similar to those found after immunisation with ISCOMS. These 
results confirm that the particulate structure of ISCOMS contributes 
to the potent induction of CTL responses and are consistent with the 
evidence noted earlier that particulate antigens may effectively 
stimulate class I MHC-restricted CTL (224, 250). In addition, it is 
known that PLG particles are phagocytosed rapidly in vivo after 
oral or parenteral administration (136, 137) and it would be 
interesting to look at the effects of macrophage depletion on the 
induction of CTL by PLG microparticles. The CTL responses induced 
by oral or parenteral immunisation with ISCOMS were higher than 
those induced by PLG, requiring fewer or lower doses of antigen. It 
was also impossible to detect CTL activity in PLG-OVA immunised 
mice without in vitro restimulation with antigen, whereas the 
lymph nodes of ISCOMS-OVA primed mice contained pCTL which 
could be activated by IL-2 alone. This suggests that OVA in ISCOMS 
primed a higher frequency of antigen-specific CTL and is also 
consistent with my findings that Quil A plays an important role in 
the induction of CTL responses by ISCOMS.
As noted above, ISCOMS appeared superior to PLG 
microparticles in inducing serum IgG responses, CTL responses and 
T cell proliferation, despite the fact that a 10-fold lower dose of 
antigen was used with ISCOMS. However, it cannot be concluded
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with certainty that PLG microparticles have no potential for use as 
vaccine vectors. Their delayed release properties (233) make it 
likely that they will stimulate long-term memory in vivo. In fact, it 
has been shown already that PLG microparticles evoke long-term 
antibody responses which persisted for a full year after a single 
parenteral immunisation (313) and it would now be important to 
compare the kinetics of the primary and memory responses of all 
types induced by the PLG microparticles and ISCOMS. Economic 
factors such as ease and cost of manufacture, as well as practical 
conditions such as stability and possible toxic side effects, must also 
be taken into account when designing novel vaccine vectors. 
Nevertheless, my results suggest that ISCOMS may provide a more 
suitable vector for use with antigens which are not in plentiful 
supply, such as recombinant protein antigens or peptides.
In summary, my results highlight that particulate 
presentation of protein antigens in PLG microparticles greatly 
increases their immunogenicity for both B and T cells, when 
administered orally or parenterally. These results suggest that the 
exceptional adjuvanticity of ISCOMS can be attributed to the 
combined effects of their particulate structure and the presence of 
the saponin adjuvant Quil A.
ISCOMS as Oral Vaccine Vectors
The results I have presented in this thesis have extended 
previous observations on the induction of immune responses by 
ISCOMS and have highlighted their potential as oral vaccine vectors 
of the future. I have shown that a number of physico-chemical and 
immunological factors contribute to the unique adjuvant properties
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of ISCOMS which are wider in scope and more effective than other 
conventional adjuvants.
Recent advances in molecular biology and in the 
understanding of microbial pathogenesis led to the idea of 
producing synthetic subunit vaccines, comprising purified protein 
antigens in an appropriate delivery system. However, as I have 
described earlier, an effective oral subunit vaccine vector must 
possess three essential properties. It must be able to withstand the 
harsh acidic and proteolytic environments of the stomach and small 
intestine; it must allow incorporated protein antigens to circumvent 
the normal regulatory mechamisms responsible for oral tolerance; 
and it must be able to effectively prime all forms of the immune 
response which would normally be provoked by natural pathogens, 
including class I MHC-restricted T cells. When taken together with 
the work of others, my results show that ISCOMS fulfill these 
requirements.
The first important property of ISCOMS is that they are 
particulate structures which present protein antigens in multimeric 
form. This may enhance the immunogenicity of orally administered 
protein in a number of ways. As well as being able to withstand the 
harsh environments (166), ISCOMS alter the uptake and processing 
of protein antigen, by targetting it to M cells overlying the Peyer's 
patches (241) and avoiding the induction of oral tolerance (229). In 
this way a relatively high concentration of immunogenic antigen 
can be achieved in the MALT inductive sites. Whether intact 
ISCOMS particles reach the systemic circulation after oral 
administration, either alone or after transport by phagocytic cells is 
not yet known and further studies using radio- or fluorescent-
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labelled ISCOMS are required in order to clarify the precise uptake 
and processing route of orally administered ISCOMS.
Although important, the particulate nature of ISCOMS is only 
one factor involved in their potent adjuvant effects. Variable 
results have been reported on the effectiveness of other particulate 
vectors such as liposomes when administered orally (314-316) and 
there has been little investigation of T cell priming using these 
vectors. In addition, while my own studies on PLG microparticles 
confirmed other reports on their oral adjuvant properties (137, 
234), ISCOMS were more efficient and required fewer feeds.
The main reason that ISCOMS are superior oral vaccine 
vectors to the other particulate vectors, is the presence of the 
saponin Quil A. My results showed that most of the adjuvant 
properties of ISCOMS could be reproduced using free Quil A. 
However, much higher doses of free Quil A were required in order 
to achieve equivalent levels of immune priming. In addition, 
incorporation within ISCOMS avoided the non-specific cytotoxic 
responses which I and others observed after the administration of 
free Quil A (192). Thus, physical linkage of adjuvant and antigen 
within the same particle greatly increased the efficacy and 
specificity of the immune responses induced.
The most important property of a vaccine vector is its ability 
to induce relevant immune responses and my results have 
confirmed that ISCOMS are capable of priming a unique range of 
local and systemic immune responses when administered orally. 
This included secretory IgA and systemic IgG responses, local and 
systemic CD4+ T cell responses and the induction of class I MHC- 
restricted CTL responses. My findings emphasise the range, 
strength and dissemination of the immune responses induced by
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oral or parenteral immunisation with ISCOMS. In particular, the 
priming of CD4+ T cell-dependent proliferative responses and both 
Thl and Th2 cytokine responses indicates the potent adjuvant 
effect of ISCOMS on CD4+ T cells, which are central to the 
development of most protective immune responses in vivo. This 
suggests that ISCOMS could form the basis for vaccines against most 
of the pathogens likely to be encountered by the mammalian host. 
My findings with ISCOMS contrast with those reported for the other 
well-studied oral adjuvants, which induce a more restricted set of 
immune responses.
Cholera toxin (CT), perhaps the best studied mucosal adjuvant, 
can effectively prime local and systemic humoral immune 
responses against co-adminstered protein antigens (142, 143). In 
addition, more recent studies have shown that CT also has potent 
adjuvant effects on T cells when administered orally, as evidenced 
by the induction of local and systemic proliferative and cytokine 
responses (317, 318). Although contrasting evidence has been 
reported recently (318), it is commonly assumed that CT 
predominantly stimulates Th2 type responses, favouring IL-4 and 
IL-5 production and the production of antibodies of the IgGl and 
IgE subclasses (56, 154, 155). This bias may limit the broad 
applicability of CT as an oral adjuvant, especially in instances where 
the induction of Th 1 responses is essential for protection, such as 
intracellular parasitic infections like Leishmania, w here 
development of Th2 responses may actually exacerbate disease 
progression (42, 319). In addition, although one study has reported 
that CT can augment the induction of class I MHC-restricted CTL 
responses against non-viable antigens (320), the ability of CT to 
induce CTL responses when admininstered orally has not yet been
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demonstrated. This activity is a prerequisite before CT can be 
considered as a potential vector for the induction of immunity 
against many viral infections.
Similar criticisms may applied to the use of live vaccine 
vectors such as atttenuated Salmonellae. Although these vectors can 
induce local and systemic humoral immunity against heterologously 
expressed antigens (110-112), there have been few reports on the 
induction of class I MHC-restricted CTL responses (321) and further 
work is required in order to address this issue. Furthermore, 
studies on the nature of the CD4+ T cell responses primed by oral 
adm inistration of Salmonellae have indicated  th a t they 
preferentially stimulate the Thl subset of CD4+T cells, based upon 
the profile of cytokines produced in vitro and IgG2a antibodies in 
vivo (56, 115, 322, 323). When the other potential problems with 
live vaccine vectors, such as reversion to virulence and stability, 
are also taken into account, then it becomes clear that ISCOMS have 
several advantages as oral vaccine vectors over the other well 
studied candidates. In this respect it is also worthwhile to note that, 
in contrast to many other immunomodulatory strategies that 
prevent the induction of oral tolerance, oral immunisation with 
ISCOMS does not induce any intestinal immunopathology, despite 
the high levels of local and systemic priming elicited (165, 324, 
325)
At present, it is premature to claim that ISCOMS represent 
perfect oral vaccine vectors, as a number of issues on the use of 
ISCOMS still have to be addressed. A major concern over the use of 
ISCOMS for human vaccination is the possible toxic side effects. In 
common with others (326), I found occasional toxicity with 
different batches of ISCOMS in mice and there is evidence that high
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doses of saponins can be highly toxic in vivo (194, 201). However, 
saponins are much less toxic when administered orally and are 
already accepted as food additives (197,198). Furthermore, I found 
ISCOMS much less toxic by the oral route and it is reported that 
mice are unusually susceptible to the toxic effects of ISCOMS, with 
larger species being more resistant (326). Indeed, recently, a 
clinical trial has begun on a human influenza ISCOMS vaccine. The 
long-term effects of ISCOMS immunisation have yet to be studied, 
although it is worth noting that in the long-term experiment that I 
performed, there was no difference in mortality between the 
ISCOMS primed and control groups for more than 12 months after 
priming. This problem is also faced by other oral adjuvants, most 
notably CT, where doses as low as l-5^g are able to cause severe 
diarrhoea in humans (147).
These concerns over toxicity have prompted attempts to 
purify saponin fractions which retain adjuvanticity, but have 
reduced toxicity. QS-21 is one such saponin purified from crude 
Quillaja extract, which has potent inherent adjuvant properties 
(201). Other studies have shown that some of the non-toxic saponin 
fractions of Quil A retain the ability to form ISCOMS (166, 279, 
327), but it remains to be seen whether these "new generation 
ISCOMS" will prove to be as effective parenteral and oral adjuvants 
as their predecessors. In addition, QS-21 enhances the adjuvant 
effects of alum, allowing it to stimulate T cells more efficiently and 
to induce cytotoxic T cells (298). Thus, non-toxic saponins may 
prove useful in augmenting the activities of conventional adjuvants. 
However, the effectiveness of such preparations when administered 
orally has not yet been investigated.
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A further area for possible improvement is the optimisation 
of methods for incorporating non-hydrophobic nominal antigens in 
ISCOMS . Initial ISCOM preparations used viral membrane extracts, 
containing hydrophobic proteins which easily incorporated into 
lipophilic ISCOMS (159, 167). However, modifications of native 
proteins, by acidification or palmitification techniques have enabled 
a wide range of purified proteins including OVA, BSA, HIVgpl20, 
cytochrome c and the C fragment of tetanus toxin to be 
incorporated within ISCOMS (164, 165, 203, 212). In most cases, 
these ISCOMS have potent immunogenicity when administered 
parenterally and the specificity of the immune responses induced, 
suggests that little epitope destruction or modification occurs after 
incorporation into ISCOMS. However, incorporation of proteins 
within ISCOMS can be technically difficult and the retention of 
immunogenicity after oral immunisation has been studied for only 
a few antigens.
Another interesting possibility is the idea of incorporating 
other immunological mediators into ISCOMS to enhance their 
adjuvant effects. For example, it may be possible to incorporate 
cytokines within ISCOMS or to incorporate monoclonal antibodies 
which could target the ISCOMS to DC or M<j>. Incorporation of CT, or 
the binding subunit CT-B, within ISCOMS may further enhance their 
oral adjuvant properties.
In summary, my results have highlighted that ISCOMS have 
several advantages over existing oral adjuvants by combining the 
benefits of a stable particulate structure with a built-in adjuvant, 
Quil A. They induce an unparalleled range of local and systemic 
immune responses and if concerns over their safety for 
admininstration to humans can be satisfied then they may form the
229
basis of future oral vaccines against almost any class of pathogenic 
organism.
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